

# WO04096148

Publication Title:

WO04096148

Abstract:

Abstract not available for WO04096148 Data supplied from the esp@cenet database - Worldwide

---

Courtesy of <http://v3.espacenet.com>

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number  
**WO 2004/096148 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number: PCT/US2004/013099

(22) International Filing Date: 26 April 2004 (26.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/465,891 25 April 2003 (25.04.2003) US  
10/676,694 30 September 2003 (30.09.2003) US

(71) Applicant (for all designated States except US): **THE KENNETH S. WARREN INSTITUTE, INC. [US/US]**; 712 Kitchawan Road, Ossining, NY 10562 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRINES, Michael** [US/US]; 1 Wepawaug Road, Woodbridge, CT 06525 (US). **CERAMI, Anthony** [US/US]; 49 Bramblebush Drive, Croton-on-Hudson, NY 10520 (US). **GHEZZI, Pietro** [IT/IT]; Via Mac Mahon No. 82, I-20155 Milan (IT). **FIORDALISO, Fbio** [IT/IT]; Via Lorenzo di Credi 10, I-20149 Milan (IT). **FRATELLI, Maddalena** [IT/IT]; Via Costanza 4, I-20146 Milan (IT). **LEIST, Marcel** [DK/DK]; Kloeverbladsgade 14.1, DK-2500 Valby (DK). **NIELSEN, Mette** [DK/DK]; Gladsaxevej 73.3. th, DK-2860 Soborg (DK). **SAGER, Thomas** [DK/DK]; Stormosevej 35, DK-2765 Smorum (DK). **PEDERSEN, Lars, Ostergaard** [DK/DK]; Ved Vigen 14, DK-2400 Copenhagen (DK). **GERWIEN, Jens** [DK/DK]; Haraldsgade 52, 1.tv, DK-2100 Copenhagen (DK). **COLEMAN, Thomas** [US/US]; 20 Emery Street, Mt. Kisco, NY 10549 (US).

(74) Agents: **CORUZZI, Laura, A. et al.**; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW).

*[Continued on next page]*

(54) Title: TISSUE PROTECTIVE CYTOKINE RECEPTOR COMPLEX, ASSAYS FOR IDENTIFYING TISSUE PROTECTIVE COMPOUNDS AND USES THEREOF

**WO 2004/096148 A2**



(57) Abstract: The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one  $\beta$ c Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CI, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

**TISSUE PROTECTIVE CYTOKINE RECEPTOR COMPLEX, ASSAYS FOR  
IDENTIFYING TISSUE PROTECTIVE COMPOUNDS AND USES THEREOF**

This application claims benefit of priority of copending U.S. Patent Application  
5 No. 10/676,694, filed September 30, 2003, which claims benefit of priority under 35  
U.S.C. § 119(e) to U.S. provisional patent Application No. 60/465,891, filed April 25,  
2003, the entire contents of each of which is incorporated herein by reference in their  
entirety.

**1. INTRODUCTION**

10 The present invention is directed to methods that target tissue protective cytokine receptor complexes having at least one beta common ( $\beta_c$ ) receptor (also known as CD131) and at least one erythropoietin (EPO) receptor for drug screening/discovery and methods of treatment or prophylaxis. In particular, the present invention is drawn to methods for identifying and screening for compounds that modulate the interaction of a  
15 tissue protective cytokine receptor complex and a tissue protective cytokine receptor complex ligand. The methods of the invention also encompass methods for treating or preventing a disease or disorder using compounds that modulate the activity of a tissue protective cytokine receptor complex such as those compounds identified by the screening methods of the invention. The invention also encompasses methods for  
20 enhancing excitable tissue function using compounds that modulate the activity of a tissue protective cytokine receptor complex such as those compounds identified by the screening methods of the invention.

## 2. BACKGROUND OF THE INVENTION

Several lines of evidence suggest that erythropoietin, as a member of the cytokine superfamily, performs important physiologic functions which are mediated through interaction with the erythropoietin receptor (EPO-R). These actions include

5 production of red blood cells, mitogenesis, modulation of calcium influx into smooth muscles and neural cells, and effects on intermediary metabolism.

EPO-R is a 68kDa protein, and is part of the Type-1 cytokine receptor family. This family includes receptors for interleukin (IL)-IL2, IL3, IL4, IL5, IL6, IL7, IL9, IL11, granulocyte macrophage – colony stimulating factor (GM-CSF), granulocyte 10 colony stimulating factor (G-CSF), Leukaemia Inhibiting Factor (LIF), Ciliary Neurotrophic Factor (CNTF), Thrombopoietin, Growth Hormone and Prolactin. These receptors are grouped together because of the homology of their extracellular domains. The conserved extracellular domain of these receptors has a length of approximately 200 amino acids, which contains four positionally conserved cysteine residues in the amino- 15 terminal region (Cys 294, Cys 283, Cys 248, Cys 238) and a Trp-Ser-X-Trp-Ser motif located proximal to the transmembrane domain. The four cysteines appear to be critical to the maintenance and the structural integrity of the receptors (Murray, 1996, Harpers Biochemistry 24<sup>th</sup> ed. pp.524-526, Appilion & Lange, Ltd.; Caravella *et al.*, 1996, Protein: Struct. Funct. Gen. 24:394-401; ).

20 Like many of the receptors within the Type-1 cytokine receptor family, the EPO-R appears to be activated by interaction its endogenous ligand EPO. The first EPO-R in the dimer binds to EPO with a high affinity and the second EPO-R then binds to the complex with a low affinity. This dimerization of the EPO-R puts the Jak2 tyrosine kinases associated with EPO-R in close association, inducing their 25 transphosphorylation. This activation leads to the tyrosine phosphorylation of several

proteins that subsequently activate several different pathways, such as phosphatidylinositol (PI) 3-kinase pathway, the Ras/MAP kinase pathway, and the STAT pathway. These pathways trigger the physiological functions mediated by erythropoietin (Kirito *et al.*, 2002, Blood 99:102-110; Livnah *et al.*, 1999, Science 283:987-990;

5 Naranda *et al.*, 2002, Endocrinology 143:2293-2302; Remy *et al.*, 1999, Science 283:990-993; and Yoshimura *et al.*, 1996, The Oncol. 1:337-339).

In addition to forming multimers, many of the members of the type-1 family incorporate one of three different signal transducing receptor components – gp130, beta common ( $\beta_c$  receptor), or the gamma subunit of the IL2 receptor ( $\gamma_c$  receptor) – into their receptor complexes. For example, the receptor complex for GM-CSF consists of GM-CSF receptor, two  $\beta_c$  receptors, and the GM-CSF ligand. The EPO-R has been known to form a complex with the  $\beta_c$  receptor (See Yutaka *et al.*, 1995, Bioch. Biophys. Res. Com. 208:1060-1066; Jubinsky *et al.*, 1997, Blood 90:1867-1873; D'Andrea *et al.*, 1998, J. Clin. Invest. 102:1951-1960). However, it has been reported 10 that these complexes failed to result in any physiologically relevant effect (Scott *et al.*, 2000, Blood, 96:1588-1590).

### 3. SUMMARY

The invention relates to targeting “tissue protective cytokine receptor complexes” (defined *infra*) for drug screening/discovery, and methods for achieving 20 tissue protection or repair *in vivo*, *e.g.*, for the prophylaxis or treatment of a variety of diseases, disorders and conditions, or for the improvement of function of excitable tissue in human subjects or other mammals. The invention is based, in part, on the applicants’ discovery that EPO receptor/ $\beta_c$  receptor complexes play a role in the protection of excitable tissues. Experiments described herein demonstrate that EPO had a protective

effect, *i.e.*, mitigated apoptosis, in wild-type cells that express both EPO receptors and  $\beta_c$  receptors; however, EPO had no protective effect in cells lacking the  $\beta_c$  receptors. In animal studies, ischemic spinal injury was inflicted in wild-type mice (which express both receptors) and in  $\beta_c$  receptor knock-out mice (which do not express the  $\beta_c$  receptor).

5 The administration of carbamylated EPO (which is non-erythropoietic and does not bind EPO receptor dimers) resulted in an improved recovery in the wild-type mice. However, neither EPO nor carbamylated EPO had an effect on recovery in the  $\beta_c$  receptor knock-out mice. These results demonstrate that expression of the  $\beta_c$  receptor is essential to achieve a tissue protective effect.

10 In one aspect, the present invention is directed to the use of tissue protective cytokine receptor complexes, comprising an EPO receptor and a  $\beta_c$ , in cell-free screening assays to identify compounds that bind tissue protective cytokine receptor complexes. In other aspects, the present invention is directed to the use of tissue protective cytokine receptor complexes, comprising an EPO receptor and a  $\beta_c$ , in cell-based screening assays to identify compounds that modulate, *i.e.*, enhance or inhibit, the activity of tissue protective cytokine receptor complexes or exhibit a tissue protective activity. In other aspects, the present invention is directed to the use of tissue protective cytokine receptor complexes, comprising an EPO receptor and a  $\beta_c$ , in animal-based screening assays to identify compounds that exhibit a tissue protective activity dependent 15 on tissue protective cytokine receptor complexes. In another particular aspect, the compounds identified by the screening methods of the invention modulate the interaction of a tissue protective cytokine receptor complex and a ligand thereof and exhibit a tissue protective activity. In other embodiments, the invention provides for methods for treating or preventing a disease, disorder or condition comprising administering a 20 compound that modulates the activity of a tissue protective cytokine receptor complex. 25

In another aspect, the invention provides for methods for enhancing the function of excitable cells, tissues, or organs by administering a compound that modulates the activity of a tissue protective cytokine receptor complex.

In certain embodiments of the screening methods of the invention, the test

5 compound is contacted with a tissue protective cytokine receptor complex in the presence and/or in the absence of a ligand of the tissue protective cytokine receptor complex, such as, but not limited to EPO. Such assays can be used to identify compounds that modulate the interaction of a ligand and a tissue protective cytokine receptor complex.

10 Cell-free assays can be used to identify compounds that bind a tissue protective cytokine receptor complex. In such embodiments, tissue protective cytokine receptor complexes or a membrane preparation of such complexes is contacted with a test compound and an indication of the binding is measured. The assay may be a direct binding assay where a compound is contacted to a tissue protective cytokine receptor

15 complex. In competitive binding assays two compounds (e.g., a test compound and a ligand, or two test compounds) are contacted to a tissue protective cytokine receptor complex to determine which of the two compounds has greater binding affinity. The assay may be a displacement binding assay where a first compound is contacted to a tissue protective cytokine receptor complex that binds to the complex and a second

20 compound is added to the assay to determine if the second compound has the ability to displace the first bound compound. In binding assays, the binding can be measured by labeling the compounds added to the assay and/or labeling a tissue protective cytokine receptor complex.

Cell-based assays can be used to identify compounds that target a tissue

25 protective cytokine receptor complex in the presence and/or absence of a ligand for a

tissue protective cytokine receptor complex. In such embodiments, a cell that expresses a tissue protective cytokine receptor complex is contacted with a test compound. To determine whether the test compound modulates the activity of a tissue protective cytokine receptor complex in the cell, a readout is observed or measured. The readout 5 can be a simple measure of the binding of the test compound to the tissue protective cytokine receptor complex. In certain embodiments, the test compound is labeled and binding of the labeled test compound to the tissue protective cytokine receptor complex is measured by detecting the label attached to the test compound. In other embodiments, the readout is a phenotypic change such as a change in cell size, shape, or apoptosis of 10 the cell. In yet other embodiments, the readout is expression of a reporter gene or a change in an indicator dye loaded into the cell or included in the culture media. In such embodiments, the cells employed in the assay are genetically engineered to express a reporter gene product upon activation of a tissue protective cytokine receptor complex.

In other embodiments, the readout is determined by enzymatic reaction of the cell. In 15 such embodiments, cells used in the assay after being contacted with a test compound are lysed. The cell lysates are then examined for indicators of the activation of a tissue protective cytokine receptor complex. For example, a cell lysates can be exposed to an antibody that binds the complex, which antibody can also attach to a support anchoring the complex. Other antibodies can then be added to the assay to detect whether the tissue 20 protective cytokine receptor complex has been activated. For example, anti-phosphotyrosine antibodies can bind to phosphorylated portions of the complex and/or to downstream components of the EPO/β common receptor complex. In certain embodiments, antibodies that can bind to phosphorylated portions of the β common receptor portion of the complex and/or antibodies can bind to phosphorylated portions of 25 the EPO receptor are used. In certain embodiments, cells expressing tissue protective

cytokine receptor complexes are contacted with antibodies that can bind to phosphorylated portions of the  $\beta$  common receptor and/or the EPO receptor. In certain embodiments, isolated tissue protective cytokine receptor complexes are contacted with antibodies that can bind to phosphorylated portions of the  $\beta$  common receptor and/or the

5 EPO receptor. In certain embodiments, antibodies that can bind to phosphorylated portions of the EPO receptor are PY-JAK2 antibodies. As downstream cytokine activation targets are identified for tissue protective cytokine receptor complexes, the readout of the screening methods of the invention can be detection of phosphorylation of downstream cellular components.

10 The presence of downstream cellular products can be used to identify compounds that target a tissue protective cytokine receptor complex. For example, following contacting of a compound with a cell expressing a tissue protective cytokine receptor complex, the cell can be examined for the presence of other cellular products such as nucleolin or neuroglobin that are indicative of activation of a tissue protective

15 cytokine receptor complex.

In certain embodiments of the screening methods of the invention, the cell is recombinantly engineered to express at least one EPO receptor or  $\beta$  common receptor. In certain embodiments, the cell is genetically engineered to overexpress a nucleic acid comprising a nucleotide sequence that encodes a  $\beta$  common receptor polypeptide or a

20 EPO receptor polypeptide. In certain embodiments, the cell is genetically engineered to overexpress a nucleic acid comprising a nucleotide sequence that encodes a  $\beta$  common receptor polypeptide and a nucleic acid comprising a nucleotide sequence that encodes a EPO receptor polypeptide. The overexpression may be achieved by operably linking the nucleic acids to a promoter genetic engineering may occur by standard transformation

25 techniques, targeted homologous recombination to achieve gene activation of

endogenous genes, or random integration and selection of cells with the activated gene.

In certain embodiments, the nucleotide sequence is derived from the same species as the cell. In certain embodiments, the cell endogenously expresses a  $\beta$  common receptor and/or a EPO receptor.

5           In one embodiment, the invention provides for a method for identifying a compound that modulates the activity of a tissue protective cytokine receptor complex in a  $\beta$  common receptor knock-out cell, comprising administering the compound to a first cell, immediately followed by subjecting the cell to a harmful agent, wherein the first cell endogenously expresses a tissue protective cytokine receptor complex and

10          administering the compound to a second cell immediately followed by subjecting the cell to the same harmful agent as the first cell, wherein the second cell is of the same type as the first cell but is deficient in expression of a tissue protective cytokine receptor complex (*i.e.*, lacking expression of  $\beta$  common receptor), such that if survival of the cell differs in the first cell as compared to the second cell, then the compound is one that

15          targets a tissue protective cytokine receptor complex. In one embodiment, the cells are derived from a  $\beta$  common receptor knock-out animal.

             Assays can be conducted in animal models to identify compounds that target a tissue protective cytokine receptor complex. In one embodiment, the invention provides for a method for identifying a compound that modulates a tissue protective activity in a mammal, comprising administering the compound to a first animal immediately following infliction of an injury, wherein the first animal endogenously expresses a tissue protective cytokine receptor complex and administering the compound to a second animal immediately following infliction of the same type of injury as inflicted to the first animal, wherein the second animal is deficient in expression of a tissue protective cytokine receptor complex, such that if recovery from the injury differs

in the first animal as compared to the second animal, then a compound that modulates a tissue protective activity is identified.

Cells expressing a tissue protective cytokine receptor complex that can be used in the screening methods of the invention include, but are not limited to, mammal, 5 insect, eukaryotic, prokaryotic, fungi, or bacteria cells. In certain embodiments, human cells are used, such as, but not limited to, pre-B cells, 293 cells, 293T cells, HeLa cells, HepG2 cells, K562 cells, or 3T3 cells. In other embodiments mouse cells are used, such as, but not limited to, BaF3 cells. In other embodiments fungi cells are used, such as, but not limited to, cells from the genera *Saccharomyces*, *Schizosaccharomyces*, *Pichia*, and 10 *Hansenula*.

According to another aspect of the invention, a method of treating or preventing a disease or disorder in a human is provided which comprises administering a therapeutically effective amount of a compound that modulates the activity of a tissue protective cytokine receptor complex to a human in need of such treatment or prevention.

15 In certain embodiments, the disease or disorder is a disease or disorder of or affecting excitable tissue.

In one embodiment, the invention provides for a method for enhancing the function of excitable cells, tissues, or organs in a human comprising administering a therapeutically effective amount of a compound that modulates the activity of a tissue protective cytokine receptor complex to a human in need thereof, wherein said enhancing 20 the function of excitable cells, tissues, or organs results in the enhancement of associative learning or memory.

In another embodiment, the invention provides for a method for modulating the activity of a tissue protective cytokine receptor complex in a human,

comprising administering a compound that modulates the activity of said complex to a human in need of such treatment or prevention.

In yet another embodiment, the invention provides for a method for treating or preventing a disease or disorder in a human comprising modulating a tissue 5 protective cytokine receptor complex in a human.

In still another embodiment, the invention provides for a method for enhancing the function of excitable cells, tissues, or organs in a human comprising modulating a tissue protective cytokine receptor complex in a human.

In embodiments of the invention for treating or preventing a disease or 10 disorder, enhancing the function of excitable cells, tissues, or organs, or modulating the activity of a tissue protective cytokine receptor complex the compound administered can be identified by the method of any one of the screening methods described herein above for identifying compounds that have a tissue protective effect or modulate the activity of a tissue protective cytokine receptor complex. In related embodiments, the compound is 15 an antibody specific for the tissue protective cytokine receptor complex. In related embodiments, compound is an antibody specific for a tissue protective cytokine receptor complex ligand. In related embodiments, the compound is a small molecule, peptide, or a member of a library. In related embodiments, the compound binds to the tissue protective cytokine receptor complex. In related embodiments, the compound enhances 20 the activity of the tissue protective cytokine receptor complex. In related embodiments, compound interferes with the activity of the tissue protective cytokine receptor complex. In related embodiments, the compound is administered in conjunction with an EPO. In certain embodiments, the compound administered is an EPO. In certain embodiments, the compound administered is not EPO. In related embodiments, the compound 25 administered is not a modified EPO or an EPO mutant. Examples of modified EPO and

mutant EPO compounds include, but are not limited to, those described in section 5.4.1.1. In certain embodiments of the invention, where the compound administered is an EPO, a modified EPO, or an EPO derivative, the compound administered does not bind the EPO receptor. In related embodiments of the invention, where the compound 5 administered is an EPO, a modified EPO, or an EPO derivative, the compound administered does not bind an EPO receptor dimer. In certain embodiments of the methods of the invention for treatment, prevention, enhancement of function of excitable tissue, and modulation of a tissue protective cytokine receptor complex, the compound administered is not an EPO, *i.e.*, any EPO, modified EPO, mutated EPO, or derivative 10 thereof.

In certain other embodiments of the methods of the invention for treatment or prevention of a disease disorder, or condition, enhancement of function of excitable tissue, or modulation of a tissue protective cytokine receptor complex, the compound administered does not bind the EPO receptor. In certain other embodiments 15 of the methods of the invention for treatment or prevention of a disease disorder, or condition, enhancement of function of excitable tissue, or modulation of a tissue protective cytokine receptor complex, the compound administered does not bind a dimer consisting of two EPO receptors. In certain other embodiments of the methods of the invention for treatment or prevention of a disease disorder, or condition, enhancement of 20 function of excitable tissue, or modulation of a tissue protective cytokine receptor complex, the compound administered binds a tissue protective cytokine receptor complex.

In embodiments of the invention for treating or preventing a disease or disorder, the disease or disorder is a mood disorder, an anxiety disorder, depression, 25 autism, an attention deficit hyperactivity disorder, Alzheimer's disease, aging, or

cognitive dysfunction. In related embodiments, the disease or disorder is caused by hypoxia, seizure disorders, neurodegenerative diseases, neurotoxin poisoning, multiple sclerosis, hypotension, cardiac arrest, radiation, or hypoglycemia. In related embodiments, the disease or disorder is ischemia or stroke. In related embodiments, the 5 disease or disorder is a neurodegenerative condition. In related embodiments, the neurodegenerative condition is stroke, Alzheimer's disease, Parkinson's disease, cerebral palsy, brain or spinal cord trauma, AIDS dementia, age-related loss of cognitive function, memory loss, amyotrophic lateral sclerosis, seizure disorders, alcoholism, retinal ischemia, aging, glaucoma or neuronal loss. In other related embodiments, the 10 disease or disorder is a neuromuscular or muscular condition. In certain embodiments, the neuromuscular or muscular condition is of a heart tissue. In certain embodiments of the methods of the invention for treatment or prevention of a disease disorder, or condition, enhancement of function of excitable tissue, or modulation of a tissue protective cytokine receptor complex, the disease disorder, condition, or excitable cells, 15 tissues, or organs, are not cerebral. In certain embodiments of the methods of the invention for treatment or prevention of a disease disorder, or condition, enhancement of function of excitable tissue, or modulation of a tissue protective cytokine receptor complex, the disease disorder, condition, or excitable cells, tissues, or organs, are not of the central nervous system including, but not limited to, renal tissues, cardiac tissues, 20 endothelial tissues, retinal tissues, vascular tissues, lung tissues, pancreas tissues, bone tissues, skin tissues, embryonic tissues, fetal tissues, kidney tissues, striated muscle tissues, liver tissues, gastrointestinal tissues reproductive tract tissues, or endocrine tissues.

In embodiments of the invention for enhancing the function of excitable 25 cells, tissues, or organs, the excitable tissue is central nervous system tissue or peripheral

nervous system tissue. In certain embodiments, the peripheral nervous system tissue is placental tissue, retinal tissue, or cardiac tissue.

In embodiments of the invention for treating or preventing a disease or disorder, enhancing the function of excitable cells, tissues, or organs, or modulating the

5 activity of a tissue protective cytokine receptor complex the administration is oral, topical, intracranial, intraluminal, inhalation, nasal, parenteral, intravenous, peripherally, intraarterial, subcutaneous, intramuscular, intraperitoneal, submucosal or intradermal administration. In related embodiments, the administration is prior to a medical or surgical procedure. In certain embodiments, the surgical procedure is tumor resection,

10 aneurysm repair, or a coronary artery bypass procedure. In certain embodiments of the invention, the medical procedure is labor or delivery.

### 3.1 TERMINOLOGY

As used herein, the term “tissue protective activity” refers to the effect of inhibiting or delaying damage or death of a cell, tissue, or organ. The tissue protective

15 activity can be against various conditions, diseases, and cellular, organ, and/or tissue damage, for example, those described in section 5.5 . Tissue protective activity may be specific to excitable tissue, cells, and/or organs having a tissue protective cytokine receptor complex, such as, but not limited to, the tissues of the central nervous system.

The term “tissue protective cytokine receptor complex” as used herein

20 means a complex comprising at least one erythropoietin receptor and at least one beta common receptor. The tissue protective cytokine receptor complex may contain multiple erythropoietin receptors and/or beta common receptors, as well as other types of receptors as described herein in section 5.1.3

The term “tissue protective cytokine receptor complex ligand” means any

25 compound that binds a tissue protective cytokine receptor complex and activates the

complex or inhibits activation by a known activating ligand. A “tissue protective cytokine receptor complex ligand” can be any type of compound, such as, but not limited to, proteins, peptides, small molecules, organic molecules, or non-organic molecules.

Non-limiting examples of tissue protective cytokine receptor complex ligands include

5 EPO, including mutants, chemical modifications, or tissue protective cytokine receptor complex-binding fragments thereof. Another example of a tissue protective cytokine receptor complex ligand is an antibody specific for the complex.

The term “preventing a disease, disorder, or condition” means delaying the onset, hindering the progress, hindering the appearance, protection against, inhibiting 10 or eliminating the emergence, or reducing the incidence, of such disease, disorder, or condition. Use of the term “prevention” is not meant to imply that all patients in a patient population administered a preventative therapy will never develop the disease, disorder, or condition targeted for prevention, but rather that the patient population will exhibit a reduction in the incidence of the disease, disorder, or condition. For example, 15 many flu vaccines are not 100% effective at preventing flu in those who administered the vaccine. Prevention also encompasses protection of excitable tissues. One skilled in the art can readily identify patients and situations for whom preventative therapy would be beneficial, such as, but not limited to, patients for whom surgery is planned, patients at risk for inherited diseases, disorders, or conditions, patients at risk for diseases, 20 disorders, or conditions precipitated by environmental factors, or portions of the population at risk for particular diseases, disorders, or conditions such as the elderly, infants, or those with weakened immune systems, or those patients with genetic or other risk factors for a disease, disorder, or condition.

The term "administered in conjunction with" in the context of the methods of the invention means administering a compound prior to, at the same time as, and/or subsequent to the onset of a disease, disorder, or condition.

#### 4. BRIEF DESCRIPTION OF THE FIGURES

5 **Figure 1** depicts the results of a competitive assay between EPO and carbamylated EPO that demonstrate that carbamylated EPO does not bind to the EPO-R.

**Figure 2** shows the presence of the  $\beta_c$  receptor within rat brain membranes.

10 **Figure 3** shows rat spinal cord tissue stained for the presence of the  $\beta_c$  receptor.

**Figure 4** shows enhanced view of rat spinal cord tissue stained for the presence of the  $\beta_c$  receptor.

**Figure 5** shows the coprecipitation of the EPO-R and  $\beta_c$  receptor.

15 **Figure 6** shows the potential configuration of the tissue protective receptor complex.

**Figure 7** shows apoptosis in isolated cardiomyocytes from normal and  $\beta_c$  receptor knockout mice in the presence and absence of EPO.

20 **Figure 8** shows photographs of Western blotting of the cell proteins separated by polyacrylamide gels using phosphotyrosine (PY)-Jak2 antibodies. The top gel shows that phosphorylated Jak2 was present in cells stimulated with EPO at 5 nM and 50nM concentrations. The bottom gel shows a control performed where membranes were stripped and reprobed with an antibody against Jak2 to confirm equal loading.

**Figure 9** shows a graph of ligand binding affinity for BaF3 cells expressing the EPO receptor. Ligand concentration in nM (x-axis) is plotted against

binding (cpm) (y-axis) for BaF3 EPO receptor expressing cells contacted with EPO receptor ligands EPO and carbamylated EPO.

Figure 10 shows a graph of ligand binding affinity for UT-7 cell membranes having the EPO receptor. Ligand concentration in nM (x-axis) is plotted 5 against binding (cpm) (y-axis) for UT-7 EPO receptor expressing cell membranes contacted with EPO receptor ligands EPO and carbamylated EPO.

Figure 11 shows histograms of, 11A, hematocrit as measured by the percent volume of hematocrit (y-axis), and, 11B, hemoglobin levels measured in concentration in mM (y-axis), in mice after administration of control (vehicle), EPO, 10 carbamylated EPO, and asialoEPO (x-axis).

Figure 12 shows a photograph of the SDS-PAGE gel with a 103 KD nucleolin protein circled.

Figure 13 shows a graph of the BBB motor score (y-axis) versus time measured in days following spinal injury (x-axis) where five groups of mice, two wild 15 type and three  $\beta_c$  knock-out, were administered either PBS, EPO, or carbamylated EPO immediately following spinal injury. The wild type group of mice administered carbamylated EPO exhibited increased motor scores throughout the 42 days post-injury time period in comparison to all other groups.

Figure 14 shows a histogram of the clinical severity measured in area 20 under curve (AUC) (y-axis) and groups of mice (x-axis) for the five groups described above in Figure 13. The wild type group of mice administered carbamylated EPO (column 1) exhibited a significant increase in clinical severity values (*i.e.*, less severity) in comparison to all other groups (columns 2-5).

## 5. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to methods for use of a heteromultimer receptor complex that mediates the tissue protective activities of tissue protective compounds. The invention provides screening methods to identify such tissue protective compounds and use of such compounds in treatment or prevention of a disease, disorder, or condition, or use of such compounds in methods for enhancing the function of excitable cells, tissues, and organs. The invention also provides for methods of treatment or prevention of disease, disorders, or conditions by administering compounds that modulate the activity of a tissue protective cytokine receptor complex, such as, but not limited to, those identified by the screening methods of the invention. The invention also provides for methods of enhancing the function of excitable cells, tissues, or organs by administering compounds that modulate the activity of a tissue protective cytokine receptor complex, such as, but not limited to, those identified by the screening methods of the invention. The invention also provides for methods for modulating the activity of a tissue protective cytokine receptor complex by administering a compound that modulates or is targeted to the tissue protective cytokine receptor complex.

The invention is based on the discovery by the inventors that EPO receptor forms a complex with  $\beta_c$  receptor within excitable cells and tissues such as brain, spinal cord and heart. The complex consists of at least one EPO-R in a complex with at least one  $\beta_c$  receptor. In addition to the  $\beta_c$  receptor, other signal transducing receptors may be used including, but not limited to, the  $\gamma_c$  receptor and GP130, segments and portions of other Type-1 cytokine receptors, including, but not limited to, GM-CSF, IL-3, IL-5, *etc.*, and orphan receptors, including, but not limited to, ROR1, NR6, HM74, *etc.* The screening methods of the invention may use such tissue protective cytokine receptor complexes in assays for identifying compounds that modulate the activity of a

tissue protective cytokine receptor complex. Such assays include binding assays to identify compounds that bind to a tissue protective cytokine receptor complex or a ligand thereof. The discovery of the applicants provided the means to identify exceptionally effective compounds for use in treatment and prevention of disease, disorders, and 5 conditions as well as enhancement of excitable cells, tissues, and organs.

Activation of a tissue protective cytokine receptor complex may lead to the upregulation of the production of protective proteins, including, but not limited to, nucleolin and globins such as neuroglobins and cytoglobin (histoglobin). In certain embodiments of the methods of the invention described herein above where tissue 10 protective activity is assayed, the step of assaying the identified compound for tissue protective activity comprises detecting the presence of nucleolin in the cell.

In certain embodiments of the methods of the invention described herein where tissue protective activity is assayed, the step of assaying the identified compound for tissue protective activity comprises detecting or measuring an increased level of 15 activity of neuroglobin or cytoglobin in a cell. Accordingly, the screening methods for identifying compounds with tissue protective activity may utilize detection of such upregulated proteins.

This tissue protective cytokine receptor complex and downstream regulators may be used in assays to identify tissue protective compounds, including, but 20 not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat various conditions of the central and peripheral nervous systems as well as those of other excitable cells, tissues, and organs.

### 5.1 THE TISSUE PROTECTIVE CYTOKINE RECEPTOR COMPLEX

The receptor complex for use in the methods of the invention comprises at 25 least one EPO receptor and at least one  $\beta_c$  receptor. Various types of naturally-occurring,

modified, and/or mutant EPO receptors and  $\beta_c$  receptors may be combined to form such complexes of varying numbers of receptors. Non-limiting examples of tissue protective cytokine receptor complexes are described below.

### 5.1.1 EPO-R

5 Mammalian EPO-R may be used in the present invention. EPO-R cDNA has been isolated from mouse liver, Tojo *et al.*, 1987, *Biochem. Biophys. Res. Comm.* 148: 443-48 and from human fetal liver (Jones *et al.*, 1990, *Blood* 76:31-35; Winkelmann *et al.*, 1990, *Blood* 76:24-30). This human cDNA encodes a polypeptide chain of about 55 kDa MW and has about 508 amino acids. Other genomic clones of 10 human EPO-R that have been isolated and sequenced are also contemplated by the present invention (Penny and Forget, 1991, *Genomics* 11:974-80; Noguchi *et al.*, 1991, *Blood* 78:2548-2556). The common structure of these EPO-R consist of about 24 amino acid residues in a signal peptide, about 226 amino acids in an extracellular domain, about 23 amino acids in a membrane-spanning domain, and about 235 amino acids in a 15 cytoplasmic domain (D'Andrea and Zon, 1990, *J. Clin. Invest.*, 86:681-687; Jones *et al.*, 1990, *Blood*, 76:31-35; Penny and Forget, 1991, *Genomics*, 11:974-80). The mature human EPO-R protein has about 484 amino acids. EPO-R is commercially available from BD Biosciences Clonetech (Palo Alto, CA) and has gene bank accession number M60459 and SwissProt accession number P19235.

20 The forms of EPO-R useful in the practice of the present invention encompass naturally occurring, synthetic and recombinant forms of human and other mammalian EPO-R related molecules. In addition, EPO-R forms useful in the practice of the present invention include proteins that represent functionally equivalent gene products. Such a functionally equivalent gene products include mutant EPO-R and 25 chemically modified EPO-R. Mutant EPO-R may contain deletions, including internal

deletions, additions, including additions yielding fusion proteins, or conservative substitutions of amino acid residues within and/or adjacent to the amino acid sequence, but that result in a “silent” change, in that the change produces a functionally equivalent EPO-R. Such amino acid substitutions may be made on the basis of similarity in

5 polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids including glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine,

10 lysine, and histidine; and negatively charged (acidic) amino acids include aspartic and glutamic acid. Other known EPO-R mutations such as those disclosed in U.S. Patent No. 5,292,654 are encompassed by the present invention as well.

Further, soluble (truncated) forms of the EPO receptor containing only the extracellular domain are also contemplated for use in the present invention such as those

15 disclosed in Harris *et al.* 1992, J. Biol. Chem. 267:15205; Yang & Jones, 1993, Blood 82:1713; and U.S. Patent Application Publication No. 20020031806.

### 5.1.2 $\beta_c$ Receptor

The  $\beta_c$  receptor is typically identified as a signaling receptor subunit associated with human GM-CSF, IL-3 and IL-5. In addition to these cytokines, the  $\beta_c$

20 receptor (*e.g.*, Swiss accession no. P32927 or Genebank No. M59941) has been demonstrated to bind EPO-R in certain instances. The conserved region of the  $\beta_c$  receptor constitutes all or part of the extracellular ligand-binding region. The present invention is based, in part, on the demonstration by the Applicants that the EPO-R and the  $\beta_c$  receptor co-exist within several excitable cells, such as the brain (see Figure 2) and

25 spinal cord (see Figures 3 and 4). Applicants also discovered that complexes of the

EPO-R and the  $\beta_c$  receptor play a role in a mechanism that lead to the physiologic process of protection and repair of tissues that express these complexes (see Figures 13 and 14).

The forms of  $\beta_c$  receptor useful in the practice of the present invention 5 encompass naturally occurring, synthetic and recombinant forms of human and other mammalian  $\beta_c$  receptor related molecules. In addition,  $\beta_c$  receptor forms useful in the practice of the present invention include proteins that represent functionally equivalent gene products. Such functionally equivalent gene products may include mutant  $\beta_c$  receptor and chemically modified  $\beta_c$  receptor. The mutant  $\beta_c$  receptors may contain 10 deletions, including internal deletions, additions, including additions yielding fusion proteins, or conservative substitutions of amino acid residues within and/or adjacent to the amino acid sequence, but that result in a “silent” change, resulting in a functionally equivalent  $\beta_c$  receptor. Mutated  $\beta_c$  receptors include, but are not limited to, I374N, F1Δ,  $\Delta$ GA, H544R, V449, A459D, L445Q, CRD4 point mutations (I374N, L356P, W358N, 15 Q375P, Y376N, W383R, and L399P), and extracellular truncations (1GH7). (See R.J. D’Andrea and T.J. Gonda, 2000, Experimental Hematology 28:231-243; D’Andrea *et al.*, 1998, J. Clin. Invest. 102:1951-1960; Jenkins *et al.*, 1999, J. Biol. Chem. 274:8669-8677).

It is also contemplated that other known signaling receptor subunits 20 including, but not limited to,  $\gamma_c$  receptor and GP-130, and orphan receptors may be used with the present invention as well.

### 5.1.3 Structure of the Heteromultimer Receptor Complex

The  $\beta_c$  receptor forms a multimer with many of the receptors it was 25 previously known to bind with, *i.e.*, GM-CSF, IL-3, and IL-5. For example, the receptor complex for GM-CSF consists of GM-CSF receptor, two  $\beta_c$  receptors, and the GM-CSF

ligand. The EPO-R has been known to form a complex with the  $\beta_c$  Receptor. (See Yutaka *et al.*, 1995, Biochem. Biophys. Res. Com. 208:1060-1066; Jubinsky *et al.*, 1997, Blood, 90:1867-1873; D'Andrea *et al.*, 1998, J. Clin. Invest. 102:1951-1960.) Similarly, according to the present invention, the  $\beta_c$  receptor forms a heteromultimer with the EPO-R to form a tissue protective receptor complex. This is based on immunoprecipitation studies demonstrating that the  $\beta_c$  receptor and EPO-R receptors coprecipitate (see Figure 5).

This tissue protective receptor complex includes at least one EPO-R and at least one  $\beta_c$  receptor. Preferably, as depicted in Figure 6, the tissue protective receptor complex will include greater than one  $\beta_c$  receptor. Tissue protective receptor complex configurations are also contemplated by the present invention that include greater than one EPO-R. Examples of tissue protective receptor complexes contemplated by the present invention include, but are not limited to, EPO-R<sub>2</sub>/  $\beta_c$  receptor<sub>2</sub>, EPO-R/  $\beta_c$  receptor<sub>2</sub>, and EPO-R/  $\beta_c$  receptor<sub>3</sub>. The most suggested configuration of the tissue protective receptor complex is EPO-R/  $\beta_c$  receptor<sub>2</sub> as depicted in Figure 6. As shown therein, without being bound by any particular theory, a possible mechanism by which the tissue protective compound binds to the tissue protective receptor complex involves the tissue protective compound first binding with the EPO-R and then subsequently two  $\beta_c$  receptors binding to the complex. This depiction is merely illustrative of one method by which a ligand may bind to the tissue protective receptor complex and those of ordinary skill in the art could reasonably envision other mechanisms by which binding can occur – the receptor complex may be preformed (EPO-R and two  $\beta_c$  receptor) prior to binding the ligand, *etc.*

The receptor polypeptides of the present invention, including full-length receptors, receptor fragments (*e.g.* ligand-binding fragments), and fusion polypeptides

can be produced in genetically engineered host cells according to conventional techniques. For example, Erythropoietin binding fragments of the EPO receptor have been identified (Barone *et al.*, *J. Biol. Chem.* 272:4985-4992). Such fragments that also complex with a  $\beta_c$  receptor may be used in the screening methods of the invention.

## 5 5.2 SCREENING ASSAYS

Tissue protective cytokine receptor complexes, such as, but not limited to, those described above can be used in screening assays to identify compounds having a tissue protective activity. Compounds identified in these assays may modulate the activity of a complex, *e.g.*, bind to a tissue protective cytokine receptor complex, or 10 modulate the interaction of a tissue protective cytokine receptor complex ligand and the complex. In addition, the compounds identified may themselves have a tissue protective activity.

This invention is particularly useful for screening compounds by using an EPO receptor- $\beta_c$  receptor complex in any of a variety of drug screening techniques. The 15 receptor complex employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed 20 form, can be used for standard binding assays. One may measure, for example, the formation of complexes between receptor and the agent being tested or examine the diminution in complex formation between the tissue protective cytokine receptor complex and an appropriate cell line, which are well known in the art. For example, see examples sections 6 and 7 below.

The tissue protective cytokine receptor complexes described above in section 5.1 can similarly be used in assays to determine biological activity, including in a panel of multiple receptors for high-throughput screening, as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of a tissue protective compound in biological fluids, as markers for tissues in which the corresponding tissue protective compound is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state), and, of course, to isolate correlative ligands.

Methods for performing the assays listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

In certain embodiments, the assays of the invention described herein may be used to identify a compound that interacts with a tissue protective cytokine receptor complex. Such assays may be carried out in the absence of a tissue protective cytokine receptor complex ligand. The interaction may be, for example, binding of the test compound to tissue protective cytokine receptor complex or activity of a tissue protective cytokine receptor complex. In such embodiments, the test compound is contacted with a tissue protective cytokine receptor complex. The compound identified is one that produces a readout, such as, but not limited to, activation of the tissue protective cytokine receptor complex, transcription of a reporter gene, cell proliferation, or a tissue protective activity. Such assays are typically performed with a control, wherein the compound is not contacted to the tissue protective cytokine receptor

complex. Where there is a difference in the readout with and without the compound, a compound that interacts with the tissue protective cytokine receptor complex is identified. Alternatively, standard levels of readout, such as, but not limited to, activity of the tissue protective cytokine receptor complex, can be measured prior to contacting 5 the tissue protective cytokine receptor complex with the test compound, and the difference in readout before and after addition of the compound can be used to identify compounds.

In certain other embodiments, the assays of the invention may be used to identify compounds that modulate, *i.e.*, enhance or interfere with, the interaction between 10 a tissue protective cytokine receptor complex ligand and a tissue protective cytokine receptor complex. Such assays may be carried out in the presence of a tissue protective cytokine receptor complex ligand, such as EPO or an antibody specific to the tissue protective cytokine receptor complex. In such embodiments, the difference in the level of readout in the presence and absence of the test compound may be detected. The level 15 of readout can then be compared to that in the absence of EPO. If the difference in the level of readout detected with and without the compound is dependent on the presence of EPO, then a compound that modulates the interaction of a tissue protective cytokine receptor complex with its ligand is identified. For example, if the difference in level of 20 readout detected results from an increase in readout in the presence of a compound, wherein the increase is dependent on the presence of EPO, an agonist of the interaction between a tissue protective cytokine receptor complex and its ligand is identified. Alternatively, if the difference in level of readout detected results from an decrease in 25 readout in the presence of a compound, wherein the decrease is dependent on the presence of EPO, then an antagonist of the interaction between a tissue protective cytokine receptor complex and its ligand is identified. The situation is reversed in

embodiments where the readout is a negative readout. For example, a readout may be present when a compound has no effect on the tissue protective cytokine receptor complex and is absent when a compound with such an effect is incorporated into the assay, then a negative readout may indicate that a compound with the desired effect has 5 been identified.

Any or all of these assays that utilize a tissue protective cytokine receptor complex are capable of being developed into reagent grade or kit format for commercialization as research and/or clinical products.

### 5.2.1 Cell-Free Assays

10 The tissue protective cytokine receptor complexes described herein may be used in cell-free assays to identify compounds having a tissue protective activity. In certain embodiments of cell-free assays, the tissue protective cytokine receptor complexes may be free in solution or attached to a solid support. The activity of a tissue protective cytokine receptor complex may be measured in a variety of ways. For 15 example, activity may be the compound's ability to bind a tissue protective cytokine receptor complex or the binding affinity of a tissue protective cytokine receptor complex and a compound. In certain embodiments, the tissue protective cytokine receptor complex is added to binding assays in the form of isolated membranes containing the tissue protective cytokine receptor complex.

20 In one embodiment, the invention provides for a method for identifying a compound that modulates a tissue protective activity comprising contacting a test compound with a tissue protective cytokine receptor complex, by measuring the level of tissue protective cytokine receptor complex activity, identifying a test compound which increases or decreases the level of tissue protective cytokine receptor complex activity as 25 compared to the level of tissue protective cytokine receptor complex activity measured in

the absence of the test compound, and assaying the identified test compound for tissue protective activity.

In a direct binding assay, either the ligand and/or the tissue protective cytokine receptor complex is contacted with a test compound under conditions that allow 5 binding of the test compound to the ligand or the receptor. The binding may take place in solution or on a solid surface. Preferably, the test compound is previously labeled for detection. Any detectable compound may be used for labeling, such as but not limited to, a luminescent, fluorescent, or radioactive isotope or group containing same, or a nonisotopic label, such as an enzyme or dye. After a period of incubation sufficient for 10 binding to take place, the reaction is exposed to conditions and manipulations that remove excess or non-specifically bound test compound. Typically, it involves washing with an appropriate buffer. Finally, the presence of a ligand bound to the test compound (e.g., EPO-test compound) or a the tissue protective cytokine receptor complex bound to the test compound is detected.

15 In a competition binding assay, test compounds are assayed for their ability to disrupt or enhance the binding of the ligand (e.g., EPO) to the tissue protective cytokine receptor complex. Labeled ligand (e.g., EPO or carbamylated EPO) may be mixed with the tissue protective cytokine receptor complex or a fragment thereof, and placed under conditions in which the interaction between them would normally occur, 20 with and without the addition of the test compound. The amount of labeled ligand (e.g., EPO) that binds the tissue protective cytokine receptor complex may be compared to the amount bound in the presence or absence of test compound.

In a preferred embodiment, to facilitate complex formation and detection, the binding assay is carried out with one or more components immobilized on a solid 25 surface. In various embodiments, the solid support could be, but is not restricted to,

polycarbonate, polystyrene, polypropylene, polyethylene, glass, nitrocellulose, dextran, nylon, polyacrylamide and agarose. The support configuration can include beads, membranes, microparticles, the interior surface of a reaction vessel such as a microtiter plate, test tube or other reaction vessel. The immobilization of the tissue protective cytokine receptor complex, or other component, can be achieved through covalent or non-covalent attachments. In one embodiment, the attachment may be indirect, *i.e.* through an attached antibody. In another embodiment, the tissue protective cytokine receptor complex and negative controls are tagged with an epitope, such as glutathione S-transferase (GST) so that the attachment to the solid surface can be mediated by a commercially available antibody such as anti-GST (Santa Cruz Biotechnology).

For example, such an affinity binding assay may be performed using a tissue protective cytokine receptor complex which is immobilized to a solid support. Typically, the non-mobilized component of the binding reaction, in this case either ligand (*e.g.*, EPO or carbamylated EPO) or the test compound, is labeled to enable detection. A variety of labeling methods are available and may be used, such as luminescent, chromophore, fluorescent, or radioactive isotope or group containing same, and nonisotopic labels, such as enzymes or dyes. In a preferred embodiment, the test compound is labeled with a fluorophore such as fluorescein isothiocyanate (FITC, available from Sigma Chemicals, St. Louis).

The labeled test compounds, or ligand (*e.g.*, EPO or carbamylated EPO) plus test compounds, are then allowed to contact with the solid support, under conditions that allow specific binding to occur. After the binding reaction has taken place, unbound and non-specifically bound test compounds are separated by means of washing the surface. Attachment of the binding partner to the solid phase can be accomplished in various ways known to those skilled in the art, including but not limited to chemical

cross-linking, non-specific adhesion to a plastic surface, interaction with an antibody attached to the solid phase, interaction between a ligand attached to the binding partner (such as biotin) and a ligand-binding protein (such as avidin or streptavidin) attached to the solid phase, and so on.

5           Preferably, the tissue protective cytokine receptor complex is added to binding assays in the form of intact cells that express the tissue protective cytokine receptor complex (see assays described in the sections 5.2.2 ), or isolated membranes containing the tissue protective cytokine receptor complex. Thus, direct binding to the tissue protective cytokine receptor complex or the ability of a test compound to modulate 10 a ligand-tissue protective cytokine receptor complex (e.g., EPO-tissue protective cytokine receptor complex) may be assayed in intact cells in culture or in animal models in the presence and absence of the test compound. A labeled ligand (e.g., EPO or carbamylated EPO) may be mixed with crude extracts obtained from such cells, and the test compound may be added. Isolated membranes may be used to identify compounds 15 that interact with the tissue protective cytokine receptor complex. For example, in a typical experiment using isolated membranes, cells may be genetically engineered to express the tissue protective cytokine receptor complex. Membranes can be harvested by standard techniques and used in an *in vitro* binding assay. Labeled ligand (e.g., <sup>125</sup>I-labeled EPO) is bound to the membranes and assayed for specific activity; specific 20 binding is determined by comparison with binding assays performed in the presence of excess unlabeled (cold) ligand.

The soluble tissue protective cytokine receptor complex ligand may also be recombinantly expressed and utilized in non-cell based assays to identify compounds that bind to the tissue protective cytokine receptor complex ligand. Alternatively, a 25 ligand binding domain of the recombinantly expressed tissue protective cytokine

receptor complex, or a fragment of the tissue protective cytokine receptor complex, can be used in the non-cell based screening assays. In another alternative embodiment, peptides corresponding to one or more of the binding domains of the tissue protective cytokine receptor complex, or fusion proteins containing one or more of the binding 5 domains of the tissue protective cytokine receptor complex can be used in non-cell based assay systems to identify compounds that bind to the cytoplasmic portion of the tissue protective cytokine receptor complex; such compounds may be useful to modulate a signal transduction pathway of the tissue protective cytokine receptor complex. In non-cell based assays the recombinantly expressed tissue protective cytokine receptor 10 complex is attached to a solid substrate such as a test tube, microtiter well or a column, by means well known to those in the art (see Ausubel *et al.*, 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY). The test compounds are then assayed for their ability to bind to the tissue protective cytokine receptor complex.

Alternatively, the binding reaction may be carried out in solution. In this 15 assay, the labeled component is allowed to interact with its binding partner(s) in solution. If the size differences between the labeled component and its binding partner(s) permit such a separation, the separation can be achieved by passing the products of the binding reaction through an ultrafilter whose pores allow passage of unbound labeled component but not of its binding partner(s) or of labeled component bound to its partner(s). 20 Separation can also be achieved using any reagent capable of capturing a binding partner of the labeled component from solution, such as an antibody against the binding partner, a ligand-binding protein which can interact with a ligand previously attached to the binding partner, and so on.

In one embodiment, for example, a phage library can be screened by 25 passing phage from a continuous phage display library through a column containing

purified tissue protective cytokine receptor complex, or a fragment, or domain, thereof, linked to a solid phase, such as plastic beads. By altering the stringency of the washing buffer, it is possible to enrich for phage that express peptides with high affinity for the tissue protective cytokine receptor complex. Phage isolated from the column can be 5 cloned and the affinities of the short peptides can be measured directly. Sequences for more than one oligonucleotide can be combined to test for even higher affinity binding to the tissue protective cytokine receptor complex or its complex with its ligand. Knowing which amino acid sequences confer the strongest binding to the tissue protective cytokine receptor complex, computer models can be used to identify the molecular 10 contacts between the tissue protective cytokine receptor complex and the test compound. This will allow the design of non-protein compounds which mimic those contacts. Such a compound may have the same activity of the peptide and can be used therapeutically, having the advantage of being efficient and less costly to produce.

In another specific embodiment of this aspect of the invention, the solid 15 support is membranes containing the tissue protective cytokine receptor complex attached to a microtiter dish. Test compounds, for example, cells that express library members, are cultivated under conditions that allow expression of the library members in the microtiter dish. Library members that bind to the protein (or nucleic acid or derivative) are harvested. Such methods, are described by way of example in Parmley 20 and Smith, 1988, Gene 73:305-318; Fowlkes *et al.*, 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited hereinabove.

Finally, the label remaining on the solid surface may be detected by any detection method known in the art. For example, if the test compound is labeled with a fluorophore, a fluorimeter may be used to detect complexes.

Various *in vitro* assays can be used to identify and verify the ability of a compound to bind a tissue protective cytokine receptor complex, to modulate the interaction of a tissue protective cytokine receptor complex and a tissue protective cytokine receptor complex ligand, or modulate the activity of a tissue protective cytokine receptor complex.

In another embodiment of the present invention, interactions between the tissue protective cytokine receptor complex or ligand (e.g., EPO or carbamylated EPO) and a test compound may be assayed *in vitro*. Known or unknown molecules are assayed for specific binding to the tissue protective cytokine receptor complex, or 10 fragments thereof, under conditions conducive to binding, and then molecules that specifically bind to the tissue protective cytokine receptor complex are identified. The two components can be measured in a variety of ways. One approach is to label one of the components with an easily detectable label, place it together with a test component(s) under conditions that allow binding to occur, perform a separation step which separates 15 bound labeled component from unbound labeled component, and then measure the amount of bound component. In one embodiment, the tissue protective cytokine receptor complex can be labeled and added to a test agent, using conditions that allow binding to occur. Binding of the test agent can be determined using polyacrylamide gel analysis to compare complexes formed in the presence and absence of the test agent.

20 Multiple *in vitro* assays can be performed simultaneously or sequentially to assess the effect of a compound on a tissue protective cytokine receptor complex-mediated process. The assessment can be made by measuring or detecting tissue protective cytokine receptor complex activity, for example, binding of a test compound to a tissue protective cytokine receptor complex, cell proliferation, cell differentiation, 25 and upregulation of a protective protein, e.g., globin. In a preferred embodiment, the *in*

*vitro* assays described herein are performed in a high throughput format (e.g., in microtiter plates).

### 5.2.2 Cell-Based Assays

A tissue protective cytokine receptor complex may be expressed in a 5 cultured cell, and the cell can then be used to screen for ligands for the receptor complex, including the natural ligand, as well as agonists and antagonists of the natural ligand.

To summarize the approach to the cell-based assay, a cDNA or gene encoding the receptor is combined with other genetic elements required for its expression (e.g., a transcription promoter), and the resulting expression vector is inserted into a host 10 cell. A vector encoding an EPO receptor or a  $\beta$  common receptor may be synthesized and used to transform or transfect a host cell with the vector of interest for use in the methods of the invention. The use of stable transformants is preferred.

Cells that express the DNA and produce functional receptor are selected and used with one of a variety of possible screening systems, as further disclosed below.

15 An example of a cell-based method for identifying a compound that modulates the interaction of a tissue protective cytokine receptor complex and a ligand thereof comprises the following steps: (a) contacting a test compound with the ligand and an tissue protective cytokine receptor complex-expressing cell; and (b) measuring the level of tissue protective cytokine receptor complex activity in the cell, such that if the 20 level of activity measured in (b) differs from the level of tissue protective cytokine receptor complex activity in the absence of the test compound, then a compound that modulates the interaction of a tissue protective cytokine receptor complex and its ligand is identified.

Another example for a method for identifying a compound that modulates 25 a tissue protective activity comprises contacting a test compound with a cell which is

recombinantly engineered to express a EPO receptor or a  $\beta$  common receptor, wherein said cell is transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a  $\beta$  common receptor or a EPO receptor polypeptide, measuring the level of tissue protective cytokine receptor complex activity

5 in the cell, identifying a test compound that increases or decreases the level of tissue protective cytokine receptor complex activity in the cell relative to the level of tissue protective cytokine receptor complex activity measured in a control cell, wherein the control cell is of the same cell type as the cell contacted with the test compound and is not transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably

10 linked to a promoter, and (ii) encodes a  $\beta$  common receptor or a EPO receptor polypeptide, and assaying the identified test compound for a tissue protective activity.

Alternatively, cell-based assays may be used to identify compounds that interact with a tissue protective cytokine receptor complex. For example, a test compound can be contacted with a tissue protective cytokine receptor complex-

15 expressing cell and the activity of the tissue protective cytokine receptor complex, as measured by binding affinity, cell proliferation, or the presence of a reporter gene transcript, can be determined. If the activity of the tissue protective cytokine receptor complex differs, e.g., is increased or decrease, in comparison to the activity of tissue protective cytokine receptor complex in the absence of the test compound, then a

20 compound that interacts with a tissue protective cytokine receptor complex is identified.

In certain embodiments of the methods of the invention described herein above where tissue protective cytokine receptor complex activity is measured, such activity is measured by cell proliferation or cell differentiation.

In certain embodiments of the methods of the invention described herein

25 above where tissue protective cytokine receptor complex activity is measured, such

activity measured is the ability of the tissue protective cytokine receptor complex to interact with a tissue protective cytokine receptor complex ligand.

Cell-based screening assays are useful for detecting both agonist and antagonist ligands. Agonists (including the natural ligand) and antagonists have 5 enormous potential in both *in vitro* and *in vivo* applications. Compounds identified as receptor agonists are useful for stimulating proliferation and development of target cells *in vitro* and *in vivo*. For example, agonist compounds are useful as components of defined cell culture media, and may be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture. Agonists may be 10 useful in specifically promoting the growth and/or development of EPO-responsive cells (including, but not limited to, nervous, heart, and retinal derived cells) in culture. Antagonists are useful as research reagents for characterizing sites of ligand-receptor interaction. *In vivo*, receptor agonists or antagonists may find application in the treatment of neural, heart and/or retinal diseases. A variety of suitable assays are known 15 in the art. These assays may be based on the detection of a biological response in a target cell.

In one embodiment, binding of ligand (*e.g.*, EPO or carbamylated EPO) to the tissue protective cytokine receptor complex may be assayed in intact cells in animal models. A labeled ligand (*e.g.*, EPO or carbamylated EPO) may be administered directly 20 to an animal, with and without a test compound. A downstream effect of the ligand (*e.g.*, EPO or carbamylated EPO) binding the tissue protective cytokine receptor complex, *e.g.*, tissue protection or cell proliferation, may be measured in the presence and the absence of test compound. For these assays, host cells to which the test compound is added may be genetically engineered to express the tissue protective cytokine receptor complex 25 and/or ligand (*e.g.*, EPO or carbamylated EPO), which may be transient, induced or

constitutive, or stable. For the purposes of the screening methods of the present invention, a wide variety of host cells may be used including, but not limited to, tissue culture cells, mammalian cells, and yeast cells. Mammalian cells such as brain cells or other cells that express the tissue protective cytokine receptor complex may be a 5 preferred cell type in which to carry out the assays of the present invention.

#### 5.2.2.1 Cells

In a preferred embodiment, the cell used in the methods of the invention is a mammalian cell. In a more preferred embodiment, the host cell is a human cell. In another embodiment, the host cells are primary cells isolated from a tissue or other 10 biological sample of interest. One skilled in the art would realize that different cell types can be used in the methods of the invention for screening or identify compounds. Cell types used may endogenously express an EPO receptor, a  $\beta$  common receptor, both an EPO receptor and a  $\beta$  common receptor, or no EPO receptor or  $\beta$  common receptor. In a preferred embodiment the host cell is derived from an excitable tissue. In a preferred 15 embodiment the host cell is derived from an excitable neuronal tissue.

By way of non-limiting examples, a responsive or excitable cells may be neuronal, retinal, muscle, heart, lung, liver, kidney, small intestine, adrenal cortex, adrenal medulla, capillary endothelial, testes, ovary, pancreas, bone, skin, or endometrial cells or tissue. Further, non-limiting examples of responsive or excitable cells include 20 photoreceptor (rods and cones), ganglion, bipolar, horizontal, amacrine, Müller, Purkinje, myocardium, pace maker, sinoatrial node, sinus node, junction tissue, atrioventricular node, bundle of His, hepatocytes, stellate, Kupffer, mesangial, renal epithelial, tubular interstitial, goblet, intestinal gland (crypts), enteral endocrine, glomerulosa, fasciculate, reticularis, chromaffin, pericyte, Leydig, Sertoli, sperm, 25 Graffian follicle, primordial follicle, islets of Langerhans,  $\alpha$ -cells,  $\beta$ -cells,  $\gamma$ -cells, F-cells,

osteoprogenitor, osteoclasts, osteoblasts, endometrial stroma, endometrial, stem and endothelial cells.

Mammalian cells suitable for use in expressing the tissue protective cytokine receptor complex and transducing a receptor-mediated signal include cells that 5 express at least one of the receptor subunits used to form the functional tissue protective receptor complex. These subunits may include those of the class I cytokine receptors. In certain embodiments of the invention, it is also preferred to use a cell from the same species as the receptor to be expressed. Within a preferred embodiment, the cell is dependent upon an exogenously supplied hematopoietic growth factor for its 10 proliferation. In certain preferred embodiments, cell lines of this type are the human TF-1 cell line (ATCC number CRL-2003) and the AML-193 cell line (ATCC number CRL-9589), which are GM-CSF-dependent human leukemic cell lines. In an alternative embodiment, suitable host cells can be engineered to produce the necessary receptor subunit or other cellular component needed for the desired cellular response. For 15 example, the murine cell line BaF3 (Palacios and Steinmetz, 1985, Cell 41:727-734; Mathey-Prevot *et al.*, 1986, Mol. Cell. Biol. 6:4133-4135) or a baby hamster kidney (BHK) cell line can be transfected to express the necessary EPO-R and  $\beta_c$  receptor. The latter approach is advantageous because cell lines can be engineered to express receptor subunits from any species, thereby overcoming potential limitations arising from species 20 specificity. In the alternative, species orthologs of the human receptor cDNA can be cloned and used within cell lines from the same species, such as a mouse cDNA in the BaF3 cell line. Cell lines that are dependent upon one hematopoietic growth factor, such as GM-CSF, can thus be engineered to become dependent upon a tissue protective receptor complex ligand.

Similarly, it will be appreciated by one of ordinary skill in the art that the above assay can be performed in other cell lines that may be transformed in a similar manner. Furthermore, cell proliferation assays may be performed in cells known to harbor both EPO and  $\beta_c$  Receptor. Such cells would preferably include neuronal cell lines including, but not limited to, P-19, PC-12, and astrocytes or other cell lines known to be EPO-responsive including, but not limited to, retinal and heart cells. The presence of both EPO and  $\beta_c$  Receptors in these cell lines can be confirmed using immunoprecipitation methods well known to those of ordinary skill in the art.

5 lines including, but not limited to, P-19, PC-12, and astrocytes or other cell lines known to be EPO-responsive including, but not limited to, retinal and heart cells. The presence of both EPO and  $\beta_c$  Receptors in these cell lines can be confirmed using immunoprecipitation methods well known to those of ordinary skill in the art.

Other host cells that can be used to recombinantly produce tissue protective cytokine receptor complex or used in the screening methods of the present invention include, but are not limited to, hybridomas, pre-B cells, 293 cells, 293T cells, HeLa cells, HepG2 cells, K562 cells, 3T3 cells. In a preferred embodiment, the host cells are immortalized cell lines derived from a source, *e.g.*, a tissue. Still other host cells that can be used in the present invention include, but are not limited to, yeast cells, 10 virally-infected cells, bacteria cells, insect cells, or plant cells.

15

Preferred mammalian host cells include but are not limited to those derived from humans, monkeys and rodents (see, for example, Kriegler M. in "Gene Transfer and Expression: A Laboratory Manual", New York, Freeman & Co. 1990), such as monkey kidney cell line transformed by SV40 (COS-7, ATCC Accession No. CRL 20 1651); human embryonic kidney cell lines (293, 293-EBNA, or 293 cells subcloned for growth in suspension culture, Graham *et al.*, 1977, J. Gen. Virol., 36:59; baby hamster kidney cells (BHK, ATCC Accession No. CCL 10); chinese hamster ovary-cells-DHFR (CHO, Urlaub and Chasin, 1980, Proc. Natl. Acad. Sci. 77; 4216); mouse sertoli cells (Mather, 1980, Biol. Reprod. 23:243-251); mouse fibroblast cells (NIH-3T3), monkey kidney cells (CVI ATCC Accession No. CCL 70); african green monkey kidney cells

(VERO-76, ATCC Accession No. CRL-1587); human cervical carcinoma cells (HELA, ATCC Accession No. CCL 2); canine kidney cells (MDCK, ATCC Accession No. CCL 34); buffalo rat liver cells (BRL 3A, ATCC Accession No. CRL 1442); human lung cells (W138, ATCC Accession No. CCL 75); human liver cells (Hep G2, HB 8065); and

5 mouse mammary tumor cells (MMT 060562, ATCC Accession No. CCL51). Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), BHK (ATCC No. CRL 1632), and BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham *et al.*, J. Gen. Virol. 36:59-72, 1977) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type

10 Culture Collection, Manassas, Va.

Other useful eukaryotic host-vector system may include yeast and insect systems. In yeast, a number of vectors containing constitutive or inducible promoters may be used with *Saccharomyces cerevisiae* (baker's yeast), *Schizosaccharomyces pombe* (fission yeast), *Pichia pastoris*, and *Hansenula polymorpha* (methylotropic yeasts). For a review see, Current Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel *et al.*, Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant *et al.*, 1987, Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp. 516-544; Glover, 1986, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous Gene Expression 15 in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular Biology of the Yeast *Saccharomyces*, 1982, Eds. Strathern *et al.*, Cold Spring Harbor Press, Vols. I and II.

Fungal cells, including yeast cells, and particularly cells of the genus *Saccharomyces*, can also be used within the present invention, such as for producing 25 receptor polypeptides, receptor fragments, polypeptide fusions, or complexes and for

cell-based assays for identifying compounds which modulate tissue protective cytokine activity. Methods for transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki *et al.*, U.S. Patent No. 4,931,373; Brake, U.S. Patent 5 No. 4,870,008; Welch *et al.*, U.S. Patent No. 5,037,743; and Murray *et al.*, U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki *et al.* (U.S. Patent No. 4,931,373), which allows 10 transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman *et al.*, U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patent Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation 15 systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guillermondii* and *Candida maltosa* are also available for use in the present invention (See, for example, Gleeson *et al.*, 1986, *J. Gen. Microbiol.* 132:3459-3465, and Cregg, U.S. Patent No. 4,882,279). *Aspergillus* cells may be 20 utilized according to the methods of McKnight *et al.*, U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino *et al.*, U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

Standard methods of introducing a nucleic acid sequence of interest into 25 host cells can be used. Transformation may be by any known method for introducing

polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus and transducing a host cell with the virus, and by direct uptake of the polynucleotide. The transformation procedure used depends upon the host to be transformed. Mammalian cell transformations (*i.e.*, transfections) by direct uptake may 5 be conducted using the calcium phosphate precipitation method of Graham & Van der Eb, 1978, *Virol.* 52:546, or the various known modifications thereof. Other methods for introducing recombinant polynucleotides into cells, particularly into mammalian cells, include dextran-mediated transfection, calcium phosphate mediated transfection, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the 10 polynucleotide(s) in liposomes, and direct microinjection of the polynucleotides into nuclei. Such methods are well-known to one of skill in the art.

Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA grown in culture, and include fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular 15 organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, and Ausubel *et al.*, eds., *Current Protocols in Molecular 20 Biology*, John Wiley and Sons, Inc., NY, 1987.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also 25 contain such components as growth factors or serum, as required.

Cultured mammalian cells are preferred hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler *et al.*, 1978, *Cell* 14:725; Corsaro and Pearson, 1981, *Somatic Cell Genetics* 7:603; Graham and Van der Eb, 1973, *Virology* 52:456), electroporation (Neumann *et al.*, 1982, *EMBO J.* 1:841-845,), DEAE-dextran mediated transfection (Ausubel *et al.*, eds., *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987), and liposome-mediated transfection (Hawley-Nelson *et al.*, 1993, *Focus* 15:73; Ciccarone *et al.*, 1993, *Focus* 15:80). The production of recombinant polypeptides, including polypeptides which are components of the receptor complex of the invention, in cultured mammalian cells is disclosed, for example, by Levinson *et al.*, U.S. Patent No. 4,713,339; Hagen *et al.*, U.S. Patent No. 4,784,950; Palmiter *et al.*, U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. (See, e.g., U.S. Patent No. 4,956,288). Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.

In a preferred embodiment, stable cell lines containing the constructs of interest are generated for high throughput screening. Such stable cell lines may be generated by introducing a construct comprising a selectable marker, allowing the cells to grow for 1-2 days in an enriched medium, and then growing the cells on a selective medium. The selectable marker in the recombinant plasmid confers resistance to the

selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as 5 "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transflectants." A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler *et al.*, 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. 10 Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy *et al.*, 1980, Cell 22:817) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler *et al.*, 1980, Natl. Acad. Sci. USA 77:3567; O'Hare *et al.*, 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance 15 to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre *et al.*, 1984, Gene 30:147) genes. A preferred selectable marker is a gene encoding 20 resistance to the antibiotic neomycin. Selection may be carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transflectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to 25 select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers

resistance to methotrexate. Other drug resistance genes (e.g., multi-drug resistance, puromycin acetyltransferase) can also be used.

In certain embodiments, BaF3, an interleukin-3 dependent pre-B cell line, which possesses the  $\beta_c$  Receptor can be transfected with recombinant EPO-R. The 5 presence of the EPO-R can then be selected by resistance to compounds such as zeocin (at 2 mg/ml) and puromycin (at 2  $\mu$ g/ml).

### 5.2.2.2 BaF3 Cell Assays

BaF3 cell assays may also be used to identify compounds that modulate the activity of a tissue protective cytokine receptor complex.

10 For example, an assay to test for proliferation of BaF3 cells via signaling through the receptor complex can be performed as follows. In a 96 well plate eight 1:2 serial dilutions of growth medium alone (RPMI 1640, 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine), and the small molecule, biologic or chemical compounds of interest. The final volume of each dilution should be about 100  $\mu$ l.

15 The BaF3 parental cell line and BaF3 cells transfected with EPO-R can then be washed three times in growth media (see above), pellets resuspended in growth medium, and cells counted and diluted in growth media to 5,000 cells/100  $\mu$ l. One hundred microliters of diluted cells can then be added to each dilution of samples. The assay plate can then be incubated in a 37° C. incubator for three to four days. A 20  $\mu$ l 20 aliquot of Alomar blue can be added to each well and the plate is incubated overnight at 37° C. The plates are read on the fluorescent plate reader at excitation wavelength of 544 and emission wavelength 590.

If the compound exhibits a tissue protective activity, the BaF3 cells should proliferate when exposed to the small molecule, biologic or chemical compound 25 of interest.

A natural ligand for the tissue protective receptor complex can also be identified by mutagenizing a cell line expressing the receptor complex and culturing it under conditions that select for autocrine growth. (See WIPO publication WO 95/21930). Within a typical procedure, BaF3 cells expressing tissue protective receptor complex and 5 the necessary additional subunits are mutagenized, such as with 2-ethylmethanesulfonate (EMS). The cells are then allowed to recover in the presence of IL-3, then transferred to a culture medium lacking IL-3 and IL-4. Surviving cells are screened for the production of a tissue protective receptor complex ligand, such as by adding soluble receptor to the culture medium or by assaying conditioned media on wild-type BaF3 cells and BaF3 10 cells expressing the receptor.

### **5.2.2.3 Reporter Gene Assays**

In certain embodiments of the invention, cells that are further engineered to express a reporter gene are used in assays to identify compounds with tissue protective activities. The reporter gene is linked to a promoter element that is responsive to the 15 receptor-linked pathway, and the assay detects activation of transcription of the reporter gene.

For example, a reporter gene assay consistent with the methods of the invention may involve testing a compound for modulation of the activity of a tissue protective cytokine receptor complex, wherein the activated complex results in 20 production of a transcription factor in the host cell. The host cell also comprises a SRE promoter element operably linked to a luciferase reporter gene the expression of which is regulated by the transcriptional activator, such that the luciferase gene product is either turned on or off (*i.e.* present or absent, or present in differing amounts) in the cell in response to the presence of a compound that activates the tissue protective cytokine 25 receptor complex.

The invention yet further provides for a method for identifying a compound that modulates a tissue protective activity, comprising contacting a test compound with a tissue protective cytokine receptor complex-expressing cell, wherein said cell is transformed with a nucleic acid comprising a nucleotide sequence that

5 encodes a reporter gene operably linked to a regulatory element associated with a tissue protective cytokine receptor complex activity, identifying a test compound that increases or decreases the level of reporter gene expression relative to the level of reporter gene expression measured in the absence of the test compound, and assaying the identified test compound for a tissue protective activity. In certain embodiments of the methods of the

10 invention, the regulatory element is a serum response element. The invention still further provides for a method of identifying a compound that modulates a tissue protective activity, comprising contacting a test compound with a cell comprising, (i) a nucleic acid sequence comprising a reporter gene operably linked to a binding site specific for a DNA binding domain of a transcriptional activator, (ii) a first fusion protein comprising (A)

15 the DNA binding domain of the transactiptional activator, and (B) a first tissue protective cytokine receptor polypeptide or a fragment thereof, and (iii) a second fusion protein comprising (A) an activation domain of the transactiptional activator and (B) a second tissue protective cytokine receptor, detecting reporter gene expression, such that if the reporter gene expression detected in the presence of the test compound differs relative to

20 the reporter gene expression detected in the absence of the test compound, a compound that modulates a tissue protective activity is identified.

Any reporter gene well-known to one of skill in the art may be used in reporter gene constructs to ascertain the effect of a compound on tissue protective cytokine mediated processes or upregulation of protective globulins. A preferred

25 promoter element in this regard is a serum response element, or SRE (see, e.g., Shaw *et*

*al.*, 1989, Cell 56:563-572,). A preferred form of such reporter gene is a luciferase gene (e.g., firefly luciferase, renilla luciferase, and click beetle luciferase) (de Wet *et al.*, 1987, Mol. Cell. Biol. 7:725,). Expression of the luciferase gene is detected by luminescence using methods known in the art (e.g., Baumgartner *et al.*, 1994, J. Biol. Chem.

5 269:29094-29101; Schenborn and Goiffin, 1993, Promega Notes 41:11). Luciferase activity assay kits are commercially available from, for example, Promega Corp., Madison, Wis. Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like. For example, a bank of cell-conditioned media samples can be assayed on a target cell to 10 identify cells that produce ligand. Positive cells are then used to produce a cDNA library in a mammalian expression vector, which is divided into pools, transfected into host cells, and expressed. Media samples from the transfected cells are then assayed, with subsequent division of pools, re-transfection, subculturing, and re-assay of positive cells to isolate a cloned cDNA encoding the ligand.

15 Examples of reporter genes include, but are not limited to, fluorescent protein (e.g., green fluorescent protein (“GFP”), yellow fluorescent protein, red fluorescent protein, cyan fluorescent protein, and blue fluorescent protein), beta-galactosidase (“beta-gal”), beta-glucuronidase, beta-lactamase, chloramphenicol acetyltransferase (“CAT”), secreted alkaline phosphatase (“SEAP”), horseradish peroxidase (“HRP”) and alkaline phosphatase (“AP”). Alternatively, a reporter gene can 20 also be a protein tag, such as, but not limited to, myc, His, FLAG, or GST, so that nonsense suppression will produce the peptide and the protein can be monitored by an ELISA, a western blot, or any other immunoassay to detect the protein tag. Such methods are well known to one of skill in the art.

The screening methods of the invention also encompass use of other reporter genes. Reporter genes may be obtained and the nucleotide sequence of the elements determined by any method well-known to one of skill in the art. The nucleotide sequence of a reporter gene can be obtained, *e.g.*, from the literature or a 5 database such as GenBank. Alternatively, a polynucleotide encoding a reporter gene may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular reporter gene is not available, but the sequence of the reporter gene is known, a nucleic acid encoding the reporter gene may be chemically synthesized or obtained from a suitable source (*e.g.*, a cDNA library, or a cDNA library 10 generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the reporter gene) by PCR amplification. Once the nucleotide sequence of a reporter gene is determined, the nucleotide sequence of the reporter gene may be manipulated using methods well-known in the art for the manipulation of nucleotide sequences, *e.g.*, recombinant DNA techniques, site directed mutagenesis, PCR, *etc.* (see, 15 for example, the techniques described in Sambrook *et al.*, 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel *et al.*, eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate reporter genes having a different amino acid sequence, for example to create 20 amino acid substitutions, deletions, and/or insertions.

In certain embodiments, the reporter gene assays described above may be carried out in the absence of a tissue protective cytokine receptor complex ligand. In such embodiments, the test compound identified is one that interacts with the tissue protective cytokine receptor complex. In certain other embodiments, the reporter gene 25 assays described above may be carried out in the presence of a tissue protective cytokine

receptor complex ligand, such as EPO. In such embodiments, difference in the level of transcription of the reporter gene in the presence and absence of the test compound may be detected. The level of transcript can then be compared to that in the absence of EPO. If the difference in the level of transcript detected with and without the compound is 5 dependent on the presence of EPO, then a compound that modulates the interaction of a tissue protective cytokine receptor complex and EPO is identified. For example, if the difference in level of transcript detected increases in the presence of a compound, wherein the increase is dependent on the presence of EPO, then an agonist of the interaction between EPO and a tissue protective cytokine receptor complex is identified.

#### 10 5.2.2.4 Yeast Two-Hybrid Assays

The "two-hybrid" system can be used to detect protein-protein interactions in the yeast *Saccharomyces cerevisiae* (Fields and Song, 1989, *Nature* 340:245-246; U.S. Patent No. 5,283,173 by Fields and Song). Because the interactions are screened for in yeast, the inter-molecular protein interactions detected in this system 15 occur under physiological conditions that mimic the conditions in mammalian cells (Chien *et al.*, 1991, *Proc. Natl. Acad. Sci. U.S.A.* 88:9578-9581). This assay utilizes the reconstitution of a transcriptional activator like GAL4 (Johnston, 1987, *Microbiol. Rev.* 51:458-476) through the interaction of two protein domains that have been fused to the two functional units of a transcriptional activator, the DNA-binding domain and the 20 activation domain. This is possible due to the bipartite nature of certain transcription factors like GAL4. Being characterized as bipartite signifies that the DNA-binding and activation functions reside in separate domains and can function in trans (Keegan *et al.*, 1986, *Science* 231:699-704). The reconstitution of the transcriptional activator is monitored by the activation of a reporter gene such as the lacZ gene that is under the 25 control of a promoter that contains a binding site (Upstream Activating Sequence or

UAS) for the DNA-binding domain of the transcriptional activator. This method is most commonly used either to detect an interaction between two known proteins (Fields and Song, 1989, *Nature* 340:245-246) or to identify interacting proteins from a population that would bind to a known protein (Durfee *et al.*, 1993, *Genes Dev.* 7:555-569; Gyuris *et al.*, 1993, *Cell* 75:791-803; Harper *et al.*, 1993, *Cell* 75:805-816; Vojtek *et al.*, 1993, *Cell* 74:205-214). Variations on the methods described herein for yeast two-hybrid assays and other methods for yeast two-hybrid assays are well known to those of skill in the art and can be used in the screening methods of the invention.

Identification of interacting proteins by the improved yeast two hybrid system is based upon the detection of expression of a reporter gene, the transcription of which is dependent upon the reconstitution of a transcriptional regulator by the interaction of two proteins, each fused to one half of the transcriptional regulator. The "bait" (*i.e.*, the tissue protective cytokine receptor complex of the present invention or derivatives or analogs thereof) and "prey" (proteins to be tested for ability to interact with the bait) proteins are expressed as fusion proteins to a DNA binding domain, and to a transcriptional regulatory domain, respectively, or vice versa.

In a specific embodiment, recombinant biological libraries expressing random peptides can be used as the source of prey nucleic acids.

In general, proteins of the bait and prey populations are provided as fusion (chimeric) proteins (preferably by recombinant expression of a chimeric coding sequence) comprising each protein contiguous to a pre-selected sequence. For one population, the pre-selected sequence is a DNA binding domain. The DNA binding domain can be any DNA binding domain, as long as it specifically recognizes a DNA sequence within a promoter. For example, the DNA binding domain is of a transcriptional activator or inhibitor. For the other population, the pre-selected sequence

is an activator or inhibitor domain of a transcriptional activator or inhibitor, respectively. The regulatory domain alone (not as a fusion to a protein sequence) and the DNA-binding domain alone (not as a fusion to a protein sequence) preferably do not detectably interact (so as to avoid false positives in the assay). The assay system further 5 includes a reporter gene operably linked to a promoter that contains a binding site for the DNA binding domain of the transcriptional activator (or inhibitor). Accordingly, in the present method of the present invention, binding of a tissue protective cytokine receptor complex fusion protein to a prey fusion protein leads to reconstitution of a transcriptional activator (or inhibitor) which activates (or inhibits) expression of the reporter gene. The 10 activation (or inhibition) of transcription of the reporter gene occurs intracellularly, *e.g.*, in prokaryotic or eukaryotic cells, preferably in cell culture.

The promoter that is operably linked to the reporter gene nucleotide sequence can be a native or non-native promoter of the nucleotide sequence, and the DNA binding site(s) that are recognized by the DNA binding domain portion of the 15 fusion protein can be native to the promoter (if the promoter normally contains such binding site(s)) or non-native to the promoter. Alternatively, the transcriptional activation binding site of the desired gene(s) can be deleted and replaced with GAL4 binding sites (Bartel *et al.*, 1993, BioTechniques 14:920-924, Chasman *et al.*, 1989, Mol. Cell. Biol. 9:4746-4749).

20 The activation domain and DNA binding domain used in the assay can be from a wide variety of transcriptional activator proteins, as long as these transcriptional activators have separable binding and transcriptional activation domains. For example, the GAL4 protein of *S. cerevisiae* (Ma *et al.*, 1987, Cell 48:847-853), the GCN4 protein of *S. cerevisiae* (Hope & Struhl, 1986, Cell 46:885-894), the ARD1 protein of *S. cerevisiae* (Thukral *et al.*, 1989, Mol. Cell. Biol. 9:2360-2369), and the human estrogen 25

receptor (Kumar *et al.*, 1987, Cell 51:941-951), have separable DNA binding and activation domains. The DNA binding domain and activation domain that are employed in the fusion proteins need not be from the same transcriptional activator. In a specific embodiment, a GAL4 or LEXA DNA binding domain is employed. In another specific embodiment, a GAL4 or herpes simplex virus VP16 (Triezenberg *et al.*, 1988, Genes Dev. 2:730-742) activation domain is employed. In a specific embodiment, amino acids 1-147 of GAL4 (Ma *et al.*, 1987, Cell 48:847-853; Ptashne *et al.*, 1990, Nature 346:329-331) is the DNA binding domain, and amino acids 411-455 of VP16 (Triezenberg *et al.*, 1988, Genes Dev. 2:730-742; Cress *et al.*, 1991, Science 251:87-90) comprise the activation domain.

In a specific embodiment, plasmids encoding the different fusion protein populations can be introduced simultaneously into a single host cell (e.g., a haploid yeast cell) containing one or more reporter genes, by co-transformation, to conduct the assay for protein-protein interactions. Or, preferably, the two fusion protein populations are introduced into a single cell either by mating (e.g., for yeast cells) or cell fusions (e.g., of mammalian cells). In a mating type assay, conjugation of haploid yeast cells of opposite mating type that have been transformed with a binding domain fusion expression construct (preferably a plasmid) and an activation (or inhibitor) domain fusion expression construct (preferably a plasmid), respectively, will deliver both constructs into the same diploid cell. The mating type of a yeast strain may be manipulated by transformation with the HO gene (Herskowitz and Jensen, 1991, Meth. Enzymol. 194:132-146).

In a preferred embodiment, a yeast interaction mating assay is employed using two different types of host cells, strain-type a and alpha of the yeast *Saccharomyces cerevisiae*. The host cell preferably contains at least two reporter genes,

each with one or more binding sites for the DNA-binding domain (e.g., of a transcriptional activator). The activator domain and DNA binding domain are each parts of chimeric proteins formed from the two respective populations of proteins. One strain of host cells, for example the a strain, contains fusions of the library of nucleotide 5 sequences with the DNA-binding domain of a transcriptional activator, such as GAL4. The hybrid proteins expressed in this set of host cells are capable of recognizing the DNA-binding site in the promoter or enhancer region in the reporter gene construct. The second set of yeast host cells, for example, the alpha strain, contains nucleotide sequences encoding fusions of a library of DNA sequences fused to the activation 10 domain of a transcriptional activator.

In a specific embodiment, the present invention provides a method of detecting one or more protein-protein interactions comprising (a) recombinantly expressing in a first population of yeast cells being of a first mating type a first fusion protein containing the sequence of a tissue protective cytokine receptor complex or a 15 fragment thereof and a DNA binding domain, wherein said first population of yeast cells contains a first nucleotide sequence operably linked to a promoter driven by one or more DNA binding sites recognized by said DNA binding domain such that an interaction of said first fusion protein with a second fusion protein, said second fusion protein comprising a transcriptional activation domain, results in increased transcription of said 20 first nucleotide sequence; (b) negatively selecting to eliminate those yeast cells in said first population in which said increased transcription of said first nucleotide sequence occurs in the absence of said second fusion protein; (c) recombinantly expressing in a second population of yeast cells of a second mating type different from said first mating type, a plurality of said second fusion proteins, each second fusion protein comprising a 25 sequence of a fragment, derivative or analog of a protein and an activation domain of a

transcriptional activator, in which the activation domain is the same in each said second fusion protein; (d) mating said first population of yeast cells with said second population of yeast cells to form a third population of diploid yeast cells, wherein said third population of diploid yeast cells contains a second nucleotide sequence operably linked 5 to a promoter driven by a DNA binding site recognized by said DNA binding domain such that an interaction of said first fusion protein with said second fusion protein results in increased transcription of said second nucleotide sequence, in which the first and second nucleotide sequences can be the same or different; and (e) detecting said increased transcription of said first and/or second nucleotide sequence, thereby detecting 10 an interaction between said first fusion protein and said second fusion protein.

In one embodiment, the invention provides for a method of identifying a compound that modulates the activity of a tissue protective cytokine receptor complex, said method comprising contacting a test compound with a cell of a modified yeast strain containing (i) a nucleotide sequence encoding a reporter gene that is operably linked to a 15 tissue protective cytokine receptor complex-responsive promoter and (ii) expresses a tissue protective cytokine receptor complex, and determining the level of activity of a tissue protective cytokine receptor complex by measuring the level of reporter gene expression, such that if the level of reporter gene activity in the presence of the compound increases or decreases relative to the level of reporter gene activity in the 20 absence of the compound, then a compound that modulates the activity of a tissue protective cytokine receptor complex is identified.

The receptor complexes can be used in interaction trap assays (such as, for example, that described in Gyuris *et al.*, 1993, Cell 75:791-803) to identify proteins which bind to a known protein to identify inhibitors of a binding interaction. This 25 system is a modified two-hybrid system, as described above which uses a LEU2 reporter

gene as the first nucleotide sequence and a lacZ reporter gene as the second nucleotide sequence, so that protein-protein interactions that result in the reconstitution of the transcriptional activator system can be selected for in cells lacking leucine and to expression of  $\beta$ -galactosidase. The DNA-binding domain may be the LexA DNA-5 binding domain, while the activator sequence may be obtained from the B42 transcriptional activation domain (Ma and Ptashne, 1987, Cell 51:113-119). The promoters of the reporter genes contain LexA binding sequences and are activated by the reconstitution of a functional transcriptional activator. Another feature of this system is that the gene encoding the DNA-binding domain fusion protein is under the influence of 10 an inducible promoter, such as a GAL promoter, so that confirmatory tests can be performed under inducing and non-inducing conditions.

In a specific embodiment, the present invention provides a method of detecting a compound that modulates the interaction of EPO and a tissue protective cytokine receptor complex. A first population of yeast cells comprising the first fusion 15 protein contain the sequence of a first tissue protective cytokine receptor such as an EPO receptor, and LexA DNA-binding domain. A second population of yeast cells comprise the second fusion protein comprising a B42 transcriptional activation domain fused to the sequence of a second tissue protective cytokine receptor, such as  $\beta$  common. The LEU2 reporter gene and a lacZ reporter gene are operably linked to promoters containing 20 LexA binding sequences, such that an interaction of said first fusion protein with a second fusion protein, results in increased transcription of said reporter genes. The populations of cells comprising the fusion proteins are grown in media lacking leucine, to select. The media contains EPO and the assay is performed in the presence and absence of a test compound. Where the level of transcription differs in the presence of a

test compound, then a compound that modulates the interaction of an EPO and a tissue protective cytokine receptor complex is identified.

Still other versions of the two-hybrid approach exist, for example, a "Contingent Replication Assay" has been reported (Nallur *et al.*, 1993, Nucleic Acids Res. 21:3867-3873; Vasavada *et al.*, 1991, Proc. Natl. Acad. Sci. USA 88:10686-10690).

In this case, the reconstitution of the transcription factor in mammalian cells due to the interaction of the two fusion proteins leads to the activation of transcription of the SV40 T antigen. This antigen allows the replication of the activation domain fusion plasmids.

Another modification of the two-hybrid approach using mammalian cells is the "Karyoplasmic Interaction Selection Strategy" that also uses the reconstitution of a transcriptional activator (Fearon *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:7958-7962).

Reporter genes used in this case have included the gene encoding the bacterial chloramphenicol acetyl transferase, the gene for cell-surface antigen CD4, and the gene encoding resistance to Hygromycin B. In both of the mammalian systems, the transcription factor that is reconstituted is a hybrid transcriptional activator in which the DNA-binding domain is from GAL4 and the activation domain is from VP16. A transcriptional activation system has been described to isolate and catalog possible protein-protein interactions within a population, and allow the comparison of such interactions between two populations (see PCT Publication WO 97/47763 published December 18, 1997).

### 5.2.3 Ligand/Tissue Protective Cytokine Receptor Complex Assays

In the cell-free and cell-based screening methods described herein, ligands of a tissue protective cytokine receptor complex can be used in the assays to identify compounds that modulate the interaction of a tissue protective cytokine receptor complex and its ligands.

In one embodiment, the invention provides for method for identifying a compound that to a tissue protective cytokine receptor complex, comprising contacting a tissue protective cytokine receptor complex with (i) a tissue protective cytokine receptor complex ligand attached to a first label and (ii) an equivalent amount of a test compound 5 attached to a second label under conditions conducive to binding, removing unbound material from the tissue protective cytokine receptor complex, and detecting the level of the first and second labels wherein if the second label is present the compound binds the complex and if the level of the first label decreases relative to the level of the first label where the labeled ligand is contacted with a tissue protective cytokine receptor complex 10 under conditions conducive to binding in the absence of a test compound after removal of unbound material, then a compound that binds to a tissue protective cytokine receptor complex is identified.

In yet another embodiment, the invention provides for method for identifying a compound that modulates the binding of a tissue protective cytokine receptor complex ligand to a tissue protective cytokine receptor complex, comprising 15 contacting a tissue protective cytokine receptor complex ligand with a tissue protective cytokine receptor complex in the presence of one or more test compounds under conditions conducive to binding, and measuring the amount of tissue protective cytokine receptor complex ligand bound to the tissue protective cytokine receptor complex, such 20 that if the amount of bound tissue protective cytokine receptor complex ligand measured in the presence of the one or more test compounds differs from the amount of bound tissue protective cytokine receptor complex ligand measured in the absence of the one or more test compounds, then a compound that modulates the binding of a tissue protective cytokine receptor complex ligand to the tissue protective cytokine receptor complex is 25 identified.

In certain embodiments of the methods of the invention described herein where binding of a tissue protective cytokine receptor complex contacted with a tissue protective cytokine receptor complex ligand is measured, the amount of bound tissue protective cytokine receptor complex ligand is measured using a tissue protective cytokine receptor complex ligand-specific antibody.

In certain embodiments of the methods of the invention described herein above where binding of a tissue protective cytokine receptor complex contacted with a tissue protective cytokine receptor complex ligand is measured, the tissue protective cytokine receptor complex ligand is labeled and binding of the tissue protective cytokine receptor complex ligand to the tissue protective cytokine receptor complex is measured by detecting the label attached to the tissue protective cytokine receptor complex ligand.

In certain embodiments of the methods of the invention described herein above where binding of a tissue protective cytokine receptor complex contacted with a tissue protective cytokine receptor complex ligand is measured, the tissue protective cytokine receptor complex ligand is labeled and binding of the labeled ligand to the tissue protective cytokine receptor complex is measured by detecting the label attached to the tissue protective cytokine receptor complex ligand. In related embodiments, the label is fluorescent.

In one embodiment, the invention provides for a method for identifying a compound that modulates the interaction between a tissue protective cytokine receptor complex and a tissue protective cytokine receptor complex ligand, comprising contacting a tissue protective cytokine receptor complex with one or more test compounds, and measuring the tissue protective cytokine receptor complex activity, such that if the activity measured in the presence of the one or more test compounds differs from the tissue protective cytokine receptor complex activity in the absence of the one or more

test compounds, then a compound that modulates the interaction between the tissue protective cytokine receptor complex and the tissue protective cytokine receptor complex ligand is identified.

In certain embodiments of the methods of the invention described herein, 5 the compound binds the tissue protective cytokine receptor complex. In certain embodiments of the methods of the invention described herein above, the compound binds the tissue protective cytokine receptor complex ligand.

#### **5.2.4 High Throughput Screening Assays**

The cell-based and non-cell based assays described herein can be utilized 10 in a high throughput format to screen libraries of compounds to identify those compounds that modulate a tissue protective cytokine receptor complex activity or modulate the interaction between a tissue protective cytokine receptor complex ligand and a tissue protective cytokine receptor complex. Examples of libraries of compounds that can be used in high throughput screening assays are disclosed in section 5.4 below.

15 High throughput screening using labeled probes can be used to identify compounds that affect the formation of specific functional sites. Functional site profiles may be compared between cells treated with a drug and untreated or control cells to identify drugs and drug candidates. Furthermore, where a specific functional site has been associated with a tissue protective activity, probes specific for such a site may be 20 used to determine the status of the site before and after drug treatment to identify a drug that alters the status of the functional site and would, therefore, be useful in cell, tissue, or organ protective therapy. In certain embodiments, treatment with the drug restores the status of the functional site to that observed in a control sample.

The screening assays of the present invention also encompass high 25 throughput screens and assays to identify modulators tissue protective cytokine receptor

complex activity. In accordance with this embodiment, the systems described below may be formulated into kits. To this end, cells expressing tissue protective cytokine receptor complex, or lysates thereof, can be packaged in a variety of containers, *e.g.*, vials, tubes, microtitre well plates, bottles, and the like. Other reagents can be included 5 in separate containers and provided with the kit; *e.g.*, positive control samples, negative control samples, buffers, cell culture media, etc. The assays of the present invention may be first optimized on a small scale (*i.e.*, in test tubes), and then scaled up for high throughput assays.

10 **5.3 ASSAYS FOR IDENTIFYING COMPOUNDS OR TESTING COMPOUNDS IDENTIFIED IN SCREENING ASSAYS**

**5.3.1 Biological Screens or Assays**

Compounds identified to have an effect on tissue protective cytokine receptor complex activity or compounds found to modulate the interaction between a tissue protective cytokine complex and a ligand may be tested for tissue protective 15 activity, *e.g.*, protecting cells, tissues or organs. A protective activities may be further tested using *in vitro* and *in vivo* assays. *In vitro* tests that are indicative of tissue protective activity include, for example, cell proliferation assays, cell differentiation assays, or detecting the presence of proteins or nucleic acids upregulated by tissue protective cytokine receptor complex activity, *e.g.*, nucleolin, neuroglobin, and 20 cytoglobin. Neuroglobin, for example, may be involved in facilitating the transport or the short-term storage of oxygen. Therefore, oxygen transport or storage assays may be used as an assay to identify or screen for compounds which modulate tissue protective cytokine activity.

Neuroglobin is expressed in cells and tissues of the central nervous 25 system in response to hypoxia or ischemia and may provide protection from injury (Sun

*et al.* 2001, PNAS 98:15306-15311; Schmid *et al.*, 2003, J. Biol. Chem. 276:1932-1935).

Cytoglobin may play a similar role in protection, but is expressed in a variety of tissues at varying levels (Pesce *et al.*, 2002, EMBO 3:1146-1151). In one embodiment of the invention, the levels of an upregulated protein in a cell may be measured before and after 5 contacting the identified test compound to a cell. In certain embodiments, the presence of a upregulated protein associated with tissue protective activity in a cell, may be used to confirm the tissue protective activities of a compound.

Nucleolin may protect cells from damage. It plays numerous roles in cells including modulation of transcription processes, sequence specific RNA-binding protein, 10 cytokinesis, nucleogenesis, signal transduction, apoptosis induced by T-cells, chromatin remodelling, or replication. It can also function as a cell surface receptor DNA/RNA helicase, DNA-dependent ATPase, protein shuttle, transcription factor component, or transcriptional repressor (Srivastava and Pollard, 1999, FASEB J., 13:1911-1922; and Ginisty *et al.*, 1999, J. Cell Sci., 112:761-772).

15 Expression of an upregulated protein may be detected by detecting mRNA levels corresponding to the protein in a cell. The mRNA can be hybridize to a probe that specifically binds a nucleic acid encoding the upregulated protein. Hybridization may consist of, for example, Northern blot, Southern blot, array hybridization, affinity chromatography, or *in situ* hybridization.

20 In another embodiment, rapid and quantitative assay systems for screening test compounds for their ability to activate a tissue protective cytokine receptor complex can be employed. Such assays, as described for example in U.S. Patent no. 5,763,198, detect modulation of tyrosine kinase or phosphatase activities involved in signal transduction by determining the tyrosine phosphorylation state of a protein

substrate using an anti-phosphotyrosine antibody and an antibody specific for the protein substrate. These assays may be practiced in a whole cell or cell-free system.

In another embodiment, the invention provides for a method for contacting a cell that expresses a tissue protective cytokine receptor complex and lysing 5 the cell to determine whether the tissue protective cytokine receptor complex has been phosphorylated. In related embodiments, the tissue protective cytokine receptor complex is precipitated with an anti-EPO receptor antibody and the precipitated complex is labeled with an anti-phosphotyrosine antibody for the  $\beta_c$  receptor.

Animal model systems can be used to demonstrate the tissue protective 10 activity of a compound or to demonstrate the safety and efficacy of the compounds identified by the screening methods of the invention described above. The compounds identified in the assays can then be tested for biological activity using animal models for a type of tissue damage, disease, condition, or syndrome of interest. These include animals engineered to contain the tissue protective cytokine receptor complex coupled to 15 a functional readout system, such as a transgenic mouse.

Animal models that can be used to test the efficacy of the cell or tissue protective activity of an identified compound include, for example, protection against the onset of Acute Experimental Allergic Encephalomyelitis (EAE) in Lewis rats, restoration or protection from diminished cognitive function in mice after receiving brain trauma 20 (Brines *et al.*, 2000, PNAS, 97:10295-10672), and protection from induced retinal ischemia (Rosenbaum *et al.*, 1997, *Vis. Res.* 37:3443-51). Such assays are described in further detail in PCT publication no. WO02/053580, which is incorporated by reference herein in its entirety. The *in vivo* tests described therein are directed towards 25 administration of EPO, however, a test compound that has been identified to have an effect on the activity of a tissue protective cytokine receptor complex could be

administered in place of EPO to test for tissue protective activity. Other assays for determining tissue protective activity of a compound are well known to those of skill in the art.

The assays designed to determine the tissue protective activity of a compound identified can be performed in the presence or absence of a tissue protective cytokine receptor complex ligand depending on whether the compound identified is one that interacts with the tissue protective cytokine receptor complex or modulates the interaction of a tissue protective cytokine receptor complex ligand and a tissue protective cytokine receptor complex.

10 In certain embodiments additional tissue protective cytokine receptor complex ligand is added to the assay to further confirm the modulation activity of a compound on the interaction of a tissue protective cytokine receptor complex ligand and a tissue protective cytokine receptor complex.

### 5.3.2 Cell Binding Assays

15 Alternatively, cell binding assays utilizing the cells disclosed above in section 5.2.2.1 can be utilized as well. For example, BaF3 cells could be transfected with EPO and  $\beta_c$  receptor as discussed above. Additionally, the small molecule, biologic or chemical compound of interest should be bound to a biological marker such as a fluorescent or radiolabeled marker.

20 In a 96 well plate eight 1:2 serial dilutions of growth medium alone (RPMI 1640, 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine), and the small molecule, biologic or chemical compounds of interest. The final volume of each dilution should be about 100  $\mu$ l.

The BaF3 parental cell line and BaF3 cells transfected with EPO-R can 25 then be washed three times in growth media (see above), pellets resuspended in growth

medium, and cells counted and diluted in growth media to 5,000 cells/100  $\mu$ l. One hundred microliters of diluted cells can then be added to each dilution of samples. The assay plate can then be incubated in a 37° C. incubator for three to four days. The cells are then washed and the plate can then be read on a fluorescent plate reader or by other 5 suitable method to detect the biomarker attached to the compound of interest.

Similarly, a competitive assay can be utilized to determine if a compound is tissue protective. In the competitive assay, a compound known to be tissue protective including, but not limited to, tissue protective cytokines such as those disclosed in U.S. Patent Application Nos. 10/188,905 and 10/185,841, can be attached to a suitable bio 10 marker.

In a 96 well plate eight 1:2 serial dilutions of growth medium alone (RPMI 1640, 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine), and the remaining wells have the tissue protective compound/biomarker, the tissue protective compound/biomarker and an excess of the small molecule, biologic, or chemical 15 compound of interest in them. The final volume of each dilution should be about 100  $\mu$ l. Once again, the BaF3 cells are seeded into the plates as disclosed above and allowed to incubate. After an appropriate amount of time, the cells are washed and the plate can then be read on a fluorescent plate reader or by other suitable method to detect the biomarker. If the readout of the plates containing tissue protective compound/biomarker 20 and compound of interest is less than the readout of the plates containing only the tissue protective compound/biomarker then the compound of interest is tissue protective.

### **5.3.3 Cytokine and Cell Proliferation/Differentiation Activity**

A receptor complex of the present invention may be helpful in identifying tissue protective compounds (small molecule, protein, chemical agents) in cytokine, cell 25 proliferation (either inducing or inhibiting) or cell differentiation (either inducing or

inhibiting) assays. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence these assays serve as a convenient confirmation of cytokine activity. The activity of a compound can be evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, 5 DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK. These cells are cultured in the presence or absence of a test compound, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic 10 breakdown of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Mosman, 1983, J. Immunol. Meth. 65:55-63). The activity of a tissue protective cytokine receptor complex may, among other means, be measured by binding of a compound or ligand to the tissue protective cytokine receptor complex, cell proliferation, cell differentiation, upregulation of proteins that have a tissue protective effect, or a 15 tissue protective activity.

#### 5.3.4 Fusion Proteins

A receptor extracellular domain can be expressed as a fusion with immunoglobulin heavy chain constant regions, typically an Fc fragment, which contains two constant region domains and a hinge region but lacks the variable region. Such 20 fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two receptor polypeptides are arrayed in close proximity to each other. In accordance with the present invention, the receptor polypeptides on the fusion should include at least one EPO-R extracellular domain and one  $\beta$  Receptor extracellular domain. Fusions of this type can be used to purify the 25 cognate ligand from solution, as an *in vitro* assay tool, to block signals *in vitro* by

specifically titrating out ligand, and as antagonists *in vivo* by administering them parenterally to bind circulating ligand and clear it from the circulation. To purify ligand, a tissue protective receptor complex chimera is added to a sample containing the ligand (e.g., cell-conditioned culture media or tissue extracts) under conditions that facilitate

5 receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength). The chimera-ligand complex is then separated by the mixture using protein A, which is immobilized on a solid support (e.g., insoluble resin beads). The ligand is then eluted using conventional chemical techniques, such as with a salt or pH gradient. In the alternative, the chimera itself can be bound to a solid support, with binding and elution

10 carried out as above. Chimeras with high binding affinity are administered parenterally (e.g., by intramuscular, subcutaneous or intravenous injection). Circulating molecules bind ligand and are cleared from circulation by normal physiological processes. For use in assays, the chimeras may be bound to a support via the F<sub>c</sub> region and used in an

15 ELISA format.

15 A preferred assay system employing a ligand-binding receptor complex fusion protein or ligand-binding receptor complex fragment uses a commercially available biosensor instrument (BIAcore<sup>TM</sup>, Pharmacia Biosensor, Piscataway, N.J.), wherein the fusion protein is immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, 1991, J. Immunol. Methods 145:229-240, and

20 Cunningham and Wells, 1993, J. Mol. Biol. 234:554-563. A fusion protein is covalently attached, using amine or sulphydryl chemistry, to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If ligand is present in the sample, it will bind to the immobilized fusion protein, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon

25 resonance of the gold film. This system allows the determination of on- and off-rates,

from which binding affinity can be calculated, and assessment of stoichiometry of binding.

Ligand-binding fusion proteins may also be used within other assay systems known in the art. Such systems include Scatchard analysis for determination of 5 binding affinity (*see*, Scatchard, 1949, Ann. NY Acad. Sci. 51:660-672) and calorimetric assays (Cunningham *et al.*, 1991, Science 253:545-548; Cunningham *et al.*, 1991, Science 254:821-825).

A receptor ligand-binding fusion protein can also be used for purification of ligand. The fusion protein is immobilized on a solid support, such as beads of 10 agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use. Methods for linking polypeptides to solid supports are known in the art, and include 15 amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulphydryl activation, and hydrazide activation. The resulting media will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor 20 polypeptide. The ligand is then eluted using changes in salt concentration or pH to disrupt ligand-receptor binding.

### 5.3.5 Other assays

One of ordinary skill in the art will recognize that the receptor complex of 20 the present invention has utility in several well known assays including but not limited to the Ligand-Receptor Assays disclosed in Current Protocols In Immunology, vol. 4, Chapter 18, 2001, John E. Coligan Ed. John Wiley and Sons.

If the compound exhibits a tissue protective activity, one of ordinary skill 25 in the art would recognize that it would be beneficial to verify the result using one of the

neuroprotective and tissue protective assays known to those skilled in the art, such as, but not limited to, P-19, PC-12, TF-1, and UT-7 cell assays. Additionally, various *in vivo* models such as animal models related to spinal cord injury, ischemic stroke, peripheral nerve damage, and the heart and eyes would be helpful in further 5 characterizing the tissue protective compound isolated. Suitable *in vitro* and *in vivo* assays are disclosed in U.S. Patent Application Nos. 10/188,905 and 10/185,841.

#### 5.3.5.1 Assays Using $\beta_c$ (-/-) Knock-out Animals

The invention also relates to the use of host cells and animals genetically engineered to inhibit or “knock-out” expression of the animal’s endogenous  $\beta_c$  receptor 10 and/or express the human  $\beta_c$  receptor (or mutants thereof). Such transgenic animals may be used in methods for identifying neuroprotective pathways and compounds which activate neuroprotective pathways.

Endogenous target gene expression can also be reduced by inactivating or “knocking out” the target gene or its promoter using targeted homologous recombination 15 (e.g., see Smithies et al., 1985, *Nature* 317, 230-234; Thomas & Capecchi, 1987, *Cell* 51, 503-512; Thompson et al., 1989, *Cell* 5, 313-321; each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional target gene (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous target gene (either the coding regions or regulatory regions of the target gene) can be 20 used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the target gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene. Such approaches are particularly suited modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive target gene (e.g., see Thomas & 25 Capecchi, 1987 and Thompson, 1989, *supra*). However this approach can be adapted for

use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors.

Once  $\beta$ c receptor (-/-) knock-out animals have been generated, the expression of the recombinant  $\beta$ c receptor gene may be assayed utilizing standard 5 techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether knock-out of the endogenous gene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques that include but are not limited to Northern blot analysis of tissue samples obtained from the animal, *in situ* 10 hybridization analysis, and RT-PCR (reverse transcriptase PCR). Samples of  $\beta$ c receptor gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the  $\beta$ c receptor transgene product.

In one embodiment of the invention,  $\beta$ c receptor (-/-) knock-out animals are used in assays to identify pathways and/or compounds that involved in a tissue 15 protective activity. For example, normal and  $\beta$ c receptor (-/-) knock-out animals may both be administered an agent or force known to cause tissue damage, *e.g.*, ischemia. Both animals may then be administered a compound and the tissue protective activity of 20 the compound can be determined. Methods for determining a tissue protective activity are well known to those in the art and examples of such methods are disclosed in PCT publication no. WO02/053580, which is incorporated by reference herein in its entirety. If a tissue protective activity is observed in the normal animals but not in the  $\beta$ c receptor (-/-) knock-out animals administered the same compound, then a compound with tissue 25 protective activities dependent on the  $\beta$ c receptor is identified. Further investigation into the identified  $\beta$ c receptor dependent tissue protective pathway may consist of determining if the compound binds to the  $\beta$ c receptor or complexes thereof, or

identifying proteins or mRNA transcripts present only in the animals exhibiting the tissue protective activity. Applicants hypothesize that secondary or redundant pathways for tissue protection may be present and that  $\beta$ c receptor (-/-) knock-out animals could be used to investigate such pathways.

5

#### 5.4 COMPOUNDS

The methods of the invention for screening and identifying compounds may utilize numerous types of compounds including, but not limited to, small molecules, organic molecules, non-organic molecules, peptides, polypeptides, peptide analogs 10 including peptides comprising non-naturally occurring amino acids, *e.g.*, D-amino acids, phosphorous analogs of amino acids, such as D-amino phosphoric acids and D-amino phosphoric acids, or amino acids having non-peptide linkages, nucleic acid analogs such as phosphorothioates and PNAs.

Compounds that can be tested and identified methods described herein 15 can include, but are not limited to, compounds obtained from any commercial source, including Aldrich (Milwaukee, WI 53233), Sigma Chemical (St. Louis, MO), Fluka Chemie AG (Buchs, Switzerland) Fluka Chemical Corp. (Ronkonkoma, NY), Eastman Chemical Company, Fine Chemicals (Kingsport, TN), Boehringer Mannheim GmbH (Mannheim, Germany), Takasago (Rockleigh, NJ), SST Corporation (Clifton, NJ), Ferro 20 (Zachary, LA 70791), Riedel-deHaen Aktiengesellschaft (Seelze, Germany), PPG Industries Inc., Fine Chemicals (Pittsburgh, PA 15272). Further any kind of natural products may be screened using the methods of the invention, including microbial, fungal, plant or animal extracts.

Libraries of polypeptides or proteins can also be used in the assays of the 25 invention. For example, the test compound may be a small molecule, an organic

molecule, a non-organic molecule, or a peptide. Examples of libraries of such compounds that can be screened in accordance with the methods of the invention include, but are not limited to, peptoids; random biooligomers; diversomers such as hydantoins, benzodiazepines and dipeptides; vinylogous polypeptides; nonpeptidal 5 peptidomimetics; oligocarbamates; peptidyl phosphonates; peptide nucleic acid libraries; antibody libraries; carbohydrate libraries; and small molecule libraries (small organic or non-organic molecule libraries). Examples of such libraries include, but are not limited to, random peptide libraries; (see, *e.g.*, Lam *et al.*, 1991, *Nature* 354:82-84; Houghten *et al.*, 1991, *Nature* 354:84-86), and combinatorial chemistry-derived molecular library 10 made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, *e.g.*, Songyang *et al.*, 1993, *Cell* 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain 15 antibodies, and FAb, F(ab')<sub>2</sub> and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

In one embodiment of the present invention, peptide libraries may be used as a source of test compounds that can be used to screen for modulators of tissue protective cytokine receptor complex interactions, such as EPO-tissue protective cytokine receptor complex. Diversity libraries, such as random or combinatorial peptide 20 or nonpeptide libraries can be screened for molecules that specifically bind to the tissue protective cytokine receptor complex. Many libraries are known in the art that can be used, *e.g.*, chemically synthesized libraries, recombinant (*e.g.*, phage display libraries), and *in vitro* translation-based libraries.

Examples of chemically synthesized libraries are described in Fodor *et al.*, 1991, *Science* 251:767-773; Houghten *et al.*, 1991, *Nature* 354:84-86; Lam *et al.*,

1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop *et al.*, 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten *et al.*, 1992, *Biotechniques* 13:412; Jayawickreme *et al.*,

5 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

Examples of phage display libraries are described in Scott & Smith, 1990, *Science* 249:386-390; Devlin *et al.*, 1990, *Science*, 249:404-406; Christian *et al.*, 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay *et al.*, 10 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

By way of examples of nonpeptide libraries, a benzodiazepine library (see *e.g.*, Bunin *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:4708-4712) can be adapted for use. Peptoid libraries (Simon *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:9367-9371) 15 can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh *et al.* (1994, *Proc. Natl. Acad. Sci. USA* 91:11138-11142).

Screening the libraries can be accomplished by any of a variety of 20 commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries: Parmley & Smith, 1989, *Adv. Exp. Med. Biol.* 251:215-218; Scott & Smith, 1990, *Science* 249:386-390; Fowlkes *et al.*, 1992; *BioTechniques* 13:422-427; Oldenburg *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu *et al.*, 1994, *Cell* 76:933-945; Staudt *et al.*, 1988, *Science* 241:577-580; Bock *et al.*, 1992, *Nature* 25 355:564-566; Tuerk *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington *et*

*al.*, 1992, *Nature* 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner *et al.*; Rebar & Pabo, 1993, *Science* 263:671-673; and PCT Publication No. WO 94/18318.

In a preferred embodiment, the combinatorial libraries are small organic molecule libraries, such as, but not limited to, benzodiazepines, isoprenoids, thiazolidinones, metathiazanones, pyrrolidines, morpholino compounds, and benzodiazepines. In another embodiment, the combinatorial libraries comprise peptoids; random bio-oligomers; benzodiazepines; diversomers such as hydantoins, benzodiazepines and dipeptides; vinylogous polypeptides; nonpeptidal peptidomimetics; oligocarbamates; peptidyl phosphonates; peptide nucleic acid libraries; antibody libraries; or carbohydrate libraries. Combinatorial libraries are themselves commercially available (see, *e.g.*, ComGenex, Princeton, New Jersey; Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Missouri; ChemStar, Ltd, Moscow, Russia; 3D Pharmaceuticals, Exton, Pennsylvania; Martek Biosciences, Columbia, Maryland; *etc.*).

15 In a preferred embodiment, the library is preselected so that the compounds of the library are more amenable for cellular uptake. For example, compounds are selected based on specific parameters such as, but not limited to, size, lipophilicity, hydrophilicity, and hydrogen bonding, which enhance the likelihood of compounds getting into the cells. In another embodiment, the compounds are analyzed 20 by three-dimensional or four-dimensional computer computation programs.

In one embodiment, the combinatorial compound library for the methods of the present invention may be synthesized. There is a great interest in synthetic methods directed toward the creation of large collections of small organic compounds, or libraries, which could be screened for pharmacological, biological or other activity. The 25 synthetic methods applied to create vast combinatorial libraries are performed in solution

or in the solid phase, *i.e.*, on a solid support. Solid-phase synthesis makes it easier to conduct multi-step reactions and to drive reactions to completion with high yields because excess reagents can be easily added and washed away after each reaction step. Solid-phase combinatorial synthesis also tends to improve isolation, purification and 5 screening. However, the more traditional solution phase chemistry supports a wider variety of organic reactions than solid-phase chemistry.

Combinatorial compound libraries of the present invention may be synthesized using the apparatus described in U.S. Patent No. 6,190,619 to Kilcoin *et al.*, which is hereby incorporated by reference in its entirety. U.S. Patent No. 6,190,619 10 discloses a synthesis apparatus capable of holding a plurality of reaction vessels for parallel synthesis of multiple discrete compounds or for combinatorial libraries of compounds.

In one embodiment, the combinatorial compound library can be synthesized in solution. The method disclosed in U.S. Patent No. 6,194,612 to Boger *et 15 al.*, which is hereby incorporated by reference in its entirety, features compounds useful as templates for solution phase synthesis of combinatorial libraries. The template is designed to permit reaction products to be easily purified from unreacted reactants using liquid/liquid or solid/liquid extractions. The compounds produced by combinatorial synthesis using the template will preferably be small organic molecules. Some 20 compounds in the library may mimic the effects of non-peptides or peptides. In contrast to solid phase synthesis of combinatorial compound libraries, liquid phase synthesis does not require the use of specialized protocols for monitoring the individual steps of a multistep solid phase synthesis (Egner *et al.*, 1995, J.Org. Chem. 60:2652; Anderson *et 25 al.*, 1995, J. Org. Chem. 60:2650; Fitch *et al.*, 1994, J. Org. Chem. 59:7955; Look *et al.*, 1994, J. Org. Chem. 49:7588; Metzger *et al.*, 1993, Angew. Chem., Int. Ed. Engl.

32:894; Youngquist *et al.*, 1994, *Rapid Commun. Mass Spect.* 8:77; Chu *et al.*, 1995, *J. Am. Chem. Soc.* 117:5419; Brummel *et al.*, 1994, *Science* 264:399; Stevanovic *et al.*, 1993, *Bioorg. Med. Chem. Lett.* 3:431).

Combinatorial compound libraries useful for the methods of the present  
5 invention can be synthesized on solid supports. In one embodiment, a split synthesis  
method, a protocol of separating and mixing solid supports during the synthesis, is used  
to synthesize a library of compounds on solid supports (see *e.g.*, Lam *et al.*, 1997, *Chem.*  
Rev.

97:41-448; Ohlmeyer *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926 and  
references cited therein). Each solid support in the final library has substantially one  
10 type of compound attached to its surface. Other methods for synthesizing combinatorial  
libraries on solid supports, wherein one product is attached to each support, will be  
known to those of skill in the art (see, *e.g.*, Nefzi *et al.*, 1997, *Chem. Rev.* 97:449-472).

As used herein, the term “solid support” is not limited to a specific type of  
solid support. Rather a large number of supports are available and are known to one  
15 skilled in the art. Solid supports include silica gels, resins, derivatized plastic films,  
glass beads, cotton, plastic beads, polystyrene beads, alumina gels, and polysaccharides.  
A suitable solid support may be selected on the basis of desired end use and suitability  
for various synthetic protocols. For example, for peptide synthesis, a solid support can  
be a resin such as p-methylbenzhydrylamine (pMBHA) resin (Peptides International,  
20 Louisville, KY), polystyrenes (*e.g.*, PAM-resin obtained from Bachem Inc., Peninsula  
Laboratories, *etc.*), including chloromethylpolystyrene, hydroxymethylpolystyrene and  
aminomethylpolystyrene, poly (dimethylacrylamide)-grafted styrene co-divinyl-benzene  
(*e.g.*, POLYHIPE resin, obtained from Aminotech, Canada), polyamide resin (obtained  
from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (*e.g.*,

TENTAGEL or ARGOGEL, Bayer, Tübingen, Germany) polydimethylacrylamide resin (obtained from Milligen/Bioscience, California), or Sepharose (Pharmacia, Sweden).

In some embodiments of the present invention, compounds can be attached to solid supports via linkers. Linkers can be integral and part of the solid support, or they may be nonintegral that are either synthesized on the solid support or attached thereto after synthesis. Linkers are useful not only for providing points of compound attachment to the solid support, but also for allowing different groups of molecules to be cleaved from the solid support under different conditions, depending on the nature of the linker. For example, linkers can be, *inter alia*, electrophilically cleaved, nucleophilically cleaved, photocleavable, enzymatically cleaved, cleaved by metals, cleaved under reductive conditions or cleaved under oxidative conditions. In a preferred embodiment, the compounds are cleaved from the solid support prior to high throughput screening of the compounds.

In certain embodiments, the compound of the invention is a cytokine.

15 Examples of cytokines that can be used in the screening methods and treatment or prevention methods of the invention include, but are not limited to, IL-1 alpha, IL-1 beta, IL-1 beta, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11, IL-13, IL-12, IL-15, IL-18, TNF-alpha, brain-derived neurotrophic factor, bone morphogenetic protein-2, beta- nerve growth factor, ciliary neurotrophic factor, epidermal growth factor, fibroblast 20 growth factor-acidic, fibroblast growth factor-basic, granulocyte-colony stimulating factor, granulocyte-colony stimulating factor, human growth hormone, granulocyte macrophage-colony stimulating factor, hepatocyte growth factor, interferon-alpha 2a, interferon-alpha 2b, interferon-alpha 1b, interferon-beta 1a, interferon-beta 1b, interferon-gamma, insulin like growth factor-i, insulin like growth factor-II, keratinocyte 25 growth factor, neurotrophin-3, platelet derived growth factor-bb, stem cell factor,

necrosis factor-alpha, tumor necrosis factor-beta, vascular endothelial growth factor, leptin, or prolactin. In certain embodiments, where the compound is a cytokine, the compound is recombinantly produced. In certain embodiments, where the compound is a cytokine, the compound is human.

5 In embodiments of the methods of the invention where the compound is a small molecule, the small molecule can be specific to an EPO receptor, such as those available from Receptron (Receptron, Inc. Mountain View, CA). Other examples of small molecules include those disclosed in Goldberg et al. (2002, J. Amer. Chem. Soc. 124:544-555) and Boger and Goldberg (2001, Bioorg. and Org. Chem. 9:557-562).

10 **5.4.1.1 Modified EPO and EPO Mutants**

In certain embodiments of the invention, the test compound used in the assay and/or the tissue protective cytokine receptor complex ligand used in assays for identifying compounds that modulate the interaction of a tissue protective cytokine receptor complex and a ligand thereof is a chemically modified EPO, a mutant EPO, or a combination thereof. For example, U.S. Patent Application No.:10/188,905, which published as 20030072737-A1 on April 17, 2003, and U.S. Patent Application No.:10/612,665 which disclose chemically modified and/or mutant EPO and which are incorporated by reference herein in their entirety. Such chemically modified and/or mutant molecules may be used in the screening assays of the invention described herein.

20 (*Also see* PCT Application No. PCT/US01/49479, U.S. Patent Application Nos. 10/188,905, and 10/185,841, which are incorporated herein by reference herein in their entirety). These tissue protective cytokines protect, maintain, enhance and/or restore the function and/or viability of erythropoietin-responsive mammalian cells, tissues and organs, which include, but are not limited to, neuronal, retinal, muscle, heart, kidney 25 cells or tissues.

Chemically modified EPO molecules that may be used in the methods of the invention include, for example, erythropoietins that have been altered by at least one modification as compared to a native erythropoietin, and preferably as compared to native human erythropoietin. The at least one modification may be a modification of at least one amino acid of the erythropoietin molecule, or a modification of at least one carbohydrate of the erythropoietin molecule. Of course, chemically modified EPO useful for the purposes herein may have a plurality of modifications compared to a native molecule, such as multiple modifications of the amino acid portion of the molecule, multiple modifications of the carbohydrate portion of the molecule, or at least one modification of the amino acid portion of the molecule and at least one modification of the carbohydrate portion of the molecule. The chemically modified EPO molecule retains its ability of protecting, maintaining, enhancing or restoring the function or viability of responsive mammalian cells, yet one or more properties of the erythropoietin molecule unrelated to the aforementioned, desirable feature may be absent as compared to the native molecule. In a preferred embodiment, the chemically modified EPO lacks erythropoietin's affects on the bone marrow, *i.e.*, increased hematocrit (erythropoiesis), vasoconstriction (high blood pressure), increased blood pressure, hyperactivation of platelets, pro-coagulant activities, and increased production of thrombocytes. More preferably, the chemically modified EPO lack erythropoiesis; most preferably the chemically modified EPO are devoid of all of erythropoietin's effects on the bone marrow.

By way of example, the chemically modified EPO of the invention may be asialoerythropoietin. In another example, the chemically modified EPO of the invention may be erythropoietin or asialoerythropoietin that has been reacted with one or more reagents that modify one or more amino groups of amino acid residues of native

erythropoietin or asialoerythropoietin. In a preferred embodiment, the chemically modified EPO is nonerythropoietic.

In one embodiment, the chemically modified EPO is an erythropoietin that has no sialic acid moieties. In a preferred embodiment, the chemically modified 5 EPO is asialoerythropoietin, and most preferably, human asialoerythropoietin. In another embodiment, the chemically modified EPO has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 sialic acid moieties. Such partially desialylated erythropoietins are referred to herein as hyposialoerythropoietins. They may be prepared by chemical or enzymatic modification of native erythropoietin, or may be obtained by expression in a system 10 which either does not sialylate the molecule at all or only partially sialylates the erythropoietin. The asialoerythropoietin and hyposialoerythropoietin of the invention are embraced regardless of the means by which the molecules are prepared.

In another preferred embodiment, the chemically modified EPO comprises at least one or more modified lysine residues or a modification of the N- 15 terminal amino group of the erythropoietin molecule, such modifications as those resulting from reaction of the lysine epsilon amino group or the N-terminal amino group with an amino-group-modifying agent or agents. The modified lysine residue or modified N-terminal amino group further may be chemically reduced. In one preferred embodiment, an erythropoietin is biotinylated, carbamylated, succinylated or acetylated 20 at one or more lysine groups or at the N-terminus. In another preferred embodiment, the lysine is reacted with an aldehyde or reducing sugar to form an imine, which optionally is then stabilized by chemical reduction such as by using sodium cyanoborohydride to form an N-alkylated lysine residue such as glucitolyl lysine, or which in the case of reducing sugars may be stabilized by Amadori or Heyns rearrangement to form an alpha- 25 deoxy alpha-amino sugar such as alpha-deoxy-alpha-fructosyllsine. In another preferred

embodiment, the lysine or N-terminal amino group is carbamylated (carbamoylated), such as by virtue of reaction with cyanate ion, alkyl-carbamylated, aryl-carbamylated, or aryl-thiocarbamylated with an alkyl-isocyanate, aryl-isocyanate, or aryl-isothiocyanate, respectively, or it may be acylated by a reactive alkylcarboxylic or arylcarboxylic acid derivative, such as by reaction with acetic anhydride, succinic anhydride or phthalic anhydride. At least one lysine group or the N-terminal amino group may also be trinitrophenyl modified by reaction with a trinitrobenzenesulfonic acid, or preferably with one of its salts. In another embodiment, lysine residues may be modified by reaction with a glyoxal, such as reaction with glyoxal, methylglyoxal or 3-  
10 deoxyglucosone to form the corresponding alpha-carboxyalkyl derivatives.

In another embodiment, a chemically modified EPO can be generated by modifying at least one tyrosine residue of erythropoietin by using an electrophilic reagent, such as but not limited to modification by nitration or iodination, to modify an aromatic ring position.

15 As noted above, a tissue protective agent useful for the purposes herein may have at least one of the aforementioned modifications, but may have more than one of the above modifications. By way of example of chemically modified EPOs with one modification to the amino acid portion of the molecule and optional modification to the carbohydrate portion of the molecule, a chemically modified EPO is  
20 carbamylerythropoietin, carbamylsialoerythropoietin, carbamylhyposialoerythropoietin, acetylerythropoietin, acetylasialoerythropoietin, acetylhypoasialoerythropoietin, succinylerythropoietin, succinylsialoerythropoietin, succinylhyposialoerythropoietin, biotinylerythropoietin, biotinylsialoerythropoietin, biotinylhyposialoerythropoietin, iodoerythropoietin, iodoasialoerythropoietin, iodohypoasialoerythropoietin, N-epsilon-  
25 carboxymethylerythropoietin, N-epsilon-carboxymethylerythropoietin, N-epsilon-

carboxymethylhyposialoerythropoietin, and glucitolylerthropoietin, glucitolylasialoerythropoietin, glucitolylasialohypoerythropoietin. These compounds are merely exemplary of the modified erythropoietins of the invention. The foregoing trivial names are merely representative of the modifications of the native erythropoietin molecule, and as hereinbefore described, the modification of the amino group may be on one or more epsilon amino groups of lysine residues, or the N-terminal amino group, or, in the instance of nitro- or iodo-modified erythropoietins, of one or more tyrosine residues. Any combination of the foregoing is embraced herein. The present invention also embraces chemically modified EPO, comprising one or more of the aforementioned chemical modifications.

In another aspect of the invention, a method is provided for the protecting, maintaining, enhancing or restoring the function or viability of responsive mammalian cells and their associated cells, tissues and organs, by administering an effective amount of any one or more of the aforementioned chemically modified EPOs or a compound that modulates the activity of a tissue protective cytokine receptor complex such as those compounds identified by the screening methods of the invention. In one particular aspect of the method, the responsive mammalian cells and their associated cells, tissues or organs are distal to the vasculature by virtue of a tight endothelial cell barrier. In another particular aspect, the cells, tissues, organs or other bodily parts are isolated from a mammalian body, such as those intended for transplant or reattachment. By way of non-limiting examples, the responsive cell or tissue may be neuronal, retinal, muscle, heart, lung, liver, kidney, small intestine, adrenal cortex, adrenal medulla, capillary endothelial, testes, ovary, pancreas, skin, bones, or endometrial cells or tissue. These examples of responsive cells are merely illustrative. In a particular embodiment, the responsive cell or its associated cells, tissues, or organs are not excitable cells, tissues, or

organs, or do not predominantly comprise excitable cells or tissues. In another particular embodiment, the mammalian cell, tissue or organ for which an aforementioned chemically modified EPO, or a compound that modulates the activity of a tissue protective cytokine receptor complex such as those compounds identified by the 5 screening methods of the invention, may be administered are those that have expended or will expend a period of time under at least one condition adverse to the viability of the cell, tissue or organ. Such conditions may include traumatic *in-situ* hypoxia or metabolic dysfunction, surgically-induced *in-situ* hypoxia or metabolic dysfunction, or *in-situ* toxin exposure; the latter may be associated with chemotherapy or radiation therapy. In one 10 embodiment, the invention protects against the adverse conditions resulting from cardio-pulmonary bypass.

The invention also provides for a screening method that uses a chemically modified EPO that is i) an erythropoietin that lacks sialic acid moieties; ii) an erythropoietin that lacks N-linked or lacks O-linked carbohydrates; iii) an erythropoietin 15 having a reduced carbohydrate content by treatment of native erythropoietin with at least one glycosidase; iv) an erythropoietin having at least one or more oxidized carbohydrates; v) an erythropoietin comprising at least one or more oxidized carbohydrates which is chemically reduced; vi) an erythropoietin comprising at least one or more modified arginine residues; vii) an erythropoietin comprising at least one or 20 more modified lysine residues or a modification of the N-terminal amino group of the erythropoietin molecule; viii) an erythropoietin comprising at least a modified tyrosine residue; ix) an erythropoietin comprising at least a modified aspartic acid or a glutamic acid residue; x) an erythropoietin comprising at least a modified tryptophan residue; xi) an erythropoietin having at least one amino group removed; xii) an erythropoietin

comprising at least an opening of at least one of the cystine linkages in the erythropoietin molecule; or xiii) a truncated erythropoietin.

In one embodiment, the chemically modified EPO for use in the methods of the invention is asialoerythropoietin or phenylglyoxal-erythropoietin. In another 5 embodiment, the chemically modified EPO is capable of traversing an endothelial cell barrier. The endothelial cell barrier can be selected from the group consisting of blood-brain barrier, blood-eye barrier, blood-testis barrier, blood-ovary barrier, and blood-uterus barrier.

The invention also provides for a chemically modified EPO or a 10 compound that modulates the activity of a tissue protective cytokine receptor complex such as those compounds identified by the screening methods of the invention for use in the methods of invention that is an erythropoietin. In preferred embodiments, the compound is asialoerythropoietin. In preferred embodiments, the compound is human asialoerythropoietin. The chemically modified EPO is preferably an erythropoietin with 15 no N-linked carbohydrates. The chemically modified EPO is preferably an erythropoietin with no O-linked carbohydrates. In one embodiment, the chemically modified EPO is an erythropoietin treated with at least one glycosidase. In another embodiment, the chemically modified EPO is periodate-oxidized erythropoietin. The periodate-oxidized erythropoietin is preferably chemically reduced with sodium 20 cyanoborohydride. In one embodiment, the chemically modified EPO is an erythropoietin comprising a R-glyoxal moiety on the one or more arginine residues, wherein R is aryl or alkyl moiety. The erythropoietin is preferably phenylglyoxal-erythropoietin. In another embodiment, the chemically modified EPO is an erythropoietin in which at least one arginine residue is modified by reaction with a 25 vicinal diketone selected from the group consisting of 2,3-butanedione and

cyclohexanedione. In yet another embodiment, the chemically modified EPO of the invention is an erythropoietin in which at least one arginine residue is reacted with 3-deoxyglucosone. In still another embodiment, the chemically modified EPO is an erythropoietin molecule comprising at least one biotinylated lysine or N-terminal amino group. The erythropoietin molecule can be a biotinylated erythropoietin.

5 The invention also provides for a chemically modified EPO that is a glucitoyl lysine erythropoietin or a fructosyl lysine erythropoietin.

In one embodiment, the chemically modified EPO of the methods of invention is an erythropoietin having at least one carbamylated lysine residue. In another 10 embodiment, the carbamylated erythropoietin is selected from the group consisting of alpha-N-carbamoylerythropoietin; N-epsilon-carbamoylerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylerythropoietin; alpha-N-carbamoylasialoerythropoietin; N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoylhyposialoerythropoietin; N-epsilon-carbamoylhyposialoerythropoietin; and alpha-N-carbamoyl, N-epsilon- 15 carbamoylhyposialoerythropoietin.

In one embodiment, the chemically modified EPO of the methods of invention is an erythropoietin in which at least one lysine residue is acylated. In another embodiment, a lysine residue of said erythropoietin is acetylated. In yet another 20 embodiment, the acetylated erythropoietin is selected from the group consisting of alpha-N-acetylerythropoietin; N-epsilon-acetylerythropoietin; alpha-N-acetyl, N-epsilon-acetylerythropoietin; alpha-N-acetylasialoerythropoietin; N-epsilon-acetylasialoerythropoietin; alpha-N-acetyl, N-epsilon-acetylasialoerythropoietin; alpha-N-acetylhyposialoerythropoietin; N-epsilon-acetylhyposialoerythropoietin; and alpha-N- 25 acetyl, N-epsilon-acetylhyposialoerythropoietin.

In one embodiment, the chemically modified EPO of the invention is an erythropoietin comprising a succinylated lysine residue. In one embodiment, the erythropoietin is selected from the group consisting of alpha-N-succinylerythropoietin; N-epsilon-succinylerythropoietin; alpha-N-succinyl, N-epsilon-succinylerythropoietin; 5 alpha-N-succinylsialoerythropoietin; N-epsilon-succinylsialoerythropoietin; alpha-N-succinyl, N-epsilon-succinylsialoerythropoietin; alpha-N-succinylhyposialoerythropoietin; N-epsilon-succinylhyposialoerythropoietin; and alpha-N-succinyl, N-epsilon-succinylhyposialoerythropoietin.

In one embodiment, the chemically modified EPO of the methods of 10 invention is an erythropoietin with at least one lysine residue modified by a 2, 4, 6-trinitrobenzenesulfonic acid salt. In one aspect of the invention, the salt is 2, 4, 6-trinitrobenzenesulfonate sodium.

In another embodiment, the chemically modified EPO of the methods of 15 invention is an erythropoietin in which at least one tyrosine residue is nitrated and/or iodinated.

In yet another embodiment, the chemically modified EPO of the methods of invention is an erythropoietin in which an aspartic acid and/or glutamic acid residue is reacted with a carbodiimide followed by reaction with an amine. In one aspect of the invention the amine is glyciamide.

20 Mutant EPO molecules can also be used, for example, the tissue protective cytokine receptor complex ligand may be a mutant EPO, which may be recombinantly produced, comprising one or more altered amino acid residue between position 11 to 15 of SEQ ID NO:10 [SEQ ID NO:1], position 44 to 51 of SEQ ID NO 10 [SEQ ID NO:2], position 100-108 of SEQ ID NO [SEQ ID NO:3], or position 146-151 25 of SEQ ID NO 10 [SEQ ID NO:4].

In another embodiment, the tissue protective cytokine receptor complex ligand is a mutant EPO comprising an altered amino acid residue at one or more of the following positions of SEQ ID NO: 10: 7, 20, 21, 29, 33, 38, 42, 59, 63, 67, 70, 83, 96, 126, 142, 143, 152, 153, 155, 156, or 161.

5 In yet another embodiment, the tissue protective cytokine receptor complex ligand is a mutant EPO comprising the amino acid sequence of SEQ ID NO: 10 with one or more of the following changes (each altered sequence has been assigned a separate sequence identification number): an alanine at residue 6 of SEQ ID NO: 10 (SEQ ID NO: 15); an alanine at residue 7 of SEQ ID NO: 10 (SEQ ID NO: 16); a serine 10 at residue 7 of SEQ ID NO: 10 (SEQ ID NO: 17); an isoleucine at residue 10 of SEQ ID NO: 10 (SEQ ID NO: 18); a serine at residue 11 of SEQ ID NO: 10 (SEQ ID NO: 19); an alanine at residue 12 of SEQ ID NO: 10 (SEQ ID NO: 20); an alanine at residue 13 of SEQ ID NO: 10 (SEQ ID NO: 21); an alanine residue 14 of SEQ ID NO: 10 (SEQ ID NO: 22); a glutamic acid at residue 14 of SEQ ID NO: 10 (SEQ ID NO: 23); a glutamine 15 at residue 14 of SEQ ID NO: 10 (SEQ ID NO: 24); an alanine at residue 15 of SEQ ID NO: 10 (SEQ ID NO: 25); a phenylalanine at residue 15 of SEQ ID NO: 10 (SEQ ID NO: 26); an isoleucine at residue 15 of SEQ ID NO: 10 (SEQ ID NO: 27); a glutamic acid at residue 20 of SEQ ID NO: 10 (SEQ ID NO: 28); an alanine at residue 20 of SEQ ID NO: 10 (SEQ ID NO: 29); an alanine at residue 21 of SEQ ID NO: 10 (SEQ ID NO: 30); a lysine at residue 24 of SEQ ID NO: 10 (SEQ ID NO: 31); a serine at residue 29 of SEQ ID NO: 10 (SEQ ID NO: 32); a tyrosine at residue 29 of SEQ ID NO: 10 (SEQ ID NO: 33); an asparagine at residue 30 of SEQ ID NO: 10 (SEQ ID NO: 34); a threonine at residue 32 of SEQ ID NO: 10 (SEQ ID NO: 35); a serine at residue 33 of SEQ ID NO: 10 (SEQ ID NO: 36); a tyrosine at residue 33 of SEQ ID NO: 10 (SEQ ID NO: 37); a 20 lysine at residue 38 of SEQ ID NO: 10 (SEQ ID NO: 38); a lysine at residue 83 of SEQ

ID NO: 10 (SEQ ID NO: 39); an asparagine at residue 42 of SEQ ID NO: 10 (SEQ ID NO: 40); an alanine at residue 42 of SEQ ID NO: 10 (SEQ ID NO: 41); an alanine at residue 43 of SEQ ID NO: 10 (SEQ ID NO: 42); an isoleucine at residue 44 of SEQ ID NO: 10 (SEQ ID NO: 43); an aspartic acid at residue 45 of SEQ ID NO: 10 (SEQ ID NO: 44); an alanine at residue 45 of SEQ ID NO: 10 (SEQ ID NO: 45); an alanine at residue 46 of SEQ ID NO: 10 (SEQ ID NO: 46); an alanine at residue 47 of SEQ ID NO: 10 (SEQ ID NO: 47); an isoleucine at residue 48 of SEQ ID NO: 10 (SEQ ID NO: 48); an alanine at residue 48 of SEQ ID NO: 10 (SEQ ID NO: 49); an alanine at residue 49 of SEQ ID NO: 10 (SEQ ID NO: 50); a serine at residue 49 of SEQ ID NO: 10 (SEQ ID NO: 51); a phenylalanine at residue 51 of SEQ ID NO: 10 (SEQ ID NO: 52); an asparagine at residue 51 of SEQ ID NO: 10 (SEQ ID NO: 53); an alanine at residue 52 of SEQ ID NO: 10 (SEQ ID NO: 54); an asparagine at residue 59 of SEQ ID NO: 10 (SEQ ID NO: 55); a threonine at residue 62 of SEQ ID NO: 10 (SEQ ID NO: 56); a serine at residue 67 of SEQ ID NO: 10 (SEQ ID NO: 57); an alanine at residue 70 of SEQ ID NO: 10 (SEQ ID NO: 58); an arginine at residue 96 of SEQ ID NO: 10 (SEQ ID NO: 59); an alanine at residue 97 of SEQ ID NO: 10 (SEQ ID NO: 60); an arginine at residue 100 of SEQ ID NO: 10 (SEQ ID NO: 61); a glutamic acid at residue 100 of SEQ ID NO: 10 (SEQ ID NO: 62); an alanine at residue 100 of SEQ ID NO: 10 (SEQ ID NO: 63); a threonine at residue 100 of SEQ ID NO: 10 (SEQ ID NO: 64); an alanine at residue 101 of SEQ ID NO: 10 (SEQ ID NO: 65); an isoleucine at residue 101 of SEQ ID NO: 10 (SEQ ID NO: 66); an alanine at residue 102 of SEQ ID NO: 10 (SEQ ID NO: 67); an alanine at residue 103 of SEQ ID NO: 10 (SEQ ID NO: 68); a glutamic acid at residue 103 of SEQ ID NO: 10 (SEQ ID NO: 69); an alanine at residue 104 of SEQ ID NO: 10 (SEQ ID NO: 70); an isoleucine at residue 104 of SEQ ID NO: 10 (SEQ ID NO: 71); an alanine at residue 105 of SEQ ID NO: 10 (SEQ ID NO: 72); an alanine at residue 106 of

SEQ ID NO: 10 (SEQ ID NO: 73); an isoleucine at residue 106 of SEQ ID NO: 10 (SEQ ID NO: 74); an alanine at residue 107 of SEQ ID NO: 10 (SEQ ID NO: 75); a leucine at residue 107 of SEQ ID NO: 10 (SEQ ID NO: 76); a lysine at residue 108 of SEQ ID NO: 10 (SEQ ID NO: 77); an alanine at residue 108 of SEQ ID NO: 10 (SEQ ID NO: 78); a 5 serine at residue 108 of SEQ ID NO: 10 (SEQ ID NO: 79); an alanine at residue 116 of SEQ ID NO: 10 (SEQ ID NO: 80); an alanine at residue 126 of SEQ ID NO: 10 (SEQ ID NO: 81); an alanine at residue 132 of SEQ ID NO: 10 (SEQ ID NO: 82); an alanine at residue 133 of SEQ ID NO: 10 (SEQ ID NO: 83); an alanine at residue 134 of SEQ ID NO: 10 (SEQ ID NO: 84); an alanine at residue 140 of SEQ ID NO: 10 (SEQ ID NO: 85); an isoleucine at residue 142 of SEQ ID NO: 10 (SEQ ID NO: 86); an alanine at residue 143 of SEQ ID NO: 10 (SEQ ID NO: 87); an alanine at residue 146 of SEQ ID NO: 10 (SEQ ID NO: 88); a lysine at residue 147 of SEQ ID NO: 10 (SEQ ID NO: 89); an alanine at residue 147 of SEQ ID NO: 10 (SEQ ID NO: 90); a tyrosine at residue 148 of SEQ ID NO: 10 (SEQ ID NO: 91); an alanine at residue 148 of SEQ ID NO: 10 (SEQ ID NO: 92); an alanine at residue 149 of SEQ ID NO: 10 (SEQ ID NO: 93); an alanine at 15 residue 150 of SEQ ID NO: 10 (SEQ ID NO: 94); a glutamic acid at residue 150 of SEQ ID NO: 10 (SEQ ID NO: 95); an alanine at residue 151 of SEQ ID NO: 10 (SEQ ID NO: 96); an alanine at residue 152 of SEQ ID NO: 10 (SEQ ID NO: 97); a tryptophan at residue 152 of SEQ ID NO: 10 (SEQ ID NO: 98); an alanine at residue 153 of SEQ ID NO: 10 (SEQ ID NO: 99); an alanine at residue 154 of SEQ ID NO: 10 (SEQ ID NO: 100); an alanine at residue 155 of SEQ ID NO: 10 (SEQ ID NO: 101); an alanine at 20 residue 158 of SEQ ID NO: 10 (SEQ ID NO: 102); a serine at residue 160 of SEQ ID NO: 10 (SEQ ID NO: 103); an alanine at residue 161 of SEQ ID NO: 10 (SEQ ID NO: 104); or an alanine at residue 162 of SEQ ID NO: 10 (SEQ ID NO: 105). In one 25 embodiment, the tissue protective cytokine receptor complex ligand is a mutant EPO that

comprises the amino acid sequence of SEQ ID NO: 10 with one or more of the amino acid residue substitutions of SEQ ID NOs: 15-105 and 119.

In yet another embodiment, the tissue protective cytokine receptor complex ligand is a mutant EPO that comprises the amino acid sequence of SEQ ID NO: 5 10 with a deletion of amino acid residues 44-49 of SEQ ID NO: 10.

In still another embodiment, the tissue protective cytokine receptor complex ligand is a mutant EPO that comprises the amino acid sequence of SEQ ID NO: 10 with at least one of the following changes (each altered sequence has been assigned a separate sequence identification number): i) an aspartic acid at residue 45, and a 10 glutamic acid at residue 100 of SEQ ID NO: 10 (SEQ ID NO: 106); ii) an asparagine at residue 30, a threonine at residue 32 of SEQ ID NO: 10 (SEQ ID NO: 107); iii) an aspartic acid at residue 45, a glutamic acid at residue 150 SEQ ID NO: 10 (SEQ ID NO: 108); iv) a glutamic acid at residue 103, and a serine at residue 108 of SEQ ID NO: 10 (SEQ ID NO: 109); v) an alanine at residue 140 and an alanine at residue 52 of SEQ ID 15 NO: 10 (SEQ ID NO: 110); vi) an alanine at residue 140, an alanine at residue 52, an alanine at residue 45 of SEQ ID NO: 10 (SEQ ID NO: 111); vii) an alanine at residue 97, and an alanine at residue 152 of SEQ ID NO: 10 (SEQ ID NO: 112); viii) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45 of SEQ ID NO: 10 (SEQ ID NO: 113); ix) an alanine at residue 97, an alanine at residue 152, an alanine at residue 20 45, and an alanine at residue 52 of SEQ ID NO: 10 (SEQ ID NO: 114); x) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45, an alanine at residue 52, and an alanine at residue 140 of SEQ ID NO: 10 (SEQ ID NO: 115); xi) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45, an alanine at residue 52, an alanine at residue 140, an alanine at residue 154, a lysine at residue 24, a lysine at 25 residue 38, a lysine at residue 83, a lysine at residue 24 and an alanine at residue 15 of

SEQ ID NO: 10 (SEQ ID NO: 116); xii) a lysine at residue 24, a lysine at residue 38, and a lysine at residue 83 SEQ ID NO: 10 (SEQ ID NO: 117); or xiii) a lysine at residue 24 and an alanine at residue 15 SEQ ID NO: 10 (SEQ ID NO: 118). In one embodiment, the tissue protective cytokine receptor complex ligand is a mutant EPO that comprises 5 the amino acid sequence of SEQ ID NO: 10 with at least one of the following amino acid residue substitutions of SEQ ID NOS: 106-118.

The tissue protective cytokine receptor complex ligand is a mutant EPO and may comprise the amino acid sequence of SEQ ID NO: 10 with at least one of the following changes, *i.e.* substitutions, (each change or combination of changes listed has 10 been assigned a separate sequence identification number): i) an aspartic acid at residue 45, and a glutamic acid at residue 100 of SEQ ID NO: 10 (SEQ ID NO: 106); ii) an asparagine at residue 30, a threonine at residue 32 of SEQ ID NO: 10 (SEQ ID NO: 107); iii) an aspartic acid at residue 45, a glutamic acid at residue 150 SEQ ID NO: 10 (SEQ ID NO: 108); iv) a glutamic acid at residue 103, and a serine at residue 108 of SEQ 15 ID NO: 10 (SEQ ID NO: 109); v) an alanine at residue 140 and an alanine at residue 52 of SEQ ID NO: 10 (SEQ ID NO: 110); vi) an alanine at residue 140, an alanine at residue 52, an alanine at residue 45 of SEQ ID NO: 10 (SEQ ID NO: 111); vii) an alanine at residue 97, and an alanine at residue 152 of SEQ ID NO: 10 (SEQ ID NO: 112); viii) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45 of 20 SEQ ID NO: 10 (SEQ ID NO: 113); ix) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45, and an alanine at residue 52 of SEQ ID NO: 10 (SEQ ID NO: 114); x) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45, an alanine at residue 52, and an alanine at residue 140 of SEQ ID NO: 10 (SEQ ID NO: 115); xi) an alanine at residue 97, an alanine at residue 152, an alanine at residue 45, an 25 alanine at residue 52, an alanine at residue 140, an alanine at residue 154, a lysine at

residue 24, a lysine at residue 38, a lysine at residue 83, a lysine at residue 24 and an alanine at residue 15 of SEQ ID NO: 10 (SEQ ID NO: 116); xii) a lysine at residue 24, a lysine at residue 38, and a lysine at residue 83 SEQ ID NO: 10 (SEQ ID NO: 117); or xiii) a lysine at residue 24 and an alanine at residue 15 SEQ ID NO: 10 (SEQ ID NO: 118).

According to another aspect of the invention, the tissue protective cytokine receptor complex ligand is a mutant EPO comprising at least one of the following amino acid residue substitutions: (each change or combination of changes listed has been assigned a separate sequence identification number): a tryptophan at 10 residue 152 of SEQ ID NO: 10 (SEQ ID NO: 98); an alanine at residue 14 and an alanine at residue 15 of SEQ ID NO: 10 (SEQ ID NO: 119); an alanine at residue 6 of SEQ ID NO: 10 (SEQ ID NO: 15); an alanine at residue 7 of SEQ ID NO: 10 (SEQ ID NO: 16); an alanine at residue 43 of SEQ ID NO: 10 (SEQ ID NO: 42); an alanine at residue 42 of SEQ ID NO: 10 (SEQ ID NO: 41); an alanine at residue 48 of SEQ ID NO: 10 (SEQ ID NO: 49); an alanine at residue 49 of SEQ ID NO: 10 (SEQ ID NO: 50); an threonine at 15 residue 32 of SEQ ID NO: 10 (SEQ ID NO: 35); an alanine at residue 133 of SEQ ID NO: 10 (SEQ ID NO: 83); an alanine at residue 134 of SEQ ID NO: 10 (SEQ ID NO: 84); an alanine at residue 147 of SEQ ID NO: 10 (SEQ ID NO: 90); an alanine at residue 148 of SEQ ID NO: 10 (SEQ ID NO: 92); an alanine at residue 150 of SEQ ID NO: 10 20 (SEQ ID NO: 94); an alanine at residue 151 of SEQ ID NO: 10 (SEQ ID NO: 96); an alanine at residue 158 of SEQ ID NO: 10 (SEQ ID NO: 102); an alanine at residue 161 of SEQ ID NO: 10 (SEQ ID NO: 104); or an alanine at residue 162 of SEQ ID NO: 10 (SEQ ID NO: 105).

#### 5.4.1.2 Antibodies

In certain embodiments of the invention the compound tested in the screening assays above is an antibody. The ligand may also be an antibody specific for a tissue protective receptor cytokine receptor complex in screening assays designed to identify compounds that modulate the interaction of a known ligand with the tissue

5 protective receptor cytokine receptor complex. Described herein are methods for the production of such antibodies. The antibodies identified may also be useful for tissue protection. The antibodies identified may also be useful for as compounds in the methods for treatment or prevention of a disease, disorder, or condition.

Such antibodies may include, but are not limited to, polyclonal antibodies, 10 monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be utilized in conjunction with, for example, compound screening schemes, as described above, for the evaluation of the effect of test compounds 15 on activity of a tissue protective receptor cytokine receptor complex or a tissue protective activity.

For the production of antibodies specific to a tissue protective receptor cytokine receptor complex, various host animals may be immunized by injection with an 20 tissue protective receptor cytokine receptor complex, or a portion thereof. An antigenic portion of tissue protective receptor cytokine receptor complex can be readily predicted by algorithms known in the art.

Host animals may include, but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and 25 incomplete), mineral gels such as aluminum hydroxide, surface active substances such as

lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as a tissue protective receptor cytokine receptor complex, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with tissue protective receptor cytokine receptor complex, or portion thereof, supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256, 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor *et al.*, 1983, *Immunology Today* 4: 72; Cole *et al.*, 1983, *Proc. Natl. Acad. Sci. USA* 80, 2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, *Proc. Natl. Acad. Sci.*, 81: 6851-6855; Neuberger *et al.*, 1984, *Nature* 312: 604-608; Takeda *et al.*, 1985, *Nature*, 314: 452-454) by splicing

the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine 5 mAb and a human immunoglobulin constant region (see, e.g., Cabilly *et al.*, U.S. Patent No. 4,816,567; and Boss *et al.*, U.S. Patent No. 4,816397, which are incorporated herein by reference in their entirety).

In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (see PCT International Publication No. WO 89/12690, 10 published December 12, 1989). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote *et al.*, 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole *et al.*, 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). Techniques developed for the production of "chimeric antibodies" (Morrison *et* 15 *al.*, 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855; Neuberger *et al.*, 1984, Nature 312:604-608; Takeda *et al.*, 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for a tissue protective receptor cytokine receptor complex together with genes from a human antibody molecule of appropriate biological activity can also be used; such antibodies are within the scope of this invention.

20 Humanized antibodies are also provided (see U.S. Patent No. 5,225,539 by Winter). An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarity determining regions (CDRs). The extent of the framework region and CDRs have been precisely defined (see, "Sequences of Proteins of Immunological 25 Interest", Kabat, E. *et al.*, U.S. Department of Health and Human Services (1983)).

Briefly, humanized antibodies are antibody molecules from non-human species having one or more CDRs from the non-human species and a framework region from a human immunoglobulin molecule. Such CDRS-grafted antibodies have been successfully constructed against various antigens, for example, antibodies against IL-2 receptor as 5 described in Queen *et al.*, 1989, Proc. Natl. Acad. Sci. USA 86:10029; antibodies against the cell surface receptor CAMPATH as described in Riechmann *et al.*, 1988, Nature 332:323; antibodies against hepatitis B in Co *et al.*, 1991, Proc. Natl. Acad. Sci. USA 88:2869; as well as against viral antigens of the respiratory syncytial virus in Tempest *et al.*, 1991, Bio-Technology 9:267. Humanized antibodies are most preferred for 10 therapeutic use in humans.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242: 423-426; Huston *et al.*, 1988, Proc. Natl. Acad. Sci. USA 85: 5879-5883; and Ward *et al.*, 1989, Nature 334: 544-546) can be adapted to produce single chain antibodies specific for a tissue 15 protective receptor cytokine receptor complex, or portions thereof. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the 20 F(ab')2 fragments, which can be produced by pepsin digestion of the antibody molecule and the Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, Science, 246: 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a tissue protective receptor cytokine receptor complex can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" the tissue protective receptor cytokine receptor complex, using techniques well known to those skilled in the art (see, *e.g.*, Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. 5 Immunol. 147(8):2429-2438). For example antibodies which bind to the tissue protective receptor cytokine receptor complex and competitively inhibit the binding of EPO or other known ligands to the tissue protective receptor cytokine receptor complex can be used to generate anti-idiotypes that "mimic" the binding domain of the tissue protective receptor cytokine receptor complex and, therefore, bind and neutralize tissue 10 protective receptor cytokine receptor complex ligands. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize the native ligand, which can be followed by administration of a compound identified by the methods of the invention that provides tissue protection, which may be superior in comparison to the protection provided by a native ligand. Alternatively, antibodies to the 15 tissue protective receptor cytokine receptor complex that can act as agonists of the tissue protective receptor cytokine receptor complex activity can be generated. Such antibodies will bind to the tissue protective receptor cytokine receptor complex and activate the signal transducing activity of the receptor complex. In addition, antibodies that act as antagonist of the tissue protective receptor cytokine receptor complex activity, *i.e.* 20 inhibit the activation of the tissue protective receptor cytokine receptor complex would be useful as a negative control in assays for identifying compounds that modulate the activity of a tissue protective receptor cytokine receptor complex. Methods for assaying for such agonists and antagonists are described in detail in the sections above.

#### 5.4.2 Characterization of the Structure of Compounds

The structure of a test compound identified by the screening methods of the invention can be determined various methods by known to those of skill in the art.

For example, X-ray crystallography can be used to elucidate the structure of a

5 compound. For a review of x-ray crystallography see, *e.g.*, Blundell *et al.* 2002, *Nat Rev Drug Discov* 1(1):45-54.

In certain embodiments, vibrational spectroscopy (*e.g.*, but not limited to, infrared (IR) spectroscopy or Raman spectroscopy) can be used for elucidating the structure of a compound. An improved Raman spectrometer is described in US Patent

10 No. 5,786,893 to Fink *et al.*, which is hereby incorporated by reference. Vibrational microscopy can be measured in a spatially resolved fashion to address single beads by integration of a visible microscope and spectrometer. A microscopic infrared

spectrometer is described in U.S. Patent No. 5,581,085 to Reffner *et al.*, which is hereby incorporated by reference in its entirety. An instrument that simultaneously performs a

15 microscopic infrared and microscopic Raman analysis on a sample is described in U.S.

Patent No. 5,841,139 to Sostek *et al.*, which is hereby incorporated by reference in its entirety. In one embodiment of the method, compounds are synthesized on polystyrene beads doped with chemically modified styrene monomers such that each resulting bead has a characteristic pattern of absorption lines in the vibrational (IR or Raman) spectrum,

20 by methods including but not limited to those described by Fenniri *et al.*, 2000, *J. Am.*

Chem. Soc.

123:8151-8152. Using methods of split-pool synthesis familiar to one of skill in the art, the library of compounds is prepared so that the spectroscopic pattern of the bead identifies one of the components of the compound on the bead. Beads that have been separated according to their ability to bind a tissue protective cytokine receptor complex can be identified by their vibrational spectrum.

Mass spectrometry (e.g., electrospray ionization ("ESI") and matrix-assisted laser desorption-ionization ("MALDI"), Fourier-transform ion cyclotron resonance ("FT-ICR") can be used both for high-throughput screening of compounds that bind to a tissue protective cytokine receptor complex and elucidating the structure of 5 the compound.

MALDI uses a pulsed laser for desorption of the ions and a time-of-flight analyzer, and has been used for the detection of noncovalent tRNA:amino-acyl-tRNA synthetase complexes (Gruic-Sovulj *et al.*, 1997, *J. Biol. Chem.* 272:32084-32091). However, covalent cross-linking between the target nucleic acid and the compound is 10 usually required for detection, since a non-covalently bound complex may dissociate during the MALDI process.

ESI mass spectrometry ("ESI-MS") has been of greater utility for studying non-covalent molecular interactions because, unlike the MALDI process, ESI-MS generates molecular ions with little to no fragmentation (Xavier *et al.*, 2000, *Trends Biotechnol.* 18(8):349-356). ESI-MS has been used to study the complexes formed by 15 HIV Tat peptide and protein with the TAR RNA (Sannes-Lowery *et al.*, 1997, *Anal. Chem.* 69:5130-5135).

Fourier-transform ion cyclotron resonance ("FT-ICR") mass spectrometry provides high-resolution spectra, isotope-resolved precursor ion selection, and accurate 20 mass assignments (Xavier *et al.*, 2000, *Trends Biotechnol.* 18(8):349-356). FT-ICR has been used to study the interaction of aminoglycoside antibiotics with cognate and non-cognate RNAs (Hofstadler *et al.*, 1999, *Anal. Chem.* 71:3436-3440; Griffey *et al.*, 1999, *Proc. Natl. Acad. Sci. USA* 96:10129-10133). As true for all of the mass spectrometry methods discussed herein, FT-ICR does not require labeling of the tissue protective 25 cytokine receptor complex or a compound.

An advantage of mass spectroscopy is not only the elucidation of the structure of a compound, but also the determination of the structure of the compound bound to a tissue protective cytokine receptor complex. Such information can enable the discovery of a consensus structure of a compound that specifically binds to a tissue protective cytokine receptor complex.

NMR spectroscopy methods can also be used to characterize compounds that are associated with a tissue protective cytokine receptor complex. For example, complexed molecules can be examined by qualitatively determining changes in chemical shift, specifically from distances measured using relaxation effects, and NMR-based approaches have been used in the identification of small molecule binders of protein drug targets (Xavier *et al.*, 2000, Trends Biotechnol. 18(8):349-356). The determination of structure-activity relationships (“SAR”) by NMR is the first method for NMR described in which small molecules that bind adjacent subsites are identified by two-dimensional  $^1\text{H}$ - $^{15}\text{N}$  spectra of the target protein (Shuker *et al.*, 1996, Science 274:1531-1534). The signal from the bound molecule is monitored by employing line broadening, transferred NOEs and pulsed field gradient diffusion measurements (Moore, 1999, Curr. Opin. Biotechnol. 10:54-58). A strategy for lead generation by NMR using a library of small molecules has been recently described (Fejzo *et al.*, 1999, Chem. Biol. 6:755-769).

Other examples of NMR methods that can be used for the invention include, but are not limited to, one-dimensional, two-dimensional, three dimension, four dimensional NMR methods as well as correlation spectroscopy (“COSY”), and nuclear Overhauser effect (“NOE”) spectroscopy. Such methods of structure determination of compounds are well known to one of skill in the art.

Similar to mass spectroscopy, an advantage of NMR is the not only the elucidation of the structure of a compound, but also the determination of the structure of the compound bound to a tissue protective cytokine receptor complex.

### 5.5 THERAPEUTIC USE

5 One of ordinary skill in the art would recognize that compounds identified by the present assays, and are useful as therapeutics for treatment or prevention of various diseases, disorders, and conditions. One skilled in the art would also recognize that such compounds can be used to achieve modulation of a tissue protective cytokine receptor complex. In certain embodiments of the invention, modulating the activity of a 10 tissue protective cytokine receptor complex can be achieved by a compound that enhances or inhibits the interaction of the complex with a ligand of the complex. Both *in vitro* and *in vivo* techniques that can be used for assessing the therapeutic indications of, for example, the compounds identified by the inventive assays disclosed above are disclosed in PCT Application No. PCT/US01/49479, U.S. Patent Application Nos. 15 10/188,905 and 10/185,841, incorporated herein by reference.

The aforementioned compounds identified by the methods of the invention may be useful generally for the prevention, therapeutic treatment, or prophylactic treatment of human diseases or disorders of the central nervous system or peripheral nervous system which have primarily neurological or psychiatric symptoms, 20 ophthalmic diseases, cardiovascular diseases, cardiopulmonary diseases, respiratory diseases, kidney, urinary and reproductive diseases, bone diseases, skin diseases, gastrointestinal diseases and endocrine and metabolic abnormalities. Examples of use include, but are not limited to, protection against and repair of injury resulting from 25 trauma and resulting inflammation to the brain (ischemic stroke, blunt trauma, subarachnoid hemorrhage), spinal cord (ischemia, blunt force trauma), peripheral nerves

(sciatic nerve injury, diabetic neuropathy, carpal tunnel syndrome), retinal (macular edema), and heart (myocardial infarct, chronic heart failure). In particular, such diseases, disorders, and conditions include hypoxic conditions, which adversely affect excitable tissues, such as excitable tissues in the central nervous system tissue, peripheral nervous system tissue, or cardiac tissue or retinal tissue such as, for example, brain, heart, or retina/eye. Therefore, the compounds identified by the methods of the invention can be used to treat or prevent damage to excitable tissue resulting from hypoxic conditions in a variety of conditions and circumstances. Non-limiting examples of such conditions and circumstances are provided in the table herein below.

10                   In the example of the protection of neuronal tissue pathologies treatable and preventable using compounds identified by the methods of the invention, such pathologies include those which result from reduced oxygenation of neuronal tissues. Any condition which reduces the availability of oxygen to neuronal tissue, resulting in stress, damage, and finally, neuronal cell death, can be treated using compounds 15 identified by the methods of the present invention. Generally referred to as hypoxia and/or ischemia, these conditions arise from or include, but are not limited to, stroke, vascular occlusion, prenatal or postnatal oxygen deprivation, suffocation, choking, near drowning, carbon monoxide poisoning, smoke inhalation, trauma, including surgery and radiotherapy, asphyxia, epilepsy, hypoglycemia, chronic obstructive pulmonary disease, 20 emphysema, adult respiratory distress syndrome, hypotensive shock, septic shock, anaphylactic shock, insulin shock, sickle cell crisis, cardiac arrest, dysrhythmia, nitrogen narcosis, and neurological deficits caused by heart-lung bypass procedures.

                  In one embodiment, for example, the compounds identified by the methods of the present invention identified using the inventive assay could be 25 administered alone or as part of a composition to prevent injury or tissue damage

resulting from risk of injury or tissue damage prior to, during, or subsequent to a surgical procedure or a medical procedure. For example, surgical procedures may include tumor resection or aneurysm repair, medical procedures such as chemotherapy, and natural processes such as labor or delivery. Other pathologies caused by or resulting from

5 hypoglycemia which are treatable using compounds identified by the methods of the present invention include insulin overdose, also referred to as iatrogenic hyperinsulinemia, insulinoma, growth hormone deficiency, hypocortisolism, drug overdose, and certain tumors.

Other pathologies resulting from excitable neuronal tissue damage include  
10 seizure disorders, such as epilepsy, convulsions, or chronic seizure disorders. Other treatable conditions and diseases include, but are not limited to, diseases such as stroke, multiple sclerosis, hypotension, cardiac arrest, Alzheimer's disease, Parkinson's disease, cerebral palsy, brain or spinal cord trauma, AIDS dementia, age-related loss of cognitive function, memory loss, amyotrophic lateral sclerosis, seizure disorders, alcoholism,  
15 retinal ischemia, optic nerve damage resulting from glaucoma, and neuronal loss.

The specific compounds identified by the methods of the present invention may be used to treat or prevent inflammation resulting from disease conditions or various traumas, such as physically or chemically induced inflammation. Such traumas could include angitis, chronic bronchitis, pancreatitis, osteomyelitis, rheumatoid  
20 arthritis, glomerulonephritis, optic neuritis, temporal arteritis, encephalitis, meningitis, transverse myelitis, dermatomyositis, polymyositis, necrotizing fascilitis, hepatitis, and necrotizing enterocolitis.

The compounds identified by the methods of the present invention may be used to treat or prevent conditions of, and damage to, retinal tissue. Such disorders  
25 include, but are not limited to retinal ischemia, macular degeneration, retinal detachment,

retinitis pigmentosa, arteriosclerotic retinopathy, hypertensive retinopathy, retinal artery blockage, retinal vein blockage, hypotension, and diabetic retinopathy.

In another embodiment, the compounds identified by the methods of the present invention and principles of the invention may be used to prevent or treat injury resulting from radiation damage to excitable tissue. A further utility of the compounds identified by the methods of the present invention is in the treatment of neurotoxin poisoning, such as domoic acid shellfish poisoning, neurolathyrism, and Guam disease, amyotrophic lateral sclerosis, and Parkinson's disease.

As mentioned above, the present invention is also directed to compounds identified by the methods of the present invention for use in enhancing excitable tissue function in a mammal by peripheral administration of a tissue protective cytokine as described above. Various diseases and conditions are amenable to treatment using this method, and further, this method is useful for enhancing cognitive function in the absence of any condition or disease. These uses of the present invention are described in further detail below and include enhancement of learning and training in both human and non-human mammals.

Conditions and diseases treatable or preventable using compounds identified by the methods of the present invention directed to the central nervous system include but are not limited to mood disorders, anxiety disorders, depression, autism, attention deficit hyperactivity disorder, and cognitive dysfunction. These conditions benefit from enhancement of neuronal function. Other disorders treatable in accordance with the teachings of the present invention include sleep disruption, for example, sleep apnea and travel-related disorders; subarachnoid and aneurismal bleeds, hypotensive shock, concussive injury, septic shock, anaphylactic shock, and sequelae of various encephalitides and meningitides, for example, connective tissue disease-related

cerebritides such as lupus. Other uses include prevention of or protection from poisoning by neurotoxins, such as domoic acid shellfish poisoning, neurolathyrism, and Guam disease, amyotrophic lateral sclerosis, Parkinson's disease; postoperative treatment for embolic or ischemic injury; whole brain irradiation; sickle cell crisis; and

5 eclampsia.

A further group of conditions treatable or preventable using compounds identified by the methods of the present invention include mitochondrial dysfunction, of either a hereditary or acquired nature, which are the cause of a variety of neurological diseases typified by neuronal injury and death. For example, Leigh disease (subacute 10 necrotizing encephalopathy) is characterized by progressive visual loss and encephalopathy, due to neuronal drop out, and myopathy. In these cases, defective mitochondrial metabolism fails to supply enough high energy substrates to fuel the metabolism of excitable cells. An erythropoietin receptor activity modulator optimizes failing function in a variety of mitochondrial diseases. As mentioned above, hypoxic 15 conditions adversely affect excitable tissues. The excitable tissues include, but are not limited to, central nervous system tissue, peripheral nervous system tissue, and heart tissue. In addition to the conditions described above, the compounds identified by the methods of the present invention are useful in the treatment of inhalation poisoning such as carbon monoxide and smoke inhalation, severe asthma, adult respiratory distress 20 syndrome, and choking and near drowning. Further conditions which create hypoxic conditions or by other means induce excitable tissue damage include hypoglycemia that may occur in inappropriate dosing of insulin, or with insulin-producing neoplasms (insulinoma).

Various neuropsychologic disorders which are believed to originate from 25 excitable tissue damage are treatable using compounds identified by the methods of the

present invention. Chronic disorders in which neuronal damage is involved and for which treatment or prevention by the present invention is provided include disorders relating to the central nervous system and/or peripheral nervous system including age-related loss of cognitive function and senile dementia, chronic seizure disorders,

5     Alzheimer's disease, Parkinson's disease, dementia, memory loss, amyotrophic lateral sclerosis, multiple sclerosis, tuberous sclerosis, Wilson's Disease, cerebral and progressive supranuclear palsy, Guam disease, Lewy body dementia, prion diseases, such as spongiform encephalopathies, *e.g.*, Creutzfeldt-Jakob disease, Huntington's disease, myotonic dystrophy, Freidrich's ataxia and other ataxias, as well as Gilles de la

10    Tourette's syndrome, seizure disorders such as epilepsy and chronic seizure disorder, stroke, brain or spinal cord trauma, AIDS dementia, alcoholism, autism, retinal ischemia, glaucoma, autonomic function disorders such as hypertension and sleep disorders, and neuropsychiatric disorders that include, but are not limited to schizophrenia, schizoaffective disorder, attention deficit disorder, dysthymic disorder, major depressive

15    disorder, mania, obsessive-compulsive disorder, psychoactive substance use disorders, anxiety, panic disorder, as well as unipolar and bipolar affective disorders. Additional neuropsychiatric and neurodegenerative disorders include, for example, those listed in the American Psychiatric Association's Diagnostic and Statistical manual of Mental Disorders (DSM), the most current version of which is incorporated herein by reference

20    in its entirety.

In another embodiment, recombinant chimeric toxin molecules comprising erythropoietin can be used for therapeutic delivery of toxins to treat or prevent a proliferative disorder, such as cancer, or viral disorder, such as subacute sclerosing panencephalitis.

The following table lists additional exemplary, non-limiting indications as to the various conditions and diseases amenable to treatment by the aforementioned tissue protective cytokines.

<i>Cell, tissue or organ</i>	<i>Dysfunction or pathology</i>	<i>Condition or disease</i>	<i>Type</i>
Heart	Ischemia	Coronary artery disease	Acute, chronic Stable, unstable
		Myocardial infarction	Dressler's syndrome
		Angina	
		Congenital heart disease	Valvular Cardiomyopathy
		Prinzmetal angina	
		Cardiac rupture	Aneurysmatic Septal perforation
		Angitis	
	Arrhythmia	Tachy-, bradyarrhythmia <i>Supraventricular,</i> ventricular Conduction abnormalities	Stable, unstable Hypersensitive carotid sinus node
		Congestive heart failure	Cardiomyopathies, such as idiopathic familial, infective, metabolic, storage disease, deficiencies, connective tissue disorder, infiltration and granulomas, neurovascular
		Myocarditis	Autoimmune, infective, idiopathic
		Cor pulmonale	
	Blunt and penetrating trauma		
	Toxins	Cocaine toxicity	
Vascular	Hypertension	Primary, secondary	
	Decompression sickness		
	Fibromuscular hyperplasia		
	Aneurysm	Dissecting, ruptured, enlarging	
Lungs	Obstructive	Asthma Chronic bronchitis, Emphysema and airway obstruction	
	Ischemic lung disease	Pulmonary embolism, Pulmonary thrombosis, Fat embolism	
	Environmental lung diseases		
	Ischemic lung disease	Pulmonary embolism Pulmonary thrombosis	
	Interstitial lung disease	Idiopathic pulmonary fibrosis	
	Congenital	Cystic fibrosis	
	Cor pulmonale		
	Trauma		

<i>Cell, tissue or organ</i>	<i>Dysfunction or pathology</i>	<i>Condition or disease</i>	<i>Type</i>
	Pneumonia and pneumonitides	Infectious, parasitic, toxic, traumatic, burn, aspiration	
	Sarcoidosis		
Pancreas	Endocrine	Diabetes mellitus, type I and II	Beta cell failure, dysfunction Diabetic neuropathy
		Other endocrine cell failure of the pancreas	
	Exocrine	Exocrine pancreas failure	pancreatitis
Bone	Osteopenia	Primary secondary	Hypogonadism immobilisation Postmenopausal Age-related Hyperparathyroidism Hyperthyroidism Calcium, magnesium, phosphorus and/or vitamin D deficiency
	Osteomyelitis		
	Avascular necrosis		
	Trauma		
	Paget's disease		
Skin	Alopecia	Areata Totalis	Primary Secondary Male pattern baldness
	Vitiligo	Localized generalized	Primary secondary
	Diabetic ulceration		
	Peripheral vascular disease		
	Burn injuries		
Autoimmune disorders	Lupus erythematoses, Sjogren, Rheumatoid arthritis, Glomerulonephritis, Angitis		
	Langerhan's histiocytosis		
Eye	Optic neuritis		
	Blunt and penetrating injuries, Infections, Sarcoid, Sickle C disease, Retinal detachment, Temporal arteritis		
	Retinal ischemia, Macular degeneration, Retinitis pigmentosa, Arteriosclerotic retinopathy, Hypertensive retinopathy, Retinal artery blockage, Retinal vein blockage, Hypotension, Diabetic retinopathy, and Macular edema		
Embryonic and fetal disorders	Asphyxia		
	Ischemia		

<i>Cell, tissue or organ</i>	<i>Dysfunction or pathology</i>	<i>Condition or disease</i>	<i>Type</i>
CNS	Chronic fatigue syndrome, acute and chronic hypoosmolar and hyperosmolar syndromes, AIDS Dementia, Electrocution		
	Encephalitis	Rabies, Herpes	
	Meningitis		
	Subdural hematoma		
	Nicotine addiction		
	Drug abuse and withdrawal	Cocaine, heroin, crack, marijuana, LSD, PCP, poly-drug abuse, ecstasy, opioids, sedative hypnotics, amphetamines, caffeine	
	Obsessive-compulsive disorders		
	Spinal stenosis, Transverse myelitis, Guillain Barre, Trauma, Nerve root compression, Tumoral compression, Heat stroke		
ENT	Tinnitus Meuniere's syndrome Hearing loss		
	Traumatic injury, barotraumas		
Kidney	Renal failure	Acute, chronic	Vascular/ischemic, interstitial disease, diabetic kidney disease, nephrotic syndromes, infections, injury, contrast-induced, chemotherapy-induced, CPB-induced, or preventive
	Henoch S. Purpura		
Striated muscle	Autoimmune disorders	Myasthenia gravis Dermatomyositis Polymyositis	
	Myopathies	Inherited metabolic, endocrine and toxic	
	Heat stroke		
	Crush injury		
	Rhabdomyolysis		
	Mitochondrial disease		
	Infection	Necrotizing fasciitis	
Sexual dysfunction	Central and peripheral (e.g. erectile dysfunction)	Impotence secondary to medication, (diabetes)	
Liver	Hepatitis	Viral, bacterial, parasitic	
	Ischemic disease		
	Cirrhosis, fatty liver		
	Infiltrative/metabolic diseases		
Gastrointestinal	Ischemic bowel disease		

<i>Cell, tissue or organ</i>	<i>Dysfunction or pathology</i>	<i>Condition or disease</i>	<i>Type</i>
	Inflammatory bowel disease		
	Necrotizing enterocolitis		
Organ transplantation	Treatment of donor and recipient		
Reproductive tract	Infertility	Vascular Autoimmune Uterine abnormalities Implantation disorders	
Endocrine	Glandular hyper- and hypofunction		

As mentioned above, these diseases, disorders or conditions are merely illustrative of the range of benefits provided by the compounds identified by the methods of the present invention. Accordingly, this invention generally provides preventative, 5 therapeutic, or prophylactic treatment of the consequences of mechanical trauma or of human diseases. Prevention or therapeutic or prophylactic treatment for diseases, disorders or conditions of the CNS and/or peripheral nervous system are contemplated. Prevention or therapeutic or prophylactic treatment for diseases, disorders or conditions which have a psychiatric component is provided. Prevention or therapeutic or 10 prophylactic treatment for diseases, disorders or conditions including but not limited to those having an ophthalmic, cardiovascular, cardiopulmonary, respiratory, kidney, urinary, reproductive, gastrointestinal, endocrine, or metabolic component is provided.

In one embodiment, such a pharmaceutical composition comprising a compound that modulates the activity of a tissue protective cytokine receptor complex 15 can be administered systemically to protect or enhance the target cells, tissue or organ. Such administration may be parenterally, via inhalation, or transmucosally, *e.g.*, orally, nasally, rectally, intravaginally, sublingually, submucosally or transdermally. Preferably, administration is parenteral, *e.g.*, via intravenous or intraperitoneal injection, and also including, but is not limited to, intra-arterial, intramuscular, intradermal and 20 subcutaneous administration.

Selection of the preferred effective dose or amount of a compound will be readily determinable by a skilled artisan based upon considering several factors, which will be known to one of ordinary skill in the art. Such factors include the particular form of erythropoietin and/or compounds identified by the methods of the present invention, 5 and the pharmacokinetic parameters such as bioavailability, metabolism, half-life, *etc.*, which will have been established during the usual development procedures typically employed in obtaining regulatory approval for a pharmaceutical compound. Further factors in considering the dose include the condition or disease to be treated or the benefit to be achieved in a normal individual, the body mass of the patient, the route of 10 administration, whether administration is acute or chronic, concomitant medications, and other factors well known to affect the efficacy of administered pharmaceutical agents. Thus the precise dosage should be decided according to the judgment of the practitioner and each patient's circumstances, *e.g.*, depending upon the condition and the immune status of the individual patient, and according to standard clinical techniques.

15 The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

20

## 6. EXAMPLES

### 6.1 EXAMPLE 1: COMPETITIVE EPO BIOASSAY

The competitive binding assay described below was performed to determine whether carbamylated EPO binds to the EPO-R. UT-7 cells which express EPO-R were utilized to determine whether carbamylated EPO competitively inhibits

binding of rhEPO to the EPO-R. With binding of rhEPO to the EPO-R, cells exhibited proliferation. Inhibition of the proliferation is indicative of competitive binding.

### Methods

For the purpose of the competitive binding assay, erythroleukemic UT-7 cells (Komatsu, N. *et al.*, 1991, *Cancer Res.*, 51:341-8) were obtained from DSMZ (Braunschweig, Germany, ACC137). The assays of the carbamylated EPO and rhEPO were performed as described in Leveque *et al.* (1996, *Hematol Oncol* 14:137-46) over 48 hours. A WST-1 reduction (Roche #1 644 807) was used to quantitate the living cells. Signal to noise ratio of the assay was 8-15, and the half-maximal effective concentration of carbamylated EPO and rhEPO determined by a four parameter fit from concentration response curves using at least 6 drug concentrations. In this particular assay, the assays were performed with rhEPO, then separately with carbamylated EPO, and then the assay were performed with both rhEPO and carbamylated EPO.

The results show that cell proliferation was 0.6-fold and 1.7-fold greater, respectively, when rhEPO was administered as well as when carbamylated EPO and rhEPO were both incorporated into the assay. Carbamylated EPO alone, demonstrated no effect on cell proliferation even when used at increased concentrations.

Figure 1 shows the concentration of the test compound (rhEPO and carbamylated EPO) on the x-axis, plotted against cell proliferation on the y-axis. Figure 20 1 clearly shows that the presence of carbamylated EPO does not impact rhEPO's ability to stimulate the proliferation of UT-7 cells within the assay, since the competitive assay with both carbamylated EPO and rhEPO did not exhibit a decrease in cell proliferation.,

These results suggest that the carbamylated EPO does not bind to the classical EPO-R dimer complex present on UT-7 cells.

## 6.2 EXAMPLE 2: WESTERN BLOT OF RAT BRAIN MEMBRANE

Rat brain cells have been shown to be responsive to EPO. Membrane proteins of rat brain cells were isolated to determine whether these EPO responsive cells express either the  $\beta_c$  receptor or the  $\beta_c$  receptor associated with IL-3 specific receptor 5 component.

### Methods

Rat membrane proteins were isolated using the following protocol. Rat brain was homogenized in PBS containing protease inhibitors (25  $\mu$ g/ml Leupeptin (5mg/ml in stock), 10  $\mu$ g/ml Aprotin (1mg/ml in stock), 1 mM PMSF (100 mM in stock) 10 20X. The homogenized tissue was then centrifuged at 3,800 rpm for 5 minutes at 4° C. The supernatant is then collected and further centrifuged at 14,000 rpm for 30 minutes at 4° C. The pellet resulting from is centrifugation is then homogenized in PBS containing the protease inhibitor and 1% Triton X-100. This homogenate is then further centrifuged at 14,000 rpm for 30 minutes at 4° C. The resulting supernatant contains the membrane 15 proteins.

The membrane proteins were then separated by gel electrophoresis. The membrane proteins were blocked overnight with 1X casein (Vector 10X Casein Soln., Cat#: SP-5020) at 4° C. Using a Vector Avidin/Biotin Blocking Kit (Cat #: SP-2001) avidin and biotin blocks were generated. An avidin block is generated by adding 2 drops 20 of avidin per 10 ml 1X PBS-0.1% Tween-20/1X Casein for 20 mins, rinsing the block briefly, and then washing the block with 1X PBS-0.1% Tween -20/1X Casein for 10 mins. A biotin block was generated in a similar manner, by adding 2 drops of biotin per 10 ml 1X PBS-0.1% Tween-20/1X Casein for 20 mins, rinsing the block briefly, and then washing the block with 1X PBS-0.1% Tween -20/1X Casein for 10 mins. The 25 primary antibody (Common  $\beta$  Unit K-17 (Santa Cruz Biotechnology, Inc., Santa Cruz,

CA), dilution 1:200) was incubated for 1 hour at room temperature. The blocks were then washed four times for 10 minutes each with 1X PBS-0.1% Tween -20/1X Casein. A secondary incubation from the VECTASTAIN ABC kit (Peroxidase Rabbit IgG, Cat#: PK-4001) at a 1:1000 dilution (1 drop in 60 ml 1X PBS-0.1% Tween -20/1X Casein) 5 was performed for 1 hour at room temperature. The block was then washed 3 times for 10 mins each with 1X PBS-0.1% Tween -20. During the wash the AB reagent was prepared in 1X PBS-0.1% Tween -20: 2 drops of reagent A of the kit into 10 ml 1X PBS-0.1% Tween -20, mix well, 2 drops of reagent B, mix well, and incubate for 30 minutes at room temperature to allow complex formation. The membranes were then incubated 10 for 30 minutes at room temperature, then washed 3 times for 10 minutes each with 1X PBS-0.1% Tween -20. The substrate solution from the Vector Peroxidase Substrate Kit DAB in distilled water was prepared (2 drops of Buffer Stock Solution added to 10 ml distilled water, mixed, 4 drops DAB Stock Solution, mixed, 2 drops of Hydrogen Peroxide Solution, mixed) just prior to adding to the blots. The blot with the substrate 15 was then incubated at room temperature for 10 minutes or until the color developed. The blots were then washed with 2 changes of distilled water. This procedure was also repeated using a primary antibody for the IL-3 specific subunit (T-20, Santa Cruz Biotechnology, Inc., Santa Cruz, CA).

The results indicated that both the  $\beta_c$  receptor and  $\beta_c$  receptor specific to 20 IL-3 were identified in rat brain cell membranes.

**Figure 2** shows photographs of polyacrylamide gels of the separated membrane proteins. The first gel shows a 130 KD protein that corresponds to the  $\beta_c$  receptor. The second gel shows a 70KD protein that corresponds to the form of the  $\beta_c$  receptor specific to IL-3 receptor protein. The results clearly demonstrate the presence 25 of the  $\beta_c$  receptor (band at 130 kD) in an erythropoietin-responsive cell (brain). This

finding suggests that a tissue protective cytokine receptor complex may form in brain cell membranes, since both EPO receptors and  $\beta_c$  receptors are present in the membranes.

### 6.3 EXAMPLE 3: IMMUNOHISTOCHEMISTRY FOR $\beta_c$ RECEPTOR IN RAT SPINAL CORD

5 A rat spinal cord section was stained in order to test for the presence of  $\beta_c$  receptors.

#### Methods

The spinal cord of a rat was removed and fixed in paraffin. The embedded tissue was then sectioned (6 um). The section of spinal cord was then stained 10 using anti- $\beta_c$  receptor antibody (K-17, Santa Cruz Biotechnology, Inc., Santa Cruz, CA.

**Figure 3** shows a photograph the sectioned spinal cord stained for  $\beta_c$  receptor using anti  $\beta_c$  receptor antibody. The stain indicates the  $\beta_c$  receptor is present within the spinal cord.

15 **Figure 4** shows a photograph of a close up of the stained areas of the sectioned spinal cord demonstrating reactivity with the anti- $\beta_c$  receptor antibody.

This finding suggests the presence of tissue protective cytokine receptor complexes in spinal cord tissue, since  $\beta_c$  receptors and EPO receptors are present in these tissues.

### 6.4 EXAMPLE 4: COPRECIPITATION OF EPO-R AND $\beta_c$ RECEPTOR

20 To determine whether EPO receptor and  $\beta_c$  receptor are associated with one another in cells, receptor antibodies were used to coprecipitate complexes from cells that express both receptors. Membrane proteins from P-19 cells were separated by eletrophoresis on polyacrylamide gels and Western blots were performed to stain for EPO receptor and  $\beta_c$  receptor.

25 **Methods**

The immunoprecipitation of the EPO-R and  $\beta_c$  receptor from P-19 cells, neural-like embryonal carcinoma cells, was performed in accordance with the protocol outlined in Jubinsky *et al.*, 1997, (Blood 90:1867-1873). Using the antibodies specific to the receptor as described above in section 6.3 . Immunoprecipitates were then run on a 5 polyacrylymide gel and transferred by Western and stained using antibodies specific for EPO receptors and  $\beta_c$  receptors.

Figure 5 depicts a Western blot of the samples coimmunoprecipitated with the EPO-R and  $\beta_c$  receptor antibodies. Lane 1 shows the results of immunoprecipitation of the EPO-R in the absence of EPO on a western blot with the  $\beta_c$  10 receptor antibody (top) and the EPO-R antibody (bottom). A band representing the  $\beta_c$  receptor can clearly be seen on the gel (arrow pointing to appropriate band, top). The arrow on the top gel, stained with  $\beta_c$  receptor antibody, indicates the position where EPO receptor migrate if it were present in the sample. Lane 2 shows the results of immunoprecipitation of the EPO-R in the presence of EPO on a western blot with the  $\beta_c$  15 receptor antibody (top) and the EPO-R antibody (bottom). Lane 3 shows reverse immunoprecipitation, the band (bottom) indicates the presence of EPO-R in the sample immunoprecipitated using the  $\beta_c$  receptor antibody. The first arrow on the bottom gel, stained with EPO-R antibody, points to a band at about 103 kD that was identified as nucleolin (see Example 10, below). The second arrow on the bottom gel, stained with 20 EPO-R antibody, points to a band at about 68 kD that was identified as EPO receptor (see Example 10, below).

The results suggest that EPO-R and  $\beta_c$  receptor form a complex in cells where both receptors are expressed. Finally, complexes were formed whether or not EPO itself was present (compare Lane 1 to Lane 2), suggesting that EPO is not necessary 25 for formation of a tissue protective cytokine receptor complex.

## 6.5 EXAMPLE 5: APOPTOSIS IN CARDIOMYOCYTES WITH AND WITHOUT $\beta_c$ RECEPTOR

Apoptosis in cardiomyocytes was induced in wild type cardiomyocytes from normal mice and in cardiomyocytes from  $\beta_c$  chain knockout (-/-) mice to determine 5 whether  $\beta_c$  receptors played a role in the protective activity of EPO on cells in preventing or delaying apoptosis.

### Methods

Cardiomyocytes were isolated from either wild type C57BL/6-129Sv or strain matched common beta chain knockout  $\beta_c$  (-/-) mice (Robb *et al.*, 1995, P.N.A.S. 10 U.S.A. 92:9565-9569) as described (Fiordaliso *et al.*, 2001, Diabetes 50:2363-2375). Apoptotic cell death was induced by incubating in staurosporine (Sigma, 0.1  $\mu$ M) in the presence or absence of erythropoietin (100ng/ml). Wild type and  $\beta_c$  (-/-) cardiomyocyte cells served as controls (Columns 1 and 2 of Figure 7) where apoptosis was not induced. Apoptosis was induced in wild type and  $\beta_c$  (-/-) cardiomyocyte cells (Columns 3 and 4 15 of Figure 7), wild type cardiomyocyte cells in the presence of EPO or carbamylated EPO (Columns 5 and 6 of Figure 7), and  $\beta_c$  (-/-) cardiomyocyte cells in the presence of EPO (Column 7 of Figure 7).

Following 16 hours incubation, cells were fixed and processed for *in situ* detection of fragmented DNA using TUNEL (Roche Diagnostics).

20 The results are shown in Figure 7, which shows the percent apoptosis (y-axis) in isolated cardiomyocytes from normal and  $\beta_c$  receptor knockout mice in the presence and absence of EPO (Columns 3-7). The percent apoptosis for  $\beta_c$  (-/-) cardiomyocyte cells where apoptosis was induced in the presence of EPO (Column 7) did not significantly differ from the percent apoptosis in wild type and  $\beta_c$  (-/-) 25 cardiomyocyte cells in the absence of EPO (see Columns 3 and 4).

The results suggest that the tissue protective activity of EPO is dependent on the presence of a  $\beta_c$  receptor in these cells.

#### 6.6 EXAMPLE 6: DOWNSTREAM KINASE ACTIVATION VIA THE EPO RECEPTOR

5 To determine whether EPO and carbamylated EPO of varying concentrations were capable of inducing downstream kinase activity in cells expressing the EPO receptor, EPO receptor expressing cells were examined for the presence of an activated kinase, phosphorylated Jak2, in the presence of EPO and carbamylated EPO.

##### Methods

10 BaF/3/EPOR cells were stimulated for 10 min. with EPO or carbamylated EPO at different concentrations. Activation of Jak2 was analyzed by Western blotting of cell lysates using an antibody recognizing tyrosine-phosphorylated Jak2 (PY-Jak2). Membranes were stripped and reprobed with an antibody against Jak2 to confirm equal loading.

15 **Figure 8** shows Western blots of the cell proteins separated by polyacrylamide gel electrophoresis and stained using PY-Jak2 antibodies. The top shows that phosphorylated Jak2 was present in cells stimulated with EPO at 5 nM and 50nM concentrations.

The results suggest that carbamylated EPO cannot induce downstream 20 activation of the classical EPO receptor homodimer in cells expressing the EPO receptor. This suggests carbamylated EPO does not bind to the classical EPO receptor homodimer.

#### 6.7 EXAMPLE 7: BAF3/EPOR CELL-BINDING ASSAY

To determine whether cells expressing the EPO receptor bind EPO and carbamylated EPO, BaF3 cells were contacted with each ligand and binding affinity was 25 measured in a competitive binding assay.

Methods

0.1 nM  $^{125}\text{I}$  EPO and graded doses of unlabelled EPO and carbamylated EPO, respectively were incubated 30 min at RT in PBS in 106 wells. The membranes were washed on filters and counted for membrane bound  $^{125}\text{I}$  EPO in a gammacounter.

5 The receptor bound fraction of radioligand was plotted as bound  $^{125}\text{I}$  EPO against graded doses of unlabelled ligand.

Figure 9 shows a graph of ligand binding affinity for BaF3 cells expressing the EPO receptor. Ligand concentration in nM (x-axis) is plotted against binding (cpm) (y-axis) for BaF3 EPO receptor expressing cells contacted with EPO

10 receptor ligands EPO and carbamylated EPO.

The BaF-3/EPO-R cells bind EPO with an affinity of about 1 nM, whereas no carbamylated EPO binding was detectable. The results indicate that carbamylated EPO does not competitively inhibit binding of EPO to cells expressing the EPO receptor.

15 **6.8 EXAMPLE 8: UT-7 MEMBRANE ASSAY**

To determine whether cells expressing the classical EPO receptor dimer bind EPO and carbamylated EPO, UT-7 cell membranes were contacted with each ligand and binding affinity was measured in a competitive binding assay.

Methods

20 One hundred micrograms of UT-7 membranes were incubated 30 min at room temperature in 200  $\mu\text{l}$  PBS with 0.1 nM  $^{125}\text{I}$  EPO and graded doses of unlabelled EPO and carbamylated EPO, respectively. The membranes were washed on filters and counted for membrane bound  $^{125}\text{I}$  EPO in a gammacounter. The receptor-bound fraction of radioligand was plotted as bound  $^{125}\text{I}$  EPO against graded doses of unlabelled ligand.

The UT-7 membranes bind EPO with an affinity of 0.1 –0.5 nM. In contrast, no carbamylated EPO binding was detected.

Figure 10 shows a graph of ligand binding affinity for UT-7 cell membranes having the EPO receptor. Ligand concentration in nM (x-axis) is plotted against binding (cpm) (y-axis) for UT-7 EPO receptor expressing cell membranes contacted with EPO receptor ligands EPO and carbamylated EPO.

The results indicate that carbamylated EPO does not competitively inhibit binding of EPO to cells expressing both the classical EPO receptor dimer.

#### 6.9 EXAMPLE 9: HEMOTOCRIT AND HEMOGLOBULIN CONCENTRATIONS

Mice were administered EPO and modified EPO to determine whether carbamylated EPO or asialoEPO have the same erythropoietic capabilities, *i.e.*, increased hematocrit and increased hemoglobin, as EPO.

##### Methods

Mice were injected intravenously 5 times per week with 50 $\mu$ g/kg of EPO, carbamylated EPO and asialoEPO for 4 weeks. Serum hemoglobin concentrations and the hematocrite were determined by a hemoglobinometer using blood (<50  $\mu$ l) withdrawn from the retroorbital plexus under isoflurane anesthesia.

Figure 11 shows histograms of 11A, hematocrit levels as measured by the percent volume of hematocrit (y-axis), and 11B, hemoglobin levels measured in concentration in mM (y-axis), in mice after administration of control (vehicle), EPO, carbamylated EPO, and asialoEPO (x-axis).

The results indicate that carbamylated EPO and asialoEPO administered to mice do not induce the increased hematocrit and hemoglobin exhibited by mice which were administered EPO. This suggests that carbamylated EPO and asialoEPO interact

differently with cells *in vivo* in comparison to EPO. When combined with the experimental results of the above binding assays, these results confirm that carbamylated EPO and asialoEPO do not bind the EPO receptor and therefore cannot impart the erythropoietic activities of EPO.

5    **6.10 EXAMPLE 10: DETECTING THE PRESENCE OF NUCLEOLIN**

The precipitation using Western blot and the  $\beta_c$  receptor antibody described in Example 4 above was further analyzed. In particular, the protein corresponding to the 103 KD band shown in Figure 5 five Lane 1 (top) further analyzed to determine the identity of another protein that had precipitated in the samples.

10    **Methods**

P19 cells were grown to 70% confluence in complete medium. They were treated with 10 ng/ml EPO or saline (C) for 15 min, then detached by tapping on the flask, spun for 7 min at 700 rpm and resuspended in lysis buffer (TBS with protease inhibitors, 2mM CaCl, 1% Triton and 1%NP40) to give a final concentration of 1mg 15 protein/ml. CaCl was present in the lysis buffer, and freezing or vortexing were avoided, to maintain protein interactions. After removal of debris by centrifugation for 10 min at 120000 rpm, the lysate was incubated with protein A sepharose (Pharmacia, 10 microL drained gel/ml) for 1h at room temperature to remove non specific binding.

20    The supernatant was then incubated with protein A Sepharose (10 microL gel/ml) previously coupled to the antibody for 1h and washed three times with lysis buffer. Either an antibody against beta common chain (K17, Santa Cruz Biotechnologies) or a mixture of two antibodies against EPO-R (M20 and h194, Santa Cruz Biotechnologies) at a final dilution of 1:200 were used and the incubation was run overnight at 4°C. Protein A sepharose beads were then washed five times with low 25    detergent lysis buffer (the same as above, except 0.5% Triton and no NP40) and bound

proteins were dissociated by the addition of 30 microL of 2x Laemmli sample buffer with 5% beta-mercaptoethanol and run on a 10% SDS-PAGE.

The 103 kD band was excised from Coomassie blue stained gel, destained for few hours in 25 mM ammonium bicarbonate/40% ethanol and washed with a 5 sequential increasing percentage of acetonitrile. Proteins were in gel-digested overnight at 30°C with trypsin (Promega, Madison WI) at a concentration of 12 ng/ml in a 25 mM ammonium bicarbonate/10% acetonitrile solution. Peptide mass fingerprinting (PMF) was performed on a Bruker ReflexIIITM matrix-assisted laser desorption/ionization (MALDI) mass spectrometer using a-cyano-4-hydroxycinnamic acid (Bruker Daltonics Billerica, MA) as a matrix. The mass spectra were externally calibrated with a mixture of 10 7 standard peptides in the range between 1000 to 3000 Da. Data generated were subjected to database (NCBInr) searching using as programs Mascot (<http://www.matrixscience.com>) and Profound (<http://prowl.rockefeller.edu/>) allowing up to 1 missed trypsin cleavage and a mass tolerance of  $\pm 0.2$  Da. Mass spectrometry was 15 used to determine the identity of nucleolin.

The results suggest that the P19 cells expressing the EPO receptor and the  $\beta_c$  receptor that form a tissue protective cytokine receptor complex produce nucleolin in response to administration of EPO. **Figure 12** shows a photograph of the SDS-PAGE gel with a 103 KD nucleolin protein circled.

20 **6.11 EXAMPLE 11: SPINAL CORD INJURY IN  $\beta_c$  RECEPTOR KNOCK-OUT MICE**

Spinal cord injury was induced in  $\beta_c$  chain knockout (-/-) mice and normal (wild type) mice to further investigate the results described above in cardiomyocytes from  $\beta_c$  knockout mice and to determine whether  $\beta_c$  receptors played a role in the 25 protective activity of EPO following spinal injury.

Methods

Spinal cord injury was performed in mice using a modification of the protocol of Farooque (2000, *Acta Neuropathol (Berl)* 100:13-22). The technique produced an animal model that was used to test treatment of damaged excitable cells, 5 tissues, and organs using EPO and carbamylated EPO. Specifically, C57/bl6 (wild) or  $\beta_c$  receptors knock-out (null) mice of 8-16 weeks of age were used. Each animal was confirmed null by PCR analysis of DNA obtained from the tail. Spinal injury was inflicted in five groups of mice each containing 4-9 mice. Two groups of wild type mice and three groups of null mice. During spinal injury, animals were anesthetized with 10 isoflurane and a normal core temperature maintained. A laminectomy was performed at T3 and a 2 mm stainless steel rod was applied to the dura with 15 grams of force for 4 minutes and then removed.

Immediately following injury, a single dose of carbamylated EPO was administered to the first group of null mice, a single dose of EPO was administered to the 15 second group of null mice, PBS was administered as a control to the third group of null mice, a single dose of carbamylated EPO was administered to the first group of wild type mice, and a single dose of PBS was administered to the second group of wild type mice.

Animals were then assessed for 42 days using the scoring system of Basso et al. (1995, *J. Neurotrauma* 12:1-21). The Basso, Beattie, Bresnahan (BBB) scale is a 20 21-point scale for testing normal overground motor locomotion that is commonly used to measure of functional recovery following spinal cord injury. The BBB score is very sensitive for detecting fine motor deficits and also assesses the degree of recovery after a spinal cord injury. BBB motor scores were plotted versus number of days post injury for all groups of animals. Clinical severity was then calculated measuring the area under the 25 curve (AUC) of the plot of BBB versus number of days post injury. Clinical severity

values among groups of mice were analyzed statically for differences and a bar graph showing the clinical severity values for each group was generated.

The results confirm those in cardiomyocyte cells and suggest that the tissue protective activity of EPO is dependent on the presence of a  $\beta_c$  receptor in animals.

5 The results are shown in **Figure 13**, which shows the BBB motor score (y-axis) versus time in days following injury (x-axis). The wild type group of mice administered carbamylated EPO exhibited increased motor scores throughout the 42 post-injury time period in comparison to all other groups. The results are shown in **Figure 14**, which shows the clinical severity measured in area under curve (AUC) (y-axis) and groups of mice (x-axis). The wild type group of mice administered carbamylated EPO (column 1) exhibited a significant increase in clinical severity values (*i.e.*, less severity) in comparison to all other groups (columns 2-5). The group of null mice administered EPO (column 5) exhibited very high mortality in comparison to all other groups. The results suggest that a  $\beta_c$  receptor is necessary to achieve the therapeutic benefit of EPO in 10 treating injury.

15

The invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the 20 invention. Indeed various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All references cited herein are incorporated by reference herein in their 25 entireties for all purposes.

## WHAT IS CLAIMED:

1. A method for identifying a compound that modulates a tissue protective activity, comprising:
  - 5 (a) contacting a test compound with a tissue protective cytokine receptor complex;
  - (b) measuring the level of tissue protective cytokine receptor complex activity;
  - (c) identifying a test compound which increases or decreases the level of tissue protective cytokine receptor complex activity as compared to the level of tissue protective cytokine receptor complex activity measured in the absence of the test compound; and
  - (d) assaying the identified test compound for tissue protective activity.
- 10 2. The method of claim 1 wherein the tissue protective cytokine receptor complex activity is measured by measuring the binding of the test compound to the tissue protective cytokine receptor complex.
- 15 3. The method of claim 2, wherein the test compound is labeled and binding of the labeled test compound to the tissue protective cytokine receptor complex is measured by detecting the label attached to the test compound.
- 20 4. The method of claim 2 wherein the tissue protective cytokine receptor complex activity is measured by measuring the binding of the test compound to the tissue protective cytokine receptor complex.
5. A method for identifying a compound that modulates a tissue protective activity, comprising:
  - 25 (a) contacting a test compound with a tissue protective cytokine receptor complex-expressing cell; and
  - (b) measuring the level of tissue protective cytokine receptor complex activity in the cell;

(c) identifying a test compound which increases or decreases the tissue protective cytokine receptor complex activity as compared to the level of tissue protective cytokine receptor complex activity measured in the absence of the test compound; and

5 (d) assaying for the identified test compound for a tissue protective activity.

6. The method of Claim 5, wherein the tissue protective cytokine receptor complex activity is measured by a cell proliferation assay.

7. The method of Claim 5, wherein the cell is recombinantly engineered to express at least one EPO or  $\beta$  common receptors.

10 8. The method of Claim 7, wherein the cell endogenously expresses an EPO receptor and is transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a  $\beta$  common receptor polypeptide.

9. The method of Claim 7, wherein the cell endogenously expresses a  $\beta$  common receptor and is transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes an EPO receptor polypeptide.

15

10. The method of Claim 8 or 9, wherein the nucleotide sequence is derived from the same species as the cell.

11. A method for identifying a compound that modulates a tissue protective activity, comprising:

20 (a) contacting a test compound with a cell which is recombinantly engineered to express an EPO receptor, wherein said cell is transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a  $\beta$  common receptor polypeptide;

(b) measuring the level of tissue protective cytokine receptor complex activity in the cell;

25 (c) identifying a test compound that increases or decreases the level of tissue protective cytokine receptor complex activity in the cell relative to the level of tissue protective cytokine receptor complex activity measured in a control cell,

wherein the control cell is of the same cell type as the cell of step (a) and is not transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a  $\beta$  common receptor polypeptide; and

5 (d) assaying the identified test compound for a tissue protective activity.

12. A method for identifying a compound that modulates a tissue protective activity, comprising:

10 (a) contacting a test compound with a recombinant cell that expresses a  $\beta$  common receptor, wherein said cell is transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a EPO receptor polypeptide;

15 (b) measuring the level of tissue protective cytokine receptor complex activity in the cell;

20 (c) identifying a test compound that increases or decreases the level of tissue protective cytokine receptor complex activity in the cell relative to the level of tissue protective cytokine receptor complex activity measured in a control cell, wherein the control cell is of the same cell type as the cell of step (a) and is not transformed with a nucleic acid comprising a nucleotide sequence that (i) is operably linked to a promoter, and (ii) encodes a  $\beta$  common receptor polypeptide; and

25 (d) assaying the identified test compound for a tissue protective activity.

13. A method for identifying a compound that modulates a tissue protective activity, comprising:

25 (a) contacting a test compound with a tissue protective cytokine receptor complex-expressing cell, wherein said cell is transformed with a nucleic acid comprising a nucleotide sequence that encodes a reporter gene operably linked to a regulatory element associated with a tissue protective cytokine receptor complex activity;

30 (b) identifying a test compound that increases or decreases the level of reporter gene expression relative to the level of reporter gene expression measured in the absence of the test compound, and

(c) assaying the identified test compound for a tissue protective activity.

14. The method of Claim 13, wherein the regulatory element is a serum response element.

15. A method of identifying a compound that modulates a tissue protective activity, comprising:

5 (a) contacting a test compound with a cell comprising:

- (i) a nucleic acid sequence comprising a reporter gene operably linked to a binding site specific for a DNA binding domain of a transcriptional activator;
- (ii) a first fusion protein comprising (A) the DNA binding domain of the transcriptional activator, and (B) a first tissue protective cytokine receptor polypeptide or a fragment thereof; and
- (iii) a second fusion protein comprising (A) an activation domain of the transcriptional activator and (B) a second tissue protective cytokine receptor,

15 (b) detecting reporter gene expression,

such that if the reporter gene expression in (b) differs relative to the reporter gene expression detected in the absence of the test compound, a compound that modulates a tissue protective activity is identified.

16. The method of any one of Claims 5, 11, 12, 13, or 15, wherein the cell is a  
20 prokaryotic cell.

17. The method of any one of Claims 5, 11, 12, 13, or 15, wherein the cell is a eukaryotic cell.

18. The method of Claim 17, wherein the eukaryotic cell is a human cell.

19. The method of any one of Claims 5, 11, 12, 13, or 15, wherein the cell  
25 endogenously expresses at least one receptor of the tissue protective cytokine receptor complex.

20. The method of any one of Claims 5, 11, 12, 13, or 15, wherein the cell is a BaF3 cell.

21. A method of identifying a compound that modulates the activity of a tissue protective cytokine receptor complex, said method comprising:

(a) contacting a test compound with a cell of a modified yeast strain containing (i) a nucleotide sequence encoding a reporter gene that is operably linked to a tissue protective cytokine receptor complex-responsive promoter and (ii) expresses a tissue protective cytokine receptor complex; and

(b) determining the level of activity of a tissue protective cytokine receptor complex by measuring the level of reporter gene expression, such that if the level of reporter gene activity in the presence of the compound increases or decreases relative to the level of reporter gene activity in the absence of the compound, then a compound that modulates the activity of a tissue protective cytokine receptor complex is identified.

22. A method for identifying a compound that binds to a tissue protective cytokine receptor complex, comprising:

(a) contacting a tissue protective cytokine receptor complex with (i) a tissue protective cytokine receptor complex ligand attached to a first label and (ii) an equivalent amount of a test compound attached to a second label under conditions conducive to binding;

(b) removing unbound material from the tissue protective cytokine receptor complex; and

(c) detecting the level of the first and second labels wherein if the second label is present the compound binds the complex and if the level of the first label decreases relative to the level of the first label where the labeled ligand is contacted with a tissue protective cytokine receptor complex under conditions conducive to binding in the absence of a test compound after removal of unbound material,

then a compound that binds to a tissue protective cytokine receptor complex y is identified.

23. A method for identifying a compound that modulates the binding of a tissue protective cytokine receptor complex ligand to a tissue protective cytokine receptor complex, comprising:

(a) contacting a tissue protective cytokine receptor complex ligand with a tissue protective cytokine receptor complex in the presence of one or more test compounds under conditions conducive to binding; and  
(b) measuring the amount of tissue protective cytokine receptor complex ligand bound to the tissue protective cytokine receptor complex;  
such that if the amount of bound tissue protective cytokine receptor complex ligand measured in (b) differs from the amount of bound tissue protective cytokine receptor complex ligand measured in the absence of the one or more test compounds, then a compound that modulates the binding of a tissue protective cytokine receptor complex ligand to the tissue protective cytokine receptor complex is identified.  
10

24. The method of Claim 23, wherein the amount of bound tissue protective cytokine receptor complex ligand is measured using a tissue protective cytokine receptor complex ligand-specific antibody.  
15  
25. The method of Claim 23, wherein the tissue protective cytokine receptor complex ligand is labeled and binding of the tissue protective cytokine receptor complex ligand to the tissue protective cytokine receptor complex is measured by detecting the label attached to the tissue protective cytokine receptor complex ligand.

26. The method of any one of Claim 23, wherein the tissue protective cytokine receptor complex ligand is labeled and binding of the labeled ligand to the tissue protective cytokine receptor complex is measured by detecting the label attached to the tissue protective cytokine receptor complex ligand.  
20

27. The method of Claim 24, wherein the label is fluorescent.

28. A method for identifying a compound that modulates the interaction between a tissue protective cytokine receptor complex and a tissue protective cytokine receptor complex ligand, comprising:  
25  
(a) contacting a tissue protective cytokine receptor complex with one or more test compounds; and  
(b) measuring the tissue protective cytokine receptor complex activity,

such that if the activity measured in (b) differs from the tissue protective cytokine receptor complex activity in the absence of the one or more test compounds, then a compound that modulates the interaction between the tissue protective cytokine receptor complex and the tissue protective cytokine receptor complex ligand is identified.

- 5 29. The method of any one of Claims 1, 5, 11, 12, or 28, wherein the tissue protective cytokine receptor complex activity is measured by cell proliferation or cell differentiation.
30. The method of any one of Claims 1, 5, 11, 12, or 28, wherein the tissue protective cytokine receptor complex activity measured is the ability of the tissue protective 10 cytokine receptor complex to interact with a tissue protective cytokine receptor complex ligand.
31. The method of any one of Claims 1, 5, 11, 12, 13, 22, or 28, wherein the step of assaying the identified compound for tissue protective activity comprises detecting the presence of nucleolin in the cell.
- 15 32. The method of any one of Claims 1, 5, 11, 12, 13, 22, or 28, wherein the step of assaying the identified compound for tissue protective activity comprises detecting or measuring an increased level of activity of neuroglobin or cytoglobin in a cell.
33. The method of any one of Claims 1, 22, 23, or 28, wherein the tissue protective cytokine receptor complex is in solution.
- 20 34. The method of any one of Claims 1, 22, 23, or 28, wherein the tissue protective cytokine receptor complex is in a cell.
35. The method of Claim 23, or 28, wherein the compound inhibits the binding of a tissue protective cytokine receptor complex ligand to a tissue protective cytokine receptor complex.
- 25 36. The method of Claim 23, or 28, wherein the compound enhances the binding of a tissue protective cytokine receptor complex ligand to a tissue protective cytokine receptor complex.

37. The method of any one of Claims 1, 22, 23, or 28, wherein the tissue protective cytokine receptor complex contacted in step (a) is on a cell surface.

38. The method of any one of Claims 1, 22, 23, or 28, wherein the tissue protective cytokine receptor complex is on an isolated cell membrane.

5 39. The method of any one of Claims 1, 22, 23, or 28, wherein the tissue protective cytokine receptor complex is immobilized to a solid surface.

40. The method of Claim 39, wherein the solid surface is a microtiter dish.

41. The method of Claim 39, wherein the solid surface is a chip.

42. A method for identifying a compound that binds a tissue protective cytokine 10 receptor complex, comprising:

(a) contacting a test compound with a ligand-binding tissue protective receptor complex fragment comprising at least one EPO receptor extracellular domain and at least one  $\beta$  common receptor extracellular domain fused to an F<sub>c</sub> fragment attached to a solid support; and  
15 (b) removing unbound test compounds from the solid support;  
(c) identifying the compound attached to the tissue protective cytokine receptor complex fragment,  
such that a compound bound to the solid support is identified as a compound that binds to a tissue protective cytokine receptor complex.

20 43. The method of any one of Claims 1, 5, 11, 12, 13, 15, 16, 22, 23, 28, or 42, wherein the test compound is an antibody specific for the tissue protective cytokine receptor complex.

44. The method of any one of Claims 16, 22, 23, 28, or 42, wherein the test 25 compound is an antibody specific for a tissue protective cytokine receptor complex ligand.

45. The method of any one of Claims 1, 5, 11, 12, 13, 15, 16, 22, 23, 28, or 42, wherein the test compound is a small molecule.

46. The method of any one of Claims 1, 5, 11, 12, 13, 15, 16, 22, 23, 28, or 42, wherein the test compound is a peptide.

47. The method of any one of Claims 1, 5, 11, 12, 13, 15, 16, 22, 23, 28, or 42, wherein the test compound is a member of a library.

5 48. The method of any one of Claims 16, 22, 23, 28, or 42, wherein the tissue protective cytokine receptor complex ligand is an EPO.

49. The method of any one of Claims 1, 5, 11, 12, 13, 28, or 42, wherein the compound binds the tissue protective cytokine receptor complex.

10 50. The method of any one of Claims 16, 23, 28, or 42, wherein the compound binds the tissue protective cytokine receptor complex ligand.

51. A method for identifying a compound that modulates a tissue protective activity in a mammal, comprising:

- (a) administering the compound to a first animal immediately following infliction of an injury, wherein the first animal endogenously expresses a tissue protective cytokine receptor complex; and
- (b) administering the compound to a second animal immediately following infliction of the same injury as in step (a), wherein the second animal is deficient in expression of a tissue protective cytokine receptor complex;

20 such that if recovery from the injury differs in the animal of step (a) as compared to the animal of step (b), a compound that modulates a tissue protective activity is identified.

52. A method of treating or preventing a disease or disorder in a human comprising administering a therapeutically effective amount of a compound that modulates the 25 activity of a tissue protective cytokine receptor complex to a human in need of such treatment or prevention, with the proviso that the compound is not an EPO.

53. The method of claim 52 wherein the disease or disorder is a disease or disorder of or affecting excitable tissue.

54. A method for enhancing the function of excitable cells, tissues, or organs in a human comprising administering a therapeutically effective amount of a compound that 5 modulates the activity of a tissue protective cytokine receptor complex to a human in need thereof, wherein said enhancing the function of excitable cells, tissues, or organs results in the enhancement of associative learning or memory, with the proviso that the compound is not an EPO.

10 55. A method for modulating the activity of a tissue protective cytokine receptor complex in a human, comprising administering a compound that modulates the activity of said complex to a human in need of such treatment or prevention, with the proviso that the compound is not an EPO.

56. A method for treating or preventing a disease or disorder in a human comprising modulating a tissue protective cytokine receptor complex in a human.

15 57. A method for enhancing the function of excitable cells, tissues, or organs in a human comprising modulating a tissue protective cytokine receptor complex in a human.

58. The method of any one of claims 52, 53, 54, or 55 wherein the compound is identified by the method of any one of claims 1-5, 11-15, 21-23, 28, and 42.

20 59. The method of any one of claims 52, 53, 54, or 55 wherein the compound is an antibody specific for the tissue protective cytokine receptor complex.

60. The method of any one of claims 52, 53, 54, or 55 wherein the compound is an antibody specific for a tissue protective cytokine receptor complex ligand.

61. The method of any one of claims 52, 53, 54, or 55 wherein the compound is a small molecule, peptide, or a member of a library.

25 62. The method of any one of claims 52, 53, 54, or 55 wherein the compound binds to the tissue protective cytokine receptor complex.

63. The method of any one of claims 52, 53, 54, or 55 wherein the compound enhances the activity of the tissue protective cytokine receptor complex.

64. The method of any one of claims 52, 53, 54, or 55 wherein the compound interferes with the activity of the tissue protective cytokine receptor complex.

5 65. The method of any one of claims 52, 53, 54, or 55 wherein the compound is administered in conjunction with an EPO.

66. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is a mood disorder, an anxiety disorder, depression, autism, an attention deficit hyperactivity disorder, Alzheimer's disease, aging, or cognitive dysfunction.

10 67. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is caused by hypoxia, seizure disorders, neurodegenerative diseases, neurotoxin poisoning, multiple sclerosis, hypotension, cardiac arrest, radiation, or hypoglycemia.

68. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is ischemia or stroke.

15 69. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is a neurodegenerative condition.

70. The method of claim 69 wherein the neurodegenerative condition is stroke, Alzheimer's disease, Parkinson's disease, cerebral palsy, brain or spinal cord trauma, AIDS dementia, age-related loss of cognitive function, memory loss, amyotrophic lateral 20 sclerosis, seizure disorders, alcoholism, aging, or neuronal loss.

71. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is a neuromuscular or muscular condition.

72. The method of claim 71 wherein the neuromuscular or muscular condition is of a heart tissue.

73. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is of the heart.

74. The method of claim 73 wherein the disease or disorder is congestive heart failure, coronary artery disease, ischemia, myocardial infarction, angina, congenital heart disease, prinzmetal angina, cardiac rupture, angiitis, arrhythmia, tachy-bradyarrhythmia, supraventricular, ventricular, conduction abnormalities, myocarditis, cor pulmonale, or Blunt and penetrating trauma.

5 75. The method of any one of claims 52, 53, or 56 wherein the disease or disorder is of the eye.

10 76. The method of claim 73 wherein the disease or disorder is optic neuritis, blunt and penetrating injuries, infections, sarcoid, sickle cell disease, retinal detachment, temporal arteritis, retinal ischemia, macular degeneration, retinitis pigmentosa, arteriosclerotic retinopathy, hypertensive retinopathy, retinal artery blockage, retinal vein blockage, hypotension, diabetic retinopathy, or macular edema.

15 77. The method of claim 54 or 57 wherein the excitable tissue is central nervous system tissue or peripheral nervous system tissue.

78. The method of claim 77 wherein the peripheral nervous system tissue is placental tissue, retinal tissue, or cardiac tissue.

20 79. The method of any one of claims 52, 53, 54, or 55 wherein the administration is oral, topical, intracranial, intraluminal, inhalation, parenteral, intravenous, peripherally, intraarterial, subcutaneous, intramuscular, intraperitoneal, submucosal or intradermal administration.

80. The method of any one of claims 52, 53, 54, or 55 wherein the administration is prior to a medical, surgical, or natural procedure.

25 81. The method of claim 80 wherein the surgical procedure is tumor resection, aneurysm repair, or a coronary artery bypass procedure.

82. The method of claim 80 wherein the medical procedure is chemotherapy.
83. The method of claim 80 wherein the natural procedure is labor or delivery.

1/15




FIG. 1

2/15




FIG.2

3/15





FIG.3

SUBSTITUTE SHEET (RULE 26)

4/15



5/15




FIG.5

6/15




FIG. 6

7/15



APOPTOSIS IN ISOLATED CARDIOMYOCYTES  
EPO OR CARBAMYLATED EPO [100ng/ml]

FIG. 7

8/15



BLOT: Jak2

FIG.8

9/15




FIG. 9

10/15





FIG. 10

11/15




\* p = 0.05

FIG. 11A

12/15

## HEMOGLOBIN CONCENTRATION



\* p = 0.05

FIG. 11B

13/15




FIG. 12

14/15




FIG. 13

15/15




FIG. 14

## SEQUENCE LISTING

<110> The Kenneth Warren Institute, Inc.  
<120> TISSUE PROTECTIVE CYTOKINE RECEPTOR COMPLEX, ASSAYS FOR IDENTIFYING  
TISSUE PROTECTIVE COMPOUNDS AND USES THEREOF

<130> 10165-028-228

<140>  
<141>

<150> 10/676,694  
<151> 2003-09-30

<150> 60/465,891  
<151> 2003-04-25

<160> 212

<170> PatentIn version 3.2

<210> 1  
<211> 5  
<212> PRT  
<213> Homo sapiens

<400> 1

Val Leu Gln Arg Tyr  
1 5

<210> 2  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 2

Thr Lys Val Asn Phe Tyr Ala Trp  
1 5

<210> 3  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 3

Ser Gly Leu Arg Ser Leu Thr Thr Leu  
1 5

<210> 4  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 4

Ser Asn Phe Leu Arg Gly  
1 5

<210> 5  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 5

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Glu Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 6  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 6

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Asp Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp

180

185

190

Arg

<210> 7  
<211> 580  
<212> DNA  
<213> Homo sapiens

<400> 7  
atgggggtgc acgaatgtcc tgccctggctg tggcttctcc tgcctcgct gtcgctccct 60  
ctggggctcc cagtcctggg cgccccacca cgccctcatct gtgacagccg agtcctggag 120  
aggtacctct tggaggccaa ggaggccgag aatatcacga cgggctgtgc tgaacactgc 180  
agcttgaatg agaatatcac tgcctccagac accaaagtta atttctatgc ctggaaagagg 240  
atggaggtcg ggcagcaggc cgtagaagtc tggcagggcc tggccctgct gtcggaagct 300  
gtcctgcggg gccaggccct gttggtaaac tcttccctc cgtgggagcc cctgcactgc 360  
atgtggataa agccgtcagt ggccttcgca gcctcaccac tctgcttcgg gctctggag 420  
cccagaagga agccatctcc cctccagatg cggcctcagc tgctccactc cgaacaatca 480  
ctgctgacac tttcgcaaac tcttccgagt ctactccaat ttccctccggg gaaagctgaa 540  
gctgtacaca ggggaggcct gcaggacagg ggacagatga 580

<210> 8  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 8  
agctctcgag gcgccggagat ggggggtgcac gaatg 35

<210> 9  
<211> 36  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 9  
atgctctaga cacacctggc catctgtccc ctgtcc 36

<210> 10  
<211> 193  
<212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 11  
<211> 45  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 11  
catgtggata aagccgtcga gggccttcgc agcctcacca ctctg 45

<210> 12  
<211> 45  
<212> DNA  
<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 12  
cagagtggtg aggctgcgaa ggccctcgac ggctttatcc acatg 45

<210> 13  
<211> 45  
<212> DNA  
<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 13  
gagaatatca ctgtcccaga caccgacgtt aatttctatg cctgg 45

<210> 14  
<211> 45  
<212> DNA  
<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 14  
ccaggccatag aaattaacgt cgggtgtctgg gacagtgata ttctc 45

<210> 15  
<211> 193  
<212> PRT  
<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 15

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ala Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 16  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 16

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Ala Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 17  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 17

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu

20

25

30

Ile Cys Asp Ser Ile Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 18  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein  
<400> 18

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Ser Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 19  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 19

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Ala Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 20  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 20

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu

1

5

10

15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Ala Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 21  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 21

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Ala Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 22  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

&lt;400&gt; 22

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 23  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 23

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Glu Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 24  
<211> 193  
<212> PRT  
<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 24

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Gln Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 25  
<211> 193  
<212> PRT  
<213> Artificial

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: mutein

&lt;400&gt; 25

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Ala Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

&lt;210&gt; 26

&lt;211&gt; 193

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: mutein

&lt;400&gt; 26

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Phe Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 27

<211> 193

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: mutein

&lt;400&gt; 27

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Ile Leu Leu Glu Ala Glu Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 28

&lt;211&gt; 193

&lt;212&gt; PRT

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: mutein

&lt;400&gt; 28

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Glu Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 29  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 29

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Ala Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 30  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 30

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Ala  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 31  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 31

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Lys Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 32  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 32

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Ser Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 33  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 33

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Tyr Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 34  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 34

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Asn Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp

180 185 190

Arg

<210> 35  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

&lt;400&gt; 35

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu Thr Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 36  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 36

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Ser Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 37  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein  
<400> 37

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Tyr Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu

165

170

175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

,

<210> 38  
<211> 193  
<212> PRT  
<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 38

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Lys Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 39  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 39

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Lys Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 40  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 40

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Asn Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 41  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 41

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Ala Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile

145

150

155

160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 42  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 42

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Ala Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 43  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 43

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Ile Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg J

<210> 44  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 44

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Asp Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu

130	135	140
-----	-----	-----

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile		
145	150	155
		160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu		
165	170	175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp		
180	185	190

Arg

<210> 45  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 45

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu		
1	5	10
		15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu		
20	25	30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu		
35	40	45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu		
50	55	60

Asn Ile Thr Val Pro Asp Thr Ala Val Asn Phe Tyr Ala Trp Lys Arg		
65	70	75
		80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu		
85	90	95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser		
100	105	110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly		
115	120	125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 46  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 46

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Ala Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 47  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 47

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Ala Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 48  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 48

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Ile Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly

115

120

125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 49  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 49

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Ala Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 50  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 50

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Ala Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 51  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 51

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Ser Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser

100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 52  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 52

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Phe Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 53  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 53

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Asn Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 54  
<211> 193  
<212> PRT

<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 54

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Ala Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 55  
 <211> 193  
 <212> PRT  
 <213> Artificial .

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 55

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Asn Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 56  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 56

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Thr Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 57  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 57

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg

65

70

75

80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Ser Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 58

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 58

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Ala Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 59  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 59

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Arg Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 60  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 60

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65                   70                   75                   80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85                   90                   95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100                   105                   110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Ala Ala Val Ser Gly  
 115                   120                   125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130                   135                   140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145                   150                   155                   160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165                   170                   175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180                   185                   190

Arg

<210> 61  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 61

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1                   5                   10                   15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20                   25                   30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35                   40                   45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu

50	55	60
----	----	----

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg		
65	70	75
		80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu		
85	90	95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser		
100	105	110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Arg Gly		
115	120	125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu		
130	135	140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile		
145	150	155
		160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu		
165	170	175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp		
180	185	190

Arg

<210> 62		
<211> 193		
<212> PRT		
<213> Artificial		

<220>		
<223> Description of Artificial Sequence: mutein		

<400> 62		
----------	--	--

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu		
1	5	10
		15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu		
20	25	30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu		
35	40	45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Glu Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 63  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 63

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ala Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 64  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 64

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu

35

40

45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Thr Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 65  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 65

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Ala  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 66  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 66

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Ile  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 67  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 67

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Ala Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 68  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 68

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu

20

25

30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Ala Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 69  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 69

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125  
 ,

Leu Glu Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 70  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 70

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ala Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 71  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 71

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu

1

5

10

15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ile Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 72  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 72

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Ala Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 73  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 73

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln' Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Ala Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 74  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

&lt;400&gt; 74

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Ile Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 75  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 75

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Ala Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 76  
<211> 193  
<212> PRT  
<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 76

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 77

<211> 193

<212> PRT

<213> Artificial

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: mutein

&lt;400&gt; 77

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Lys Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 78

<211> 193

<212> PRT

<213> Artificial

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: mutein

&lt;400&gt; 78

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Ala Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

&lt;210&gt; 79

&lt;211&gt; 193

<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 79

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Ser Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 80

<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 80

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Ala Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 81  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 81

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 82  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 82

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Ala Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 83  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein  
<400> 83

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ala  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 84  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein  
<400> 84

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala, Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Ala Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 85  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 85

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Ala Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 86  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 86

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Pro Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Ile Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp

180 185 190

Arg

<210> 87  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 87

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Ala Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 88  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 88

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ala Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 89  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein  
<400> 89

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Lys Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 90  
<211> 193  
<212> PRT  
<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 90

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Ala Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 91  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 91

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Tyr Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 92  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 92

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Ala Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 93  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 93

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile

145

150

155

160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Ala  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 94  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 94

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Ala Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 95  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein  
 <400> 95

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Glu Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 96  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein  
<400> 96

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu

130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Ala Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 97  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 97

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Ala Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 98  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein  
 <400> 98

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Trp Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 99  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 99

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Ala Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 100  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 100

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Ala Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg .

<210> 101

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 101

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys. Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Ala Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 102  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 102

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Ala Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 103

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 103

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Ser Arg Thr Gly Asp  
 180 185 190

Arg

<210> 104

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 104

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Ala Arg Thr Gly Asp  
 180 185 190

Arg

<210> 105

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 105

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu

85

90

95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Ala Thr Gly Asp  
 180 185 190

Arg

<210> 106

<211> 192

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 106

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Glu His Cys Ser Leu Asn Glu Asn  
 50 55 60

Ile Thr Val Pro Asp Thr Asp Val Asn Phe Tyr Ala Trp Lys Arg Met  
 65 70 75 80

Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu  
 85 90 95

Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln  
 100 105 110

Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Glu Gly Leu  
 115 120 125

Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu Ala  
 130 135 140

Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr  
 145 150 155 160

Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg  
 165 170 175

Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg  
 180 185 190

<210> 107

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 107

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Asn Glu Thr Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 108

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 108

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu

20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Asp Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Glu Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 109

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 109

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Glu Ser Leu Thr Thr Ser Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 110

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 110

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Ala Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Ala Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 111  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 111

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Ala Val Asn Phe Tyr Ala Trp Ala Arg

65

70

75

80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Ala Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 112  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 112

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 113  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 113

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Ala Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Ala Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 114

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 114

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu

50	55	60
----	----	----

Asn Ile Thr Val Pro Asp Thr Ala Val Asn Phe Tyr Ala Trp Lys Arg		
65	70	75
		80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu		
85	90	95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser		
100	105	110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Ala Ala Val Ser Gly		
115	120	125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu		
130	135	140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile		
145	150	155
		160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu		
165	170	175

Arg Gly Ala Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp		
180	185	190

Arg

<210> 115		
<211> 193		
<212> PRT		
<213> Artificial		

<220>		
<223> Description of Artificial Sequence: mutein		

<400> 115		
-----------	--	--

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu		
1	5	10
		15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu		
20	25	30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu		
35	40	45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Ala Val Asn Phe Tyr Ala Trp Ala Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Ala Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Ala Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Ala Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 116  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 116

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Asn Ile Thr Val Pro Asp Thr Ala Val Asn Phe Tyr Ala Trp Ala Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Ala Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Ala Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Ala Leu Ala Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 117  
<211> 193  
<212> PRT  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: mutein

<400> 117

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu  
35 40 45

Ala Glu Lys Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
50 55 60

Lys Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Lys Ser Ser  
100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
180 185 190

Arg

<210> 118

<211> 193

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: mutein

<400> 118

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Arg Ala Leu Leu Glu Ala Lys Glu

35

40

45

Ala Glu Lys Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 119  
 <211> 193  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: mutein

<400> 119

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu  
 1 5 10 15

Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu  
 20 25 30

Ile Cys Asp Ser Arg Val Leu Glu Ala Ala Leu Leu Glu Ala Lys Glu  
 35 40 45

Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu  
 50 55 60

Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg  
 65 70 75 80

Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu  
 85 90 95

Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser  
 100 105 110

Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly  
 115 120 125

Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu  
 130 135 140

Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile  
 145 150 155 160

Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu  
 165 170 175

Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp  
 180 185 190

Arg

<210> 120

<211> 36

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 120

gtctactcca atttcctcga gggaaagctg aagctg

36

<210> 121

<211> 34

<212> DNA

<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 121  
gcttcagctt tccctcgagg aaattggagt agac

34

<210> 122  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 122  
ccgtcagtgg ccttgagagc ctcaccactc tg

32

<210> 123  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 123  
cagagtggtg aggctctcaa ggccactgac gg

32

<210> 124  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 124  
ccgtcagtgg ccttgagagc ctcaccactc tg

32

<210> 125  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 125  
cagagtggtg aggctctcaa ggccactgac gg

32

<210> 126  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 126  
cgcagcctca ccacttcgct tcgggctctg g

31

<210> 127  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 127  
ccagagcccg aagcgaagtg gtgaggctgc g

31

<210> 128  
<211> 40  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer

<400> 128  
gaatatcaact gtcccagacg gtggtgccctg gaagaggatg

40

<210> 129  
<211> 40  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer

<400> 129  
catcctcttc caggcaccac cgtctggac agtgatattc

40

<210> 130  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer

<400> 130  
tacctcttgg aggccgcgga ggccgagaat atc

33

<210> 131  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>

<223> Description of Artificial Sequence: primer

<400> 131

gatattctcg gcctccgcgg cctccaagag gta

33

<210> 132

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 132

gctgacactt tccgcgcact cttccgagtc tactc

35

<210> 133

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 133

gagtagactc ggaagagtgc gcggaaagtgc tcagc

35

<210> 134

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 134

atttcctccg gggagcgctg aagctgtaca cag

33

<210> 135

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 135

ctgtgtacag cttcagcgct ccccgagga aat

33

<210> 136

<211> 32

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 136  
ctccggggaa agctggcgct gtacacaggg ga

32

<210> 137  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 137  
tccccctgtgt acagcgccag ctttccccgg ag

32

<210> 138  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 138  
actgtcccaag acaccgcagt taatttctat gcctg

35

<210> 139  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 139  
caggcataga aatthaactgc ggtgtctggg acagt

35

<210> 140  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 140  
agttaatttc tatgcctggg cgaggatgga ggtcg

35

<210> 141  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 141  
cgaccctccat cctcgccccag gcatagaaaat taact 35

<210> 142  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 142  
tgccagctgca tgtggatgca gccgtcagtg gcc 33

<210> 143  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 143  
ggccactgac ggctgcatcc acatgcagct gca 33

<210> 144  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 144  
ctctgggagc ccaggcggaa gccatctccc ct 32

<210> 145  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 145  
agggggagatg gcttccgcct gggctccccag ag 32

<210> 146  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 146

gctgacactt tccgacgact cttccgagtc tactc

35

<210> 147  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 147  
gagtagactc ggaagagtgc gcggaaagtgc tcagc

35

<210> 148  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 148  
agttaatttc tatgcctggg cgaggatgga ggtcg

35

<210> 149  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 149  
cgacctccat cctcgcccaag gcatagaaat taact

35

<210> 150  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 150  
gctgacactt tccgacgact cttccgagtc tactc

35

<210> 151  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 151  
gagtagactc ggaagagtgc gcggaaagtgc tcagc

35

<210> 152  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 152  
agttaatttc tatgcctggg cgaggatgga ggtcg 35

<210> 153  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 153  
cgacctccat cctcgcccaag gcatagaaat taact 35

<210> 154  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 154  
actgtcccaag acaccgcagt taatttctat gcctg 35

<210> 155  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 155  
caggcataga aatthaactgc ggtgtctggg acagt 35

<210> 156  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 156  
tgcagctgca tgtggatgca gccgtcagtg gcc 33

<210> 157  
<211> 33  
<212> DNA  
  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 157  
ggccactgac ggctgcatcc acatgcagct gca

33

<210> 158  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 158  
atttcactccg gggagcgctg aagctgtaca cag

33

<210> 159  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 159  
ctgtgtacag cttcagcgct ccccgagga aat

33

<210> 160  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 160  
tgcagctgca tgtggatgca gccgtcagtg gcc

33

<210> 161  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 161  
ggccactgac ggctgcatcc acatgcagct gca

33

<210> 162  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 162  
atttcctccg gggagcgctg aagctgtaca cag

33

<210> 163  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 163  
ctgtgtacag cttcagcgct ccccgagga aat

33

<210> 164  
<211> 35  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 164  
actgtcccaag acaccgcagt taatttctat gcctg

35

<210> 165  
<211> 35  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 165  
caggcataga aatthaactgc ggtgtctggg acagt

35

<210> 166  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 166  
tgtggatgca gccgtcagtg gcc

33

<210> 167  
<211> 33  
  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 167  
ggccactgac ggctgcattcc acatgcagct gca 33  
  
<210> 168  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 168  
atTCCTCCG gggagcgctg aagctgtaca cag 33  
  
<210> 169  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 169  
ctgtgtacag cttcagcgct ccccgagga aat 33  
  
<210> 170  
<211> 35  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 170  
actgtcccaag acaccgcagt taatttctat gcctg 35  
  
<210> 171  
<211> 35  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 171  
caggcataga aattaactgc ggtgtctggg acagt 35

<210> 172  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 172  
agttaatttc tatgcctggg cgaggatgga ggtcg 35

<210> 173  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 173  
cgacacctccat cctcgccccag gcatagaaaat taact 35

<210> 174  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 174  
tgcagctgca tgtggatgca gccgtcagtg gcc 33

<210> 175  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 175  
ggccactgac ggctgcatcc acatgcagct gca 33

<210> 176  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 176  
atttcctccg gggagcgctg aagctgtaca cag 33

&lt;210&gt; 177

<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 177  
ctgtgtacag cttcagcgct ccccgagga aat 33

<210> 178  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 178  
actgtcccaag acacccgcagt taatttctat gcctg 35

<210> 179  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 179  
caggcataga aatataactgc ggtgtctggg acagt 35

<210> 180  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 180  
agtttaatttc tatgcctggg cgaggatgga ggtcg 35

<210> 181  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 181  
cgacacctccat cctcgcccaag gcatagaaat taact 35

<210> 182  
<211> 35

<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 182  
gctgacactt tccgcgcact cttccgagtc tactc

35

<210> 183  
<211> 35  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 183  
gagtagactc ggaagagtgc gcggaaagtgc tcagc

35

<210> 184  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 184  
tgcagctgca tgtggatgca gccgtcagtg gcc

33

<210> 185  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 185  
ggccactgac ggctgcatcc acatgcagct gca

33

<210> 186  
<211> 33  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 186  
atttcctccg gggagcgctg aagctgtaca cag

33

<210> 187  
<211> 33  
<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 187  
ctgtgtacag cttcagcgct ccccgagga aat 33

<210> 188

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 188  
actgtcccaag acaccgcagt taatttctat gcctg 35

<210> 189

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 189  
caggcataga aatctaactgc ggtgtctggg acagt 35

<210> 190

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 190  
agtttaatttc tatgcctggg cgaggatgga ggtcg 35

<210> 191

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 191  
cgacacctccat cctcgcccaag gcatagaaaat taact 35

<210> 192

<211> 35

<212> DNA

<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 192  
gctgacactt tccgcgcact cttccgagtc tactc 35

<210> 193  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 193  
gagtagactc ggaagagtgc gcggaaaagtgc tcagc 35

<210> 194  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 194  
ctccggggag cgctggcgct gtacacaggg ga 32

<210> 195  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 195  
tccccctgtgt acagcgccag cgctccccgg ag 32

<210> 196  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer

<400> 196  
caaggaggcc gagaaaaatca cgacgggctg t 31

<210> 197  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 197  
acagcccgtc gtgattttctt cggcctcctt g

31

<210> 198  
<211> 37  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 198  
actgcagttt gaatgagaaa atcactgtcc cagacac

37

<210> 199  
<211> 37  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 199  
gtgtctggga cagtgtttt ctcattcaag ctgcagt

37

<210> 200  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 200  
aggccctgtt ggtcaaatct tcccaagccgt g

31

<210> 201  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 201  
cacggctggg aagatttgac caacagggcc t

31

<210> 202  
<211> 33  
<212> DNA  
<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 202

atttcctccg gggatggctg aagctgtaca cag

33

<210> 203

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 203

ctgtgtacag cttcagccat ccccgagga aat

33

<210> 204

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 204

agccgagtcc tggaggcggc cctcttggag gccaa

35

<210> 205

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 205

ttggcctcca agagggccgc ctccaggact cggct

35

<210> 206

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 206

agccgagtcc tggagagggc cctcttggag gccaa

35

<210> 207

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: primer

<400> 207  
ttggcctcca agagggccct ctccaggact cggtc 35  
  
<210> 208  
<211> 6059  
  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Description of Artificial Sequence: plasmid  
  
<400> 208 60  
ctagagtcga cccgggcggc cgttccctt tagtgagggt taatgctcg agcagacatg  
ataagataca ttgatgagtt tggacaaacc acaactagaa tgcagtgaaa aaaatgcttt  
  
atttgtgaaa tttgtgatgc tattgcttta tttgtaaacca ttataagctg caataaacaa 120  
gttaacaaca acaattgcat tcattttatg tttcagggttc agggggagat gtgggagggtt  
ttttaaagca agtaaaaacct ctacaaatgt ggtaaaatcc gataaggatc gatccgggct 180  
ggcgtaatag cgaagaggcc cgcaccgatc gcccttccca acagttgcgc agcctgaatg  
gcgaatggac gcgcctgtta gcggcgcatt aagcgcggcg ggtgtggtgg ttacgcgcag 240  
cgtgaccgct acacttgcca gcgccttagc gcccgctctt ttcgctttct tcccttcctt  
tctcgccacg ttgcgcggct ttccccgtca agctctaaat cgggggctcc ctttagggtt 300  
ccgatttagt gcttacggc acctcgaccc caaaaaactt gattagggtg atggttcacg  
tagtgggcca tcgcctgtat agacggttt tcgcctttt acgttggagt ccacgttctt 360  
taatagtgga ctctgttcc aaactggaac aacactcaac cctatctcg tctattcttt  
tgatttataa gggattttgc cgatttcggc ctattggta aaaaatgagc tgatttaaca 420  
aaaatttaac gcgaattttta acaaaaatatt aacgcttaca atttcctgtat gcggtatttt  
ctccttacgc atctgtgcgg tatttcacac cgcatacgcg gatctgcgc a caccatggc  
ctgaaataac ctctgaaaga ggaacttggt tagtacctt ctgaggcgga aagaaccagc 480  
tgtggaatgt gtgtcagttt ggggtggaa agtccccagg ctccccagca ggcagaagta  
tgcaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtccccca ggctccccag  
caggcagaag tatgcaaagc atgcatctca attagtcagc aaccatagtc ccgccttcaa 540  
ctccgccccat cccgcccccta actccgcccc gttccgcccc ttctccgcccc catggctgac  
taatttttt tatttatgca gaggccgagg ccgcctcggc ctctgagcta ttccagaagt  
agtgaggagg ctttttttggaa ggccttaggct tttgcaaaaaa gcttgattct tctgacacaa 600  
caagtctcqaa cttaaggcta gagccaccat gattgaacaa gatggattgc acgcagggttc  
1380

tcoggccgct	tgggtggaga	ggctattcg	ctatgactgg	gcacaacaga	caatcggt	1440
ctctgatgcc	gccgtgttcc	ggctgtcagc	gcaggggcgc	ccggttcttt	ttgtcaagac	1500
cgacctgtcc	ggtgcctgta	atgaactgca	ggacgaggca	gcgccgctat	cgtggctggc	1560
cacgacgggc	gttccttgcg	cagctgtgct	cgacgttg	actgaagcgg	gaagggactg	1620
gctgctattg	ggcgaagtgc	cggggcagga	tctcctgtca	tctcacctt	ctcctgccga	1680
gaaagtatcc	atcatggctg	atgcaatgcg	gcggctgcat	acgcttgate	cggttacactg	1740
ccatttcgac	caccaagcga	aacatcgcat	cgagcgagca	cgtactcgga	tggaaggcgg	1800
tcttgcgtat	caggatgatc	tggacgaaga	gcatcagggg	ctcgccag	ccgaactgtt	1860
cgccaggctc	aaggcgcgca	tgcccgacgg	cgaggatctc	gtcgtgaccc	atggcgatgc	1920
ctgcttgcgg	aatatcatgg	tggaaaatgg	ccgctttct	ggattcatcg	actgtggccg	1980
gctgggtgtg	gcggaccgct	atcaggacat	agcgttggct	acccgtgata	ttgctgaaga	2040
gcttggcggc	aatatcatgg	ccgctttct	cgatcgttac	ggatcgccg	ctcccgattc	2100
gcagcgcattc	gcatttctatc	gcatttcttga	cgagtttttc	tgagcgggac	tctgggttc	2160
gaaatgaccg	accaagcgac	gcccaacctg	ccatcacat	ggccgcaata	aaatatctt	2220
attttcatta	catctgtgtg	ttggtttttt	gtgtgaatcg	atagcgataa	ggatccgcgt	2280
atgggtgcact	ctcagttacaa	tctgctctga	tgccgcata	ttaagccagc	cccgacaccc	2340
gcccaacaccc	gctgacgcgc	cctgacgggc	ttgtctgtc	ccggcatccg	cttacagaca	2400
agctgtgacc	gtctccggga	gctgcatgtg	tcagaggttt	tcaccgtcat	caccgaaacg	2460
cgcgagacga	aaggccctcg	tgatacgcct	atttttatag	gttaatgtca	tgataataat	2520
ggtttcttag	acgtcaggtg	gcactttcg	gggaaatgtg	cgcggaaaccc	ctatttgttt	2580
atttttctaa	atacattcaa	atatgtatcc	gctcatgaga	caataaccct	gataaaatgt	2640
tcaataataat	tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	cccttattcc	2700
cttttttgcg	gcattttgcc	ttcctgtttt	tgctcaccca	gaaacgctgg	tgaaagtaaa	2760
agatgctgaa	gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	2820
taagatcctt	gagagtttc	gccccgaaga	acgtttcca	atgatgagca	cttttaaagt	2880
tctgctatgt	ggcgccgtat	tatcccgtat	tgacgccggg	caagagcaac	tcgggtcgccg	2940
catacactat	tctcagaatg	acttggttga	gtactcacca	gtcacagaaaa	agcatcttac	3000
ggatggcatg	acagtaagag	aattatgcag	tgctgccata	accatgagtg	ataacactgc	3060
ggccaaactta	cttctgacaa	cgatcgagg	accgaaggag	ctaaccgctt	ttttgcacaa	3120
catggggat	catgttaactc	gccttgcgt	ttggaaaccg	gagctgaatg	aagccataacc	3180

aaacgcgacg cgtgacacca cgatgcctgt agcaatggca acaacgttgc gcaaactatt 3240  
aactggcgaa ctacttactc tagcttcccg gcaacaatta atagactgga tggaggcggaa 3300  
taaagttgca ggaccacttc tgcgctcggc ccttccggct ggctggttta ttgctgataa 3360  
atctggagcc ggtgagcgtg ggtctcgcgg tatcattgca gcaactgggc cagatggtaa 3420  
gccctccgt atcgttagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa 3480  
tagacagatc gctgagatag gtgcctact gattaagcat tggtaactgt cagaccaagt 3540  
ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa ggatcttaggt 3600  
gaagatocctt ttgataatc tcatgaccaa aatcccttaa cgtgagttt cgttccactg 3660  
agcgtcagac cccgtagaaa agatcaaagg atcttcttga gatccctttt ttctgcgcgt 3720  
aatctgctgc ttgcaaaca aaaaaccacc gctaccagcg gtggtttgg tgcggatca 3780  
agagctacca actcttttc cgaaggtaac tggcttcagc agagcgcaga taccataatc 3840  
tgttcttcta gtgtagccgt agttaggcca ccacitcaag aactctgttag caccgcctac 3900  
atacctcgct ctgctaattcc tgttaccagt ggctgctgcc agtggcgata agtcgtgtct 3960  
taccgggttg gactcaagac gatagttacc ggataaggcg cagcggtcgg gctgaacggg 4020  
gggttcgtgc acacagccca gcttggagcg aacgacctac accgaactga gatacctaca 4080  
gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccgg 4140  
aagcggcagg gtcggAACAG gagagcgcac gagggagctt ccagggggaa acgcctggta 4200  
tctttatagt cctgtcgggt ttgccacact ctgactttag gtcgatTTT tgcgtatgtc 4260  
gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg gccttttac gttcctggc 4320  
cttttgcgg cttttgctc acatggctcg acagatctt aatattggcc attagccata 4380  
ttattcattt gttatatacg ataaatcaat attggctatt ggccattgca tacgttgtat 4440  
ctatatacata atatgtacat ttatattggc tcatgtccaa tatgaccgcc atgttggcat 4500  
tgattattga ctatgttata atagtaatca attacgggggt cattagttca tagccatata 4560  
atggagttcc gcgttacata acttacgta aatggcccgctt ctggctgacc gccaacgc 4620  
ccccgccccat tgacgtcaat aatgacgtat gttccatag taacgccaat agggactttc 4680  
cattgacgtc aatgggtgga gtatTTacgg taaaactgccc acttggcagt acatcaagt 4740  
tatcatatgc caagtccgccc ccctattgac gtcaatgacg gtaaatggcc cgccctggcat 4800  
tatgcccagt acatgacctt acgggacttt cctacttggc agtacatcta cgtatttagtc 4860  
atcgcttata ccatgggtgat gcggtttgg cagttacacca atgggcgtgg atagcggttt 4920  
gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gtttggcact 4980

caaaaatcaac	gggactttcc	aaaatgtcgt	aacaactgcg	atcgccccgc	ccgttgacgc	5040
aaatgggcgg	taggcgtgt	cggtgggagg	tctatataag	cagagctcgt	ttagtgaacc	5100
gtcagatcac	tagaagcttt	attgcggtag	tttatcacag	ttaaattgct	aacgcagtca	5160
gtgcgtctga	cacaacagtc	tcgaacttaa	gctgcagtga	ctctcttaag	gtgccttgc	5220
agaagtttgt	cgtgaggcac	tggcaggta	agtatcaagg	ttacaagaca	ggtttaagga	5280
gaccaataga	aactgggctt	gtcgagacag	agaagactct	tgcgtttctg	ataggcacct	5340
attggcttta	ctgacatcca	cttgccttt	ctctccacag	gtgtccactc	ccagttcaat	5400
tacagctctt	aaggctagag	tacttaatac	gactcaactat	aggctagcct	cgagcgcgga	5460
gatgggggtg	cacgaatgtc	ctgcctggct	gtggcttctc	ctgtccctgc	tgtcgctccc	5520
tctggccctc	ccagtctgg	gcgcgcacc	acgcctcatac	tgtgacagcc	gagtccctgga	5580
gaggtacctc	ttggaggcca	aggaggccga	gaatatcacg	acgggctgtg	ctgaacactg	5640
cagcttgaat	gagaatatca	ctgtcccaga	caccaaagtt	aatttctatg	cctggaagag	5700
gatggagggtc	gggcagcagg	ccgtagaagt	ctggcagggc	ctggccctgc	tgtcggaagc	5760
tgtcctgcgg	ggccaggccc	tgttggtcaa	ctcttccag	ccgtgggagc	ccctgcagct	5820
gcatgtggat	aaagccgtca	gtggccttcg	cagcctcacc	actctgcttc	gggctctgcg	5880
agcccaagaag	gaagccatct	cccttccaga	tgcggcctca	gctgctccac	tccgaacaat	5940
cactgctgac	actttccgca	aactcttccg	agtctactcc	aatttccctcc	ggggaaagct	6000
gaagctgtac	acaggggagg	cctgcaggac	aggggaccat	catcaccatc	accattgat	6059

<210> 209  
 <211> 6059  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: plasmid

<400> 209	ctagagtcga	cccgccggc	cgcttccctt	tagtgagggt	taatgcttcg	agcagacatg	60
	ataagataca	ttgatgagtt	tggacaaacc	acaactagaa	tgcagtgaaa	aaaatgcttt	120
	atttgtgaaa	tttgtgatgc	tattgcttta	tttgtaacca	ttataagctg	caataaacaa	180
	gttaacaaca	acaattgcat	tcattttatg	tttcaggttc	agggggagat	gtgggaggtt	240
	ttttaaagca	agtaaaacct	ctacaaatgt	ggtaaaatcc	gataaggatc	gatccgggct	300
	ggcgtaatag	cgaagaggcc	cgcaccgatc	gccctccca	acagttgcgc	agcctgaatg	360
	gcgaatggac	gcgcctgt	gcggcgcatt	aagcgcggcg	ggtgtggtgg	ttacgcgcag	420
	cgtgaccgat	acacttgcca	gcgccttagc	gcccgctct	ttcgctttct	tccattcctt	480

tctcgccacg	ttcgccggct	ttccccgtca	agctctaaat	cgggggatcc	ctttagggtt	540
ccgatttagt	gctttacggc	acctcgaccc	caaaaaactt	gattagggtg	atggttcacg	600
tagtgggcca	tcgcccgtat	agacggtttt	tcgccccttg	acgttggagt	ccacgttctt	660
taatagtgga	ctcttggcc	aaactggaac	aacactcaac	cctatctcg	tctattctt	720
tgatttataa	gggattttgc	cgatttcggc	ctattggta	aaaaatgagc	tgatttaaca	780
aaaatttaac	gcgaatttta	acaaaatatt	aacgcttaca	atttcctgat	gcggtatttt	840
ctccttacgc	atctgtgcgg	tatttcacac	cgcatacgcg	gatctgcgca	gcaccatggc	900
ctgaaataac	ctctgaaaga	ggaacttggt	taggtacctt	ctgaggcgga	aagaaccagc	960
tgtggaatgt	gtgtcagtta	gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	1020
tgcaaagcat	gcacatctcaat	tagtcagcaa	ccaggtgtgg	aaagtccccca	ggctccccag	1080
caggcagaag	tatgcaaagc	atgcacatctca	attagtcagc	aaccatagtc	ccgccccctaa	1140
ctccgccccat	cccgcccccta	actccgcccc	gttccgcccc	ttctccgcccc	catggctgac	1200
taattttttt	tattnatgca	gaggccgagg	ccgcctcgcc	ctctgagcta	ttccagaagt	1260
agtgaggagg	cttttttggga	ggcctaggct	tttgcaaaaa	gcttgattct	tctgacacaa	1320
cagtctcgaa	cttaaggctta	gagccaccat	gattgaacaa	gatggattgc	acgcagggttc	1380
tccggccgct	tgggtggaga	ggctattcgg	ctatgactgg	gcacaacaga	caatcggtcg	1440
ctctgatgcc	gcgcgttcc	ggctgtcagc	gcaggggcgc	ccggtttttt	ttgtcaagac	1500
cgacctgtcc	ggtgcctcgt	atgaactgca	ggacgaggca	gcgccgctat	cgtggctggc	1560
cacgacgggc	gttcattgcg	cagctgtgt	cgacgttgcc	actgaagcgg	gaagggactg	1620
gctgctatttgc	ggcgaagtgc	cggggcagga	tctcattgtca	tctcaccttgc	ctcctgcccga	1680
aaaagtatcc	atcatggctg	atgcaatgcg	gcggctgcat	acgcttgcac	cggttacctg	1740
cccattcgac	caccaagcga	aacatcgcat	cgagcgagca	cgtactcgga	tggaagccgg	1800
tcttgcgtat	caggatgtac	tggacgaaga	gcatcagggg	ctcgccgccc	ccgaactgtt	1860
cggccaggctc	aaggcgcgca	tgccccacgg	cgaggatctc	gtcgtgaccc	atggcgatgc	1920
ctgcttgcgc	aatatcatgg	tggaaaatgg	ccgtttttct	ggattcatcg	actgtggccg	1980
gctgggtgtg	gcggaccgct	atcaggacat	agcgttggct	acccgtata	ttgctgaaga	2040
gcttggcggc	aatatcatgg	ccgtttttct	cggttac	ggatcgccg	ctcccgattc	2100
gcagcgcac	gccttctatc	gccttcttgc	cgagtttttc	tgagcgggac	tctggggttc	2160
gaaatgaccc	accaagcgcac	gccccacctg	ccatcacat	ggccgcaata	aaatatctt	2220
attttcattt	catctgtgt	ttggtttttt	gtgtaatcg	atagcgataa	ggatccgcgt	2280

atggtgcact ctcagtacaa tctgctctga tgccgcatac ttaagccagc cccgacaccc	2340
gcacaaacacc cgtgacgcgc cctgacgggc ttgtctgtc ccggcatccg cttacagaca	2400
agctgtgacc gtctccggga gctgcattgtc tcagagggtt tcaccgtcat caccgaaacg	2460
cgcgagacga aagggcctcg tgatacgctt atttttatag gttaatgtca tgataataat	2520
ggtttcttag acgtcaggtg gcactttcg gggaaatgtg cgccgaaccc ctatttgttt	2580
atttttctaa atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgct	2640
tcaataataat tgaaaaagga agagttatgag tattcaacat ttccgtgtcg cccttattcc	2700
ctttttgcg gcattttgcc ttccctgttt tgctcacccca gaaacgctgg tgaaagtaaa	2760
agatgctgaa gatcagttgg gtgcacgagt gggttacatc gaactggatc tcaacagcgg	2820
taagatccctt gagagtttgc gccccgaaga acgtttcca atgtatgagca cttttaaagt	2880
tctgctatgt ggcgcggat tatccogtat tgacgcggg caagagcaac tcgggtcgccg	2940
catacactat tctcagaatg acttgggttga gtactcacca gtcacagaaa agcatcttac	3000
ggatggcatg acagtaagag aattatgcag tgctgccata accatgagtg ataacactgc	3060
ggcccaactta cttctgacaa cgatcggagg accgaaggag ctaaccgctt tttgcacaa	3120
catgggggat catgtaactc gccttgatcg ttgggaaccc gagctgaatg aagccatacc	3180
aaacgacgag cgtgacacca cgatgcctgt agcaatggca acaacgttgc gcaaactatt	3240
aactggcgaa ctacttactc tagttcccg gcaacaatta atagactgga tggaggcgg	3300
taaagttgca ggaccacttc tgcgctcgcc cttccggct ggctggtttta ttgctgataa	3360
atctggagcc ggtgagcgtg ggtctcgccg tatcattgca gcactggggc cagatggtaa	3420
gccctccgt atcgttagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa	3480
tagacagatc gctgagatag gtgcctcaact gattaagcat tggtaactgt cagaccaagt	3540
ttactcataat atactttaga ttgatttaaa acttcatttt taatttaaaa ggatcttagt	3600
gaagatcctt ttgataatc tcatgaccaa aatccctaa cgtgagttt cgttccactg	3660
agcgtcagac cccgtagaaa agatcaaagg atcttcttga gatcctttt ttctgcgcgt	3720
aatctgctgc ttgcaaaacaa aaaaaccacc gctaccagcg gtggtttgg tgcggatca	3780
agagctacca actcttttc cgaaggtaac tggcttcagc agagcgcaga taccaaatac	3840
tgttcttcta gtgtagccgt agttaggcca ccacttcaag aactctgttag caccgcctac	3900
atacctcgct ctgctaatcc tgttaccagt ggctgctgcc agtggcgata agtcgtgtct	3960
taccgggttg gactcaagac gatagttacc ggataaggcg cagcggcgg gctgaacggg	4020
gggttcgtgc acacagccca gcttggagcg aacgacctac accgaactga gataacctaca	4080
gcgtgagcta tgagaaagcg ccacgcttcc cgaaggaga aaggcggaca ggtatccggt	4140

aagcggcagg gtcggaacag gagagcgcac gagggagctt ccagggggaa acgcctggta	4200
tctttatagt cctgtcggtt ttgcacccct ctgacttgag cgtcgatttt tgtgatgctc	4260
gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg gccttttac gttcctggc	4320
cttttgcgg cctttgctc acatggctcg acagatctc aatattggcc attagccata	4380
ttattcattt gttatatacg ataaatcaat attggctatt ggcatttgc tacgttgtat	4440
ctatatcata atatgtacat ttatattggc tcatgtccaa tatgaccgcc atgttggcat	4500
tgattattga ctatgttata atagtaatca attacgggtt cattagttca tagcccatat	4560
atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc gcccacgac	4620
ccccggccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggacttcc	4680
cattgacgtc aatgggttggta gtatattacgg taaaactgccc acttggcagt acatcaagt	4740
tatcatatgc caagtccgccc ccctatttgcgtt gtaatggcc cgcctggcat	4800
tatgcccagt acatgacctt acgggacttt cctacttggc agtacatcta cgtattagtc	4860
atcgcttata ccatgggtat ggggtttgg cagttacacca atgggcgtgg atagcggttt	4920
gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gtttggcac	4980
caaaatcaac gggactttcc aaaatgtcgt aacaactgcg atcgcccgcc ccgttgacgc	5040
aaatgggcgg taggcgtgtt cgggtggagg tctatataag cagagctcgt ttagtgaacc	5100
gtcagatcac tagaagcttt attgcggtag tttatcacag ttaaattgct aacgcagtca	5160
gtgcttctga cacaacagtc tcgaacttaa gctgcgttga ctctcttaag gtagccttgc	5220
agaagtttgtt cgtgaggcac tggcaggta agtataagg ttacaagaca ggtttaaagga	5280
gaccaataga aactgggctt gtcgagacag agaagactct tgcgtttctg ataggcacct	5340
attggcttta ctgacatcca ctttgccttt ctctccacag gtgtccactc ccagttcaat	5400
tacagctttt aaggcttagag tacttaatac gactcaactat aggctagccct cgagcgcgg	5460
gatgggggtt cacgaatgtc ctgcctggct gtggcttctc ctgtccctgc tgtcgtccc	5520
tctgggcctc ccagtcctgg ggcggccacc acgcctcatc tgtgacagcc gagtcctgg	5580
gaggtacctc ttggaggcca aggaggccga gaatatcactg acgggctgtt atgaaacctg	5640
cagcttgaat gagaatatac ctgtcccaaga caccaaagtt aatttctatg cctggaaagag	5700
gatggaggtc gggcagcagg ccgtagaagt ctggcaggcc ctggccctgc tgtcgttgc	5760
tgtcctgcgg ggccaggccc tgggttgcctt ctcttccatcc cctgtggagc ccctgcagct	5820
gcatgtggat aaagccgtca gtggcccttcg cagcctcacc actctgttcc gggctctgcg	5880
agcccagaag gaagccatct cccctccaga tgccgcctca gctgcctccac tccgaacaat	5940

```
cactgctgac actttccgca aactcttccg agtctactcc aatttcctcc ggggaaagct 6000
qaagctgtac acagggggagg cctgcaggac aggggaccat catcaccatc accattgtat 6059
```

```
<210> 210
<211> 6059
<212> DNA
<213> Artificial
```

<220>  
<223> Description of Artificial Sequence: plasmid

<400> 210  
ctagagtgcg cccggggcggc cgcttcctt tagtgagggt taatgcttcg agcagacatg 60  
ataagataca ttgtatgggtt tggacaaacc acaactagaa tgcagtgaaa aaaatgcttt 120  
atttgtgaaa tttgtgtatgc tattgttttta ttgttaacca ttataagctg caataaaca 180  
gttaacaaca acaattgcatt tcattttatg ttccagggttc agggggagat gtgggaggtt 240  
ttttaagca agtaaaaccc ctacaaatgt ggttaaaatcc gataaggatc gatccgggt 300  
ggcgtaatag cgaagaggcc cgacccgatc gcccctccca acagttgcgc agcctgaatg 360  
gcgaatggac gcgcctgtta gggcgccatt aagcgccgcg ggtgtgggtt ttacgcgcag 420  
cgtgaccgct acacttgcca ggccttagc gcccgcttct ttgcctttct tcccttcctt 480  
tctcgccacg ttccgggtt ttcccggtca agctctaaat cgggggctcc ctttaggggt 540  
ccgatttagt gcttacggc acctcgaccc caaaaaactt gattagggtg atggttcacg 600  
tagtggcca tcgcctgat agacggttt tcgcctttt acgttggagt ccacgttctt 660  
taatagtggc ctcttggc aaactggAAC aacactcaac cctatctcggtt tctattttttt 720  
tgatttataa gggattttgc cgatttcggc ctattggta aaaaatgagc tgatttaaca 780  
aaaatttaac gcgaaatttta acaaaatatt aacgcttaca atttccgtat gcggtatttt 840  
ctccttacgc atctgtgcgg tatttcacac cgcatacgcg gatctgcgcgca gcaccatggc 900  
ctgaaataac ctctgaaaga ggaacttggt taggtacctt ctgaggcgga aagaaccagc 960  
tgtggaatgt gtgtcagtttta ggggtggaa agtccccagg ctccccagca ggcagaagta 1020  
tgcaaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtccccca ggctccccag 1080  
caggcagaag tatgcaaagc atgcacatctca attagtcagc aaccatagtc ccgccccctaa 1140  
ctccgccccat cccgccccata actccgccccaa gttccgccccaa ttctccggcc catggctgac 1200  
taatttttttt tattttatgcg gaggccgagg ccgcctcggtt ctctgagctt ttccagaagtt 1260  
agtggaggagg cttttttggaa ggcctaggct tttgcaaaaa gcttgattct tctgacacaa 1320  
cagtctcgaa cttaaggctt gaggccacat gattgaacaa gatggattgc acgcagggttc 1380  
tccggccgct tgggtggaga ggcttattcggtt ctatgactgg gcacaacaga caatcggttg 1440

ctctgatgcc	gccgtgttcc	ggctgtcagc	gcaggggcgc	ccggttctt	ttgtcaagac	1500
cgacctgtcc	ggtgcacctga	atgaactgca	ggacgaggca	gcgccgctat	cgtggctggc	1560
cacgacgggc	gttccttgcg	cagctgtgct	cgacgttgc	actgaagcgg	gaagggactg	1620
gctgctattg	ggcgaagtgc	cggggcagga	tctcctgtca	tctcacctt	ctccgtccga	1680
gaaagtatcc	atcatggctg	atgcaatgcg	gcggctgcat	acgcttgate	cggctacctg	1740
cccattcgac	caccaagcga	aacatcgcat	cgagcgagca	cgtactcgga	tggaagccgg	1800
tcttgcgat	caggatgatc	tggacgaaga	gcatcagggg	ctcgccg	ccgaactgtt	1860
cggcaggctc	aaggcgcgca	tgcccacgg	cgaggatctc	gtcgacccc	atggcgatgc	1920
ctgcttgcgg	aatatcatgg	tggaaaatgg	ccgccttct	ggattcatcg	actgtggccg	1980
gctgggtgtg	gcggaccgct	atcaggacat	agcggtggct	accctgtata	ttgctgaaga	2040
gcttggccgc	aatggggctg	accgcctcct	cgtgcattac	ggtatgcgg	ctcccgattc	2100
gcagcgcattc	gccttctatc	gccttcttga	cgagttcttc	tgagcgggac	tctgggttc	2160
gaaatgaccg	accaagcgcac	gcccaacctg	ccatcacat	ggccgcaata	aaatatctt	2220
attttcattta	catctgtgtg	ttggtttttt	gtgtgaatcg	atagcgataa	ggatccgcgt	2280
atggtgcact	ctcagtacaa	tctgctctga	tgccgcata	ttaagccagc	cccgacaccc	2340
gcacacacccc	gctgacgcgc	cctgacgggc	ttgtctgtc	ccggcatccg	cttacagaca	2400
agctgtgacc	gtctccggga	gctgcattgt	tcagaggttt	tcaccgtcat	caccgaaacg	2460
cgcgagacga	aagggcctcg	tgatacgcct	atttttatag	gttaatgtca	tgataataat	2520
ggtttcttag	acgtcaggtg	gcactttcg	gggaaatgtg	cgcggaaaccc	ctatttgttt	2580
attttctaa	atacattcaa	atatgtatcc	gctcatgaga	caataaccct	gataaatgt	2640
tcaataataat	tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	cccttattcc	2700
ctttttgcg	gcattttgcc	ttcctgtttt	tgctcaccca	gaaacgctgg	tgaaagtaaa	2760
agatgctgaa	gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	2820
taagatcctt	gagagtttc	gccccgaaga	acgtttcca	atgatgagca	cttttaaagt	2880
tctgctatgt	ggcgccgtat	tatcccgat	tgacgcccgg	caagagcaac	tcggtcgccc	2940
catacactat	tctcagaatg	acttggttga	gtactcacca	gtcacagaaa	agcatcttac	3000
ggatggcatg	acagtaagag	aattatgcag	tgctgccata	accatgagtg	ataacactgc	3060
ggcccaactta	cttctgacaa	cgatcgagg	accgaaggag	ctaacccgtt	ttttgcacaa	3120
catggggat	catgtaactc	gccttgcatt	ttggaaaccg	gagctgaatg	aagccataacc	3180
aaacgacgag	cgtgacacca	cgatcgctgt	agcaatggca	acaacgttgc	gcaaactatt	3240

aactggcgaa	ctacttactc	tagcttcccg	gcaacaatta	atagactgga	tggaggcgga	3300
taaagttgca	ggaccacttc	tgcgctcgga	ccttccggct	ggctggttta	ttgctgataa	3360
atctggagcc	ggtgagcgtg	ggtctcgcg	tatcattgca	gcaactggggc	cagatggtaa	3420
gccctcccgt	atcgttagtta	tctacacgac	ggggagtcag	gcaactatgg	atgaacgaaa	3480
tagacagatc	gctgagatag	gtgcctcact	gattaagcat	tggtaactgt	cagaccaagt	3540
ttactcatat	atactttaga	ttgatttaaa	acttcatttt	taatttaaaa	ggatcttaggt	3600
gaagatcctt	tttgataatc	tcatgaccaa	aatcccttaa	cgtgagttt	cgttccactg	3660
agcgtcagac	cccgtagaaa	agatcaaagg	atcttcttga	gatcctttt	ttctgcgcgt	3720
aatctgctgc	ttgcaaacaa	aaaaaccacc	gctaccagcg	gtggtttgtt	tgccggatca	3780
agagctacca	actcttttgc	cgaaggtaac	tggcttcagc	agagcgcaga	taccaaatac	3840
tgttcttcta	gtgttagccgt	agttaggcca	ccacttcaag	aactctgtag	caccgcctac	3900
atacctcgct	ctgctaattcc	tgttaccagt	ggctgctgcc	agtggcgata	agtcgtgtct	3960
tacccgggttg	gactcaagac	gataagttacc	ggataaggcg	cagcggtcgg	gctgaacggg	4020
gggttcgtgc	acacagccca	gcttggagcg	aacgacctac	accgaactga	gataacctaca	4080
gcgtgagcta	tgagaaaagcg	ccacgcttcc	cgaagggaga	aaggcggaca	ggtatccggt	4140
aacggcagg	gtcggAACAG	gagagcgcac	gagggagctt	ccagggggaa	acgcctggta	4200
tctttatagt	cctgtcgggt	ttcgccacct	ctgactttag	cgtcgatttt	tgtgatgctc	4260
gtcagggggg	cgaggcctat	ggaaaaacgc	cagcaacgcg	gccttttac	ggttcctggc	4320
cttttgcgg	cctttgctc	acatggctcg	acagatcttc	aatattggcc	attagccata	4380
ttattcattt	gttatatagc	ataaatcaat	attggctatt	ggccattgca	tacgttgtat	4440
ctatatcata	atatgtacat	ttatattggc	tcatgtccaa	tatgaccgccc	atgttggcat	4500
tgattattga	ctagttatta	atagtaatca	attacgggtt	cattagttca	tagcccatat	4560
atggagttcc	gcgttacata	acttacggta	aatggccgc	ctggctgacc	gcccaacgcac	4620
ccccgccccat	tgacgtcaat	aatgacgtat	gttcccatag	taacgccaat	agggactttc	4680
cattgacgtc	aatgggtgga	gtatttacgg	taaaactgccc	acttggcagt	acatcaagtgc	4740
tatcatatgc	caagtccgcc	cccttattgac	gtcaatgacg	gtaaatggcc	cgcctggcat	4800
tatgcccagt	acatgacctt	acgggacttt	cctacttggc	agtagatctca	cgttattagtc	4860
atcgcttatta	ccatgggtat	gcccgtttgg	cagtacacca	atgggcgtgg	atagcggttt	4920
gactcacggg	gatttccaag	tctccacccc	attgacgtca	atgggagttt	gttttggcac	4980
caaaaatcaac	gggactttcc	aaaatgtcgt	aacaactgcg	atgcggcc	ccgttgcacgc	5040

aaatgggcgg taggcgtgta cgggtggagg tctatataag cagagctcg ttagtgaacc	5100
gtcagatcac tagaagcttt attgcggtag tttatcacag ttaaattgtct aacgcagtca	5160
gtgcttctga cacaacagtc tgaacttaa gctgcagtga ctctcttaag gtgcgttgc	5220
agaagtttgtt cgtgaggcac tggcaggtt agtataagg ttacaagaca gtttaagga	5280
gaccaataga aactggcatt gtcgagacag agaagactct tgcgttctg ataggcacct	5340
attggtctta ctgacatcca cttgcctt ctctccacag gtgtccactc ccagttcaat	5400
tacagctctt aaggcttagag tacttaatac gactcaactat aggctagcct cgagcgcgga	5460
gatgggggtt cacgaatgtc ctgcctggat gtggcttctc ctgtccctgc tgtcgtccc	5520
tctgggcctc ccagtcctgg gcgcaccacc acgcctcatc tgtgacagcc gagtcctgga	5580
gaggtacctc ttggaggcca aggaggccga gaatatcagc acgggtgtt ctgaacactg	5640
cagcttgaat gagaatatca ctgtcccaga caccgacgtt aatttctatg cctggaaagag	5700
gatggagggtc gggcagcagg ccgtagaagt ctggcaggc ctggccctgc tgtaggaagc	5760
tgtcctgcgg ggccaggccc tttggtcaa ctctccctag ccgtggagc ccctgcagct	5820
gcattgtggat aaagccgtca gtggcattcg cagcctcacc actctgttcc gggctctgcg	5880
agcccagaag gaagccatct cccctccaga tgcggctca gctgctccac tccgaacaat	5940
cactgctgac actttccgca aactcttccg agtctactcc aatttccctcc gggaaagct	6000
gaagctgtac acaggggagg cctgcaggac aggggaccat catcaccatc accattgtat	6059

<210> 211  
 <211> 6059  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Description of Artificial Sequence: plasmid

<400> 211	
ctagagtcga cccgggcggc cgcttccctt tagtgagggt taatgcttcg agcagacatg	60
ataagataca ttgatgagtt tggacaaacc acaactagaa tgcagtgaaa aaaatgtttt	120
atttgtgaaa tttgtgtatgc tattgttttta tttgttaacca ttataagctg caataaaacaa	180
gttaacaaca acaattgcat tcattttatg tttcaggatc agggggagat gtgggaggtt	240
ttttaaagca agtaaaaacct ctacaaatgt ggtaaaatcc gataaggatc gatccgggct	300
ggcgtaatag cgaagaggcc cgcaccgatc gcccattccca acagttgcgc agcctgaatg	360
gcgaatggac ggcgcctgtt gcccgcatt aagcgcggcg ggtgtgggtt ttacgcgcag	420
cgtgaccgct acacttgccca gcccgcatt gcccgcatt ttcgcgttttcccttccctt	480
tctcgccacg ttccggcttccgttca agctctaaat cgggggttcc cttagggtt	540

ccgatttagt gctttacggc acctcgaccc caaaaaactt gattagggtg atggttcacg	600
tagtgggcca tcgcccgtat agacggttt tcgccccttg acgttggagt ccacgttctt	660
taatagtggaa ctcttgttcc aaactggAAC aacactcaac cctatctcggt tctattctt	720
tgatttataaa gggattttgc cgatttcggc ctattggta aaaaatgagc tgatttaaca	780
aaaatttaac gcgaatttta aaaaaatatt aacgcttaca atttctgtat gcggtatTTT	840
ctccttacgc atctgtgcgg tatttcacac cgcatacgcg gatctgcgcgc gcaccatggc	900
ctgaaataac ctctgaaaga ggaacttggt taggtacctt ctgaggcgga aagaaccagc	960
tgtggaatgt gtgtcagtta ggggtgtggaa agtccccagg ctccccagca ggcagaagta	1020
tgcaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtccccca ggctccccag	1080
caggcagaag tatgcaaagc atgcacatctca attagtcagc aaccatagtc ccgccccctaa	1140
ctccgccccat cccgccccata actccgccccaa gttccgccccaa ttctccgccccatggctgac	1200
taattttttt tatttatgca gaggccgagg ccgcctcgcc ctctgagcta ttccagaagt	1260
agtgaggagg cttttttggaa ggcctaggct tttgaaaaaaaaa gcttgattct tctgacacaa	1320
cagtctcgaa cttaaggcta gagccaccat gattgaacaa gatggattgc acgcaggttc	1380
tccggccgct tgggtggaga ggctattcggt ctatgactgg gcacaacaga caatcggtcg	1440
ctctgatgcc gccgtgttcc ggctgtcagc gcaggggcgcc ccggttcttt ttgtcaagac	1500
cgacctgtcc ggtgccttgc atgaactgca ggacgaggca ggcggctat cgtggctggc	1560
cacgacgggc gttcccttgcg cagctgtgcg cgcgttgcg actgaagcgg gaaggactg	1620
gctgctatttggc ggcgaagtgc cggggcagga tctcctgtca tctcaccttgc tctctgcccga	1680
gaaagtatcc atcatggctg atgcaatgcg gcccgtgcac acgcgttgc acggctacctg	1740
cccatcgac caccaagcga aacatcgcat cgagcgagca cgtactcgga tggaaagccgg	1800
tcttgcgat caggatgatc tggacgaaga gcatcagggg ctcgcgccttgc acggctacctg	1860
cgccaggctc aaggcgcgcga tgcccgacgg cgaggatctc gtcgtgcaccc atggcgatgc	1920
ctgcttgcgg aatatcatgg tggaaaatgg ccgcgtttcttggattcatcg actgtggccg	1980
gctgggtgtg gcggaccgcgt atcaggacat acgcgttggct acccggtata ttgctgaaga	2040
gcttggcgccg gaatggctg accgcgttcttgc cgtgcgttgc ggtatcgccg ctccccattc	2100
gcagcgcacgc gccttctatc gccttcttgc ctagtttgc tgagcgggac tctgggggttc	2160
gaaatgaccg accaagcgcac gcccacactg ccatcacgtat ggccgcataaa aatatcttt	2220
attttcatttta catctgtgtg ttggttttttt gtgtgaatcg atagcgataaa ggatccgcgt	2280
atggtgcact ctcagtgacaa tctgcgttgc tgccgcatacg ttaagccagc cccgacaccc	2340

gccaacaccc	gctgacgcgc	cctgacgggc	ttgtctgtc	ccggcatccg	cttacagaca	2400
agctgtgacc	gtctccggga	gctgcatgtg	tcagaggttt	tcaccgtcat	caccgaaacg	2460
cgcgagacga	aagggcctcg	tgatacgcct	atttttatag	gttaatgtca	tgataataat	2520
ggtttcttag	acgtcaggtg	gcactttcg	gggaaatgtg	cgcggaaccc	ctatttgttt	2580
attttctaa	atacattcaa	atatgtatcc	gctcatgaga	caataaccct	gataaaatgt	2640
tcaataataat	tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	cccttattcc	2700
ctttttgcg	gcattttgcc	ttcctgtttt	tgctcaccct	gaaacgctgg	tgaaagtaaa	2760
agatgctgaa	gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	2820
taagatcctt	gagagtttcc	gccccgaaga	acgtttcca	atgatgagca	cttttaaagt	2880
tctgctatgt	ggcgccgtat	tatcccgat	tgacgcccgg	caagagcaac	tcggtcgccc	2940
catacactat	tctcagaatg	acttggttga	gtactcacca	gtcacagaaaa	agcatcttac	3000
ggatggcatg	acagtaagag	aattatgcag	tgctgccata	accatgagtg	ataacactgc	3060
ggccaactta	cttctgacaa	cgatcgagg	accgaaggag	ctaaccgctt	tttgcacaa	3120
catggggat	catgtaactc	gccttgatcg	ttggaaaccg	gagctgaatg	aagccataacc	3180
aaacgacgag	cgtgacacca	cgatcctgt	agcaatggca	acaacgttgc	gcaaactatt	3240
aactggcga	ctacttactc	tagcttcccg	gcaacaatta	atagactgga	tggaggcgg	3300
taaagttgca	ggaccacttc	tgcgctcgcc	cattccggct	ggctggttta	ttgctgataa	3360
atctggagcc	ggtgagcgtg	ggtctcgccg	tatcattgca	gcactggggc	cagatggtaa	3420
gcctcccg	atcgtagttt	tctacacgac	ggggagtcag	gcaactatgg	atgaacgaaa	3480
tagacagatc	gctgagatag	gtgcctcact	gattaagcat	tggtaactgt	cagaccaagt	3540
ttactcatat	atactttaga	ttgatttaaa	acttcatttt	taatttaaaa	ggatcttagt	3600
gaagatcctt	tttgataatc	tcatgaccaa	aatcccttaa	cgtgagtttt	cgttccactg	3660
agcgtcagac	cccgtagaaa	agatcaaagg	atcttcttga	gatccttttt	ttctgcgcgt	3720
aatctgctgc	ttgcaaaca	aaaaaccacc	gctaccagcg	gtggtttgg	tgccgatca	3780
agagctacca	actcttttc	cgaaggtaac	tggcttcagc	agagcgcaga	taccaaatac	3840
tgttcttcta	gtgtagccgt	agttaggcca	ccacttcaag	aactctgttag	caccgcctac	3900
atacctcgct	ctgctaatcc	tgttaccagt	ggctgctgcc	agtggcgata	agtcgtgtct	3960
taccgggttg	gactcaagac	gatagttacc	ggataaggcg	cagcggtcgg	gctgaacggg	4020
gggttcgtgc	acacagccca	gcttggagcg	aacgacctac	accgaactga	gataacctaca	4080
gcgtgagcta	tgagaaaagcg	ccacgcttcc	cgaagggaga	aaggcggaca	ggtatccggt	4140
aagcggcagg	gtcggAACAG	gagagcgcac	gagggagctt	ccagggggaa	acgcctggta	4200

tctttatagt cctgtcgggt ttgcacact ctgacttgag cgtcgatttt tgtgatgctc	4260
gtcagggggg cgagccat ggaaaaacgc cagcaacgcg gcctttac ggccctggc	4320
ctttgctgg cttttgttc acatggctcg acagatctc aatattggcc attagccata	4380
ttattcattg gttatatacg ataaatcaat attggctatt ggccattgca tacgttgtat	4440
ctatatcata atatgtacat ttatattggc tcatgtccaa tatgaccgcc atgttggcat	4500
tgattattga ctatgttata atagtaatca attacgggtt cattagttca tagcccatat	4560
atggagttcc gcgttacata acttacggta aatggccgc ctggctgacc gcccaacgac	4620
ccccgccccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggacttcc	4680
cattgacgtc aatgggtgga gtatccatgg taaactgccc acttggcagt acatcaagt	4740
tatcatatgc caagtccgac ccctattgac gtcaatgacg gtaaatggcc cgccctggcat	4800
tatgcccagt adatgacctt acgggacttt octacttggc agtacatcta cgtattagtc	4860
atcgcttattt ccatggtgat gcggtttgg cagttacacca atgggcgtgg atagcggttt	4920
gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac	4980
caaaatcaac gggactttcc aaaaatgtcgt aacaactgcg atcgccgcg ccgttgcacgc	5040
aaatgggcgg taggcgtgta cgggtggagg tctatataag cagagctcgt ttagtgaacc	5100
gtcagatcac tagaagcttt attgcggtag tttatcacag ttaaattgct aacgcagtca	5160
gtgcttctga cacaacagtc tcgaacttaa gctgcagtga ctctcttaag gtagccttgc	5220
agaagttggcgtt cgtgaggcac tggcaggta agtataagg ttacaagaca ggtttaaagga	5280
gaccaataga aactgggatt gtcgagacag agaagactct tgcgtttctg ataggcacct	5340
attggcttta ctgacatcca ctttgccttt ctctccacag gtgtccactc ccagttcaat	5400
tacagctttt aaggcttagag tacttaatac gactcactat aggctacgcg ctagcgcgg	5460
gatgggggtt cacgaatgtc ctgcctggct gtggcttctc ctgtccctgc tgtagcgtccc	5520
tctggccctc ccagtcctgg ggcggccacc acgcctcata tgcgtacagcc gagtcctgga	5580
gaggtacctc ttggaggcca aggaggccga gaatatcactg acgggctgtg ctgaacactg	5640
cagcttgcata gagaatatacg ctgtcccaga caccaaaatggt aatttctatg cctggaaagag	5700
gatggagggtc gggcagcagg ccgtagaagt ctggcaggcc ctggccctgc tgtagcgtccc	5760
tgttctgcgg ggccaggccc tgggttccaa ctctccctcg ccgtggcggc ccctgcagct	5820
gcatgtggat aaagccgtcg agggccctcg cagcctcacc actctgtttc gggctctgcg	5880
agcccaagaag gaagccatct cccctccaga tgcggccctca gctgctccac tccgaacaat	5940
cactgctgac actttccgca aactcttcccg agtctactcc aatttcctcc ggggaaagct	6000

gaagctgtac acaggggaggc cctgcaggac aggggaccat catcaccatc accattgat 6059

<210> 212  
<211> 6059  
<212> DNA  
<213> Artificial

<220>  
<223> Description of Artificial Sequence: plasmid

<400> 212	60
ctagagtgcga cccgggcggc cgcttccctt tagtgagggt taatgcttcg agcagacatg	60
ataagataaca ttgatgagtt tggacaaacc acaactagaa tgcagtgaaa aaaatgcttt	120
atttgtgaaa tttgtgatgc tattgcttta tttgttaacca ttataagctg caataaacaa	180
gttaacaaca acaattgcac tcattttatg tttcagggttc agggggagat gtgggagggtt	240
ttttaagca agtaaaaacct ctacaaatgt ggtaaaatcc gataaggatc gatccgggct	300
ggcgtaatag cgaagaggcc cgcaccgatc gcccctccca acagttgcgc agcctgaatg	360
gcgaatggac ggcgcgtgt aagcgcggcg ggtgtgggtt ttacgcgcag	420
cgtgaccgtt acacttgcac ggcgccttagc gcccgcctt ttcgccttct tcccttcctt	480
tctcgccacg ttccgggtt ttcccggtca agctctaaat cgggggctcc cttagggtt	540
ccgatttagt gcttacggc acctcgaccc caaaaaactt gattagggtt atggttcacg	600
tagtgggcca tcgcctgtat agacggtttt tcgcctttt acgttggagt ccacgttctt	660
taatagtgga ctcttgcctt aaactggaac aacactcaac cctatctcg tctattcttt	720
tgatttataa gggattttgc cgatttcggc ctattggta aaaaatgagc tgatttaaca	780
aaaatttaac gcgaattttt acaaaaatatt aacgcttaca atttcctgtat gcggtatttt	840
ctccttacgc atctgtgcgg tatttcacac cgcatacgatc gatctgcgcac gcaccatggc	900
ctgaaataac ctctgaaaga ggaacttggt taggtacctt ctgaggcgga aagaaccagc	960
tgtggaatgt gtgtcagtta ggggtggaa agtccccagg ctcccccagca ggcagaagta	1020
tgcaaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtccccca ggctccccag	1080
cagggcagaag tatgcaaaggc atgcacatctca attagtcagc aaccatagtc cgcgcctaa	1140
ctccgcctt cccgccttactccgc gttccgcctt ttctccgcctt catggctgac	1200
taattttttt tatttatgca gaggccgagg ccgcctcgcc ctctgagctt ttccagaagt	1260
agtgaggagg cttttttggaa ggccttaggtt tttgcaaaaa gcttgatttt tctgacacaa	1320
cagtctcgaa cttaaggctt gagccaccat gattgaacaa gatggattgc acgcagggttc	1380
tccggccgct tgggtggaga ggctattcggtt ctatgactgg gcacaacaga caatcggctg	1440
ctctgatgcc gccgtgttcc ggctgtcagc gcagggggcgcc cgggttctt ttgtcaagac	1500

cgacctgtcc	ggtgcctga	atgaactgca	ggacgaggca	gchgctat	cgtggctggc	1560
cacgacgggc	gttccttgcg	cagctgtgct	cgacgttgc	actgaagcgg	gaagggactg	1620
gctgctattg	ggcgaagtgc	cggggcagga	tctctgtca	tctcacctt	ctcctgccga	1680
gaaagtatcc	atcatggctg	atgcaatgcg	gcggctgcat	acgcttgc	cggctacctg	1740
cccattcgac	caccaagcga	aacatcgcat	cgagcgagca	cgtactcgga	tggaagccgg	1800
tcttgcgtat	caggatgatc	tggacgaaga	gcatcagggg	ctcgccag	ccgaactgtt	1860
cggcaggctc	aaggcgcgca	tgcccacgg	cgaggatctc	gtcgtgaccc	atggcgatgc	1920
ctgcttgcgg	aatatcatgg	tggaaaatgg	ccgcttttct	ggattcatcg	actgtggccg	1980
gctgggtgtg	gcggaccgct	atcaggacat	agcggtggct	acccgtgata	ttgctgaaga	2040
gcttggcggc	aatatcatgg	tggaaaatgg	ccgcttttct	ggattcatcg	actgtggccg	2100
gcagcgcatac	gccttctatc	gccttcttga	cgagtttttc	tgagcgggac	tctgggttc	2160
gaaatgacccg	accaagcgcac	gcccaccc	ccatcacgat	ggccgcaata	aaatatctt	2220
attttcattta	catctgtgtg	ttggtttttt	gtgtgaatcg	atagcgataa	ggatccgcgt	2280
atggtgcaact	ctcagtacaa	tctgtctga	tgccgcata	ttaagccagc	cccgacaccc	2340
gccaacaccc	gctgacgcgc	cctgacgggc	ttgtctgctc	ccggcatccg	cttacagaca	2400
agctgtgacc	gtctccggga	gctgcgtgt	tcagaggttt	tcaccgtcat	caccgaaacg	2460
cgcgagacga	aaggccctcg	tgatacgcct	atttttatag	gttaatgtca	tgataataat	2520
ggtttcttag	acgtcaggtg	gcactttcg	ggaaatgtg	cgccgaaccc	ctatttgttt	2580
attttctaa	atacattcaa	atatgtatcc	gctcatgaga	caataaccc	gataaatgct	2640
tcaataat	tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	cccttattcc	2700
ctttttgcg	gcattttgcc	ttcctgtttt	tgctcaccca	gaaacgctgg	tgaaagtaaa	2760
agatgctgaa	gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	2820
taagatcctt	gagagtttc	gccccgaaga	acgtttcca	atgatgagca	cttttaaagt	2880
tctgctatgt	ggcgccgtat	tatccgtat	tgacgccggg	caagagcaac	tgggtgcgg	2940
catacactat	tctcagaatg	acttggttga	gtactcacca	gtcacagaaaa	agcatcttac	3000
ggatggcatg	acagtaagag	aattatgcag	tgctgccata	accatgagtg	ataacactgc	3060
ggccaaactta	cttctgacaa	cgatcgagg	accgaaggag	ctaaccgctt	ttttgcacaa	3120
catggggat	catgtactc	gccttgcgt	ttggaaaccg	gagctgaatg	aagccataacc	3180
aaacgacgag	cgtgacacca	cgatgcgt	agcaatggca	acaacgttgc	gcaaactatt	3240
aactggcgaa	ctacttactc	tagttcccc	gcaacaatta	atagactgga	tggaggcgga	3300

taaagttgca ggaccacttc tgcgctcggc ccttcggct ggctggtttta ttgctgataa	3360
atctggagcc ggtgagcgtg ggtctcgcc tatcattgca gcactggggc cagatggtaa	3420
gcccctccgt atcgttagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa	3480
tagacagatc gctgagatag gtgcctcact gattaagcat tggtaactgt cagaccaagt	3540
ttactcataat atactttaga ttgatttaaa acttcatttt taatttaaaa ggatcttagt	3600
gaagatccctt tttgataatc tcatgaccaa aatcccttaa cgtgagttt cgttccactg	3660
agcgtcagac cccgtagaaa agatcaaagg atcttcttga gatcctttt ttctgcgcgt	3720
aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg gtggtttgtt tgccggatca	3780
agagctacca actcttttc cgaaggtaac tggcttcagc agagcgcaga taccaaatac	3840
tgttcttcta gtgtagccgt agttaggcca ccacttcaag aactctgttag caccgcctac	3900
atacctcgct ctgctaattcc tggattaccgt gggtgctgcc agtggcgata agtcgtgtct	3960
taccgggttg gactcaagac gatagttacc ggataaggcg cagcggtcgg gctgaacggg	4020
gggttcgtgc acacagccca gttggagcg aacgacctac accgaactga gataacctaca	4080
gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt	4140
aagcggcagg gtcggAACAG gagagcgcac gagggagctt ccagggggaa acgcctggta	4200
tctttatagt cctgtcggtt ttggccaccc tggactttag cgtcgatttt tggatgtc	4260
gtcagggggg cggagcctat gaaaaaacgc cagcaacgcg gccttttac gggtcctggc	4320
cttttgctgg cttttgctc acatggctcg acagatcttc aatattggcc attagccata	4380
ttatccatgg tttatatacg ataaatcaat attggctatt ggccattgca tacgttgtat	4440
ctatatcata atatgtacat ttatattggc tcatgtccaa tatgaccggcc atgttggcat	4500
tgattattga ctatgttata atagtaatca attacgggtt cattagttca tagccatata	4560
atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc gcccAACGAC	4620
ccccggccat tgacgtcaat aatgacgtat gttccatag taacgccaat agggactttc	4680
cattgacgtc aatgggtgga gtatattacgg taaaactgccc acttggcagt acatcaagt	4740
tatcatatgc caagtccggcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat	4800
tatgcccagt acatgacctt acgggacttt cctacttggc agtacatcta cgtattagtc	4860
atcgctatata ccatgggtgat ggggttttgg cagttacacca atggggcgtgg atagcggttt	4920
gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac	4980
caaaatcaac gggactttcc aaaatgtcgta aacaactgcg atcgccccgc ccgttgcgc	5040
aaatgggcgg taggcgtgta cgggtggagg tctatataag cagagctcgat ttagtgaacc	5100

gtcagatcac tagaagcttt attgcggtag tttatcacag ttaaattgct aacgcagtca	5160
gtgcttctga cacaacagtc tcgaacttaa gctgcagtga ctctcttaag gtagccttgc	5220
agaagtttgt cgtgaggcac tggcaggtt agtatcaagg ttacaagaca ggtttaagga	5280
gaccaataga aactgggctt gtcgagacag agaagactct tgcgttctg ataggcacct	5340
atgggtctta ctgacatcca ctttgccttt ctctccacag gtgtccactc ccagttcaat	5400
tacagctctt aaggctagag tacttaatac gactcaactat aggctagcct cgagcgcgga	5460
gatgggggtg cacgaatgtc ctgcctggct gtggcttctc ctgtccctgc tgtcgctccc	5520
tctgggcctc ccagtcctgg gcgcaccacc acgcctcatac tgtgacagcc gagtcctgga	5580
gaggtacctc ttggaggcca aggaggccga gaatatcacg acgggctgtg ctgaacactg	5640
cagcttgaat gagaatatca ctgtcccaga caccgacgtt aatttctatg cctggaagag	5700
gatggaggtc gggcagcagg ccgtagaagt ctggcagggc ctggccctgc tgtcggaagc	5760
tgtcctgcgg ggcaggccc tgggtgtcaa ctctccctag ccgtggagc ccctgcagct	5820
gcatgtggat aaagccgtcg agggccttcg cagcctcacc actctgtttc gggctctgcg	5880
agcccagaag gaagccatct cccctccaga tgcggccatca gctgctccac tccgaacaat	5940
cactgctgac actttccgca aactcttccg agtctactcc aatttcctcc gggaaagct	6000
gaagctgtac acaggggagg cctgcaggac aggggaccat catcaccatc accattgat	6059